[
  {
    "id": "34bb3979c070",
    "title": "Eli Lilly's Ambitious Expansion: Turning India into a Global Supply Chain Hub - Devdiscourse",
    "description": "Eli Lilly's Ambitious Expansion: Turning India into a Global Supply Chain Hub  Devdiscourse",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/Eli%20Lilly's%20Ambitiou/600/400",
    "url": "https://news.google.com/articles/CBMixgFBVV95cUxORXphWjY5SUNUbzBJbGFiYjRSa1RvSjBTcldRSkM4ajdLSHhqSVpZajVxQ2V6QjZ6Sm9zYkk4TFA3TFJZdUN1SlRxSnJ0OFBoNFlCUHlSS3J6ZHk5YjA3alNmaktXUEJvaElkd2g1Q3JJVEhKSkNZcFBJWWtPZTRPQ3dPTG5SdHREVk1YdkVZV1pVQkxHd0t1d0RYNXAxelQ1eWNWSVlFc3Q1dnd4eVdOSUlnN3FyOUExaDdGVUFpd3Y0WHFyTFHSAcsBQVVfeXFMUEhnSjVTTy1sb2FaNl9PajNXNFFLd092bDFGZllPZnNfSjhCb3JFb1Vwak4yNnB0bHRlaHJzR2Z5WndEMmZwRUZjUEQtZ1cwb0xDV3pGLUhhMWpsRDJzRWQtMkluNWxybWNmNnlNbV9hd3NQRFN5RXhuN1BIMlc5bGpnczBOWFQwMkZuU3ZWNklmTlA5RGRVT29KTC1kX05kbFZfU2tlREN4UG9OSnQzb2RKQk13X0JPQUhjOVRjbWFUQnUydFgwdlg3Ukk?oc=5",
    "publishedAt": "2026-02-17T12:17:19.000Z",
    "language": "en",
    "importance": 7,
    "summary": "릴리, 인도를 글로벌 공급 허브로 육성. 비만·알츠하이머 약 수요 폭증에 생산 인프라 대폭 확충, AR1001 경쟁 환경 심화 신호"
  },
  {
    "id": "a9f42244ce90",
    "title": "[美특징주]일라이 릴리, 인도 10억 투자…개장전 ↑ - edaily.co.kr",
    "description": "[美특징주]일라이 릴리, 인도 10억 투자…개장전 ↑  edaily.co.kr",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%5B%E7%BE%8E%ED%8A%B9%EC%A7%95%EC%A3%BC%5D%EC%9D%BC%EB%9D%BC%EC%9D%B4%20%EB%A6%B4%EB%A6%AC%2C%20%EC%9D%B8%EB%8F%84%2010%EC%96%B5/600/400",
    "url": "https://news.google.com/articles/CBMigAFBVV95cUxPa05LbXp5a3A4WFVDNW9tYWNCZ2hiM1p1bU9haHRYS2ZKWGdEQ01QMVVhY2V5VWw4RG9uaTk0YllNdGwtUlV1T3NzX3ZmMVg2aEdzNU53MmU0TjFoeEJlTm5Ib0lBdHNXOVVBMUNmeFZ4Q1pDeXZkeVZIVFl4X2hKNg?oc=5",
    "publishedAt": "2026-02-17T11:19:07.000Z",
    "language": "ko",
    "importance": 7,
    "summary": "일라이 릴리, 인도에 10억 달러 투자 결정. 생산기지 확대로 치료제 공급망 강화, 알츠하이머 시장 글로벌 경쟁 격화 예고"
  },
  {
    "id": "c7499d02830b",
    "title": "Lilly bets on India as global supply hub - Latest news from Azerbaijan",
    "description": "Lilly bets on India as global supply hub  Latest news from Azerbaijan",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Lilly%20bets%20on%20India%20/600/400",
    "url": "https://news.google.com/articles/CBMibkFVX3lxTE5fVzU2REtackxiSFo3M0NlSWNBMnp4c0pvazBITDQ4dzlaLVhkMl84RG43eTQySEFhNkFLcDlEeWpBRlh1azhiUzlmX0xfX01ZUHEwRlNONkgyQ3JNOU5WaHlHSlJhSTM1b3d0bHlB?oc=5",
    "publishedAt": "2026-02-17T10:26:20.000Z",
    "language": "en",
    "importance": 4,
    "summary": "릴리, 인도 글로벌 수출 거점화 추진. 무자로 매출 호조 속 공급망 다변화 전략으로 치매 치료제 시장 지배력 확대 목표"
  },
  {
    "id": "727ec481da9c",
    "title": "Eli Lilly Plans India Manufacturing Hub as Weight-Loss Drug Sales Surge - Fine Day 102.3",
    "description": "Eli Lilly Plans India Manufacturing Hub as Weight-Loss Drug Sales Surge  Fine Day 102.3",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/Eli%20Lilly%20Plans%20Indi/600/400",
    "url": "https://news.google.com/articles/CBMiyAFBVV95cUxON0F6NzhVTXpQWnZYZmVqMGRpRVJzUS1SY2hVNVVDOVhXZmgxOE1zTHI1eFZPbWx1MG9HNG04VUludTJ6bFVmQXRuQ1ZheGpaVUhkNjlJWjM5X0FTZ3IwRU9VcGZvSE1oUEMxZDEyWk9zWDN2Tlh2MmFQaHF1REZIcmlrajk2X3AzZG5OSTBFN2JLc3JIUjZCcWg1UEZ3N1VaOEN0cW4yVGcwV1BaeWUyTnVxUmhGREFzMkt5Q2dJZDFRV1B2cnFqZA?oc=5",
    "publishedAt": "2026-02-17T10:24:53.000Z",
    "language": "en",
    "importance": 7,
    "summary": "릴리, 체중감량 약 매출 급증에 인도 제조 허브 설립 추진. 알츠하이머 포함 글로벌 생산능력 확대, 경쟁사 압박 강화"
  },
  {
    "id": "5727524ff14b",
    "title": "Lilly targets India as global export hub amid booming Mounjaro sales, executive says - Reuters",
    "description": "Lilly targets India as global export hub amid booming Mounjaro sales, executive says  Reuters",
    "source": "Google News",
    "category": "market",
    "imageUrl": "https://picsum.photos/seed/Lilly%20targets%20India%20/600/400",
    "url": "https://news.google.com/articles/CBMi5wFBVV95cUxQcDgwRW1hSnlmWjRWcW12ZHZXamdWNkNFN29UTGdLYUNlWi1zM3MwUlFlZngwZjR0OW9fVV9OTHdpSHVGU19qQ0R3NEZBR05CT2tRVjV2SnZrcXZpSzZSREtqY0poOHRJMjI1TG1NamJELW5BdVdOMzIxWDZFekhxSFdOOXV4cllKTDVucVEwOS0wR3FuVlBFd3BMLTBMVlgzbmlLYUNaMjQ1a3N3UDdMRFJWYUxCRTBKNVg4VFB5QkFXWUFMNXhsZF9ZaTFfZm5YRVZlTlo3RTNjSF94QndyLUJzS2NFUzQ?oc=5",
    "publishedAt": "2026-02-17T09:49:28.000Z",
    "language": "en",
    "importance": 5,
    "summary": "릴리, 무자로 매출 호황 속 인도를 글로벌 수출 거점으로 전환. 알츠하이머 치료제 포함 생산 확장 계획, 시장 점유율 확대 전략"
  },
  {
    "id": "b5df0365ee4b",
    "title": "Donald Trump's Health Fuels Conspiracy Theories as Congresswoman Claims He's Taking Alzheimer's Drug - AOL.com",
    "description": "Donald Trump's Health Fuels Conspiracy Theories as Congresswoman Claims He's Taking Alzheimer's Drug  AOL.com",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Donald%20Trump's%20Healt/600/400",
    "url": "https://news.google.com/articles/CBMiiAFBVV95cUxNS2I4dmVBclBJeDJKZjk1c19tQjNzQ2tFWWZ6UTZHYXBqQU44cmFtVnkzVnRva2k1Rm5qa0NRbVZZUTdIQ1c4bW00M3FOU3FrQlA5d3R0OUZrM3hnaUctRkRXRUlPUTJMWXpTMWw2MFIzRmljMUI0NWJ3VEdSSzJMT29QLWNBRnda?oc=5",
    "publishedAt": "2026-02-17T04:08:50.000Z",
    "language": "en",
    "importance": 2,
    "summary": "트럼프 대통령 건강 논란, 알츠하이머 약물 복용설 제기. 정치적 루머 수준으로 치료제 시장에 직접 영향은 제한적"
  },
  {
    "id": "bf6977b344e6",
    "title": "Alzheimer's Disease Diagnostics Market Forecast to Reach USD 15.57 Billion by 2030 - openPR.com",
    "description": "Alzheimer's Disease Diagnostics Market Forecast to Reach USD 15.57 Billion by 2030  openPR.com",
    "source": "Google News",
    "category": "market",
    "imageUrl": "https://picsum.photos/seed/Alzheimer's%20Disease%20/600/400",
    "url": "https://news.google.com/articles/CBMinAFBVV95cUxOTG1KbXB6ZjVEM3VzaC16YmQwMXFpMlNtMFFCeUtEZy1QWmk3d3BvVjVESmREYzNMdHVTM1NNR29KQy1YLTVGeE5TMEVpVktCR0ZvV2FLTkZrVmpVS1RTQlJYcUF4dGxQTF91UXAzd2JQOTRrMnhpMFdYUUVUaDBqOXVFcm8xdmtmNFlyY0tEb3BEOTJTMk5TRHhuR08?oc=5",
    "publishedAt": "2026-02-17T02:19:50.000Z",
    "language": "en",
    "importance": 6,
    "summary": "알츠하이머 진단 시장 2030년 155.7억 달러 도달 전망. 조기진단 수요 급증이 치료제 시장 확대와 맞물려 투자 기회 증대"
  },
  {
    "id": "4c240edbac0b",
    "title": "양동원 서울성모병원 부원장 “레켐비·슈퍼브레인 병용, 치매 진행 지연 효과”[전문가 인사이트] - 팜이데일리",
    "description": "양동원 서울성모병원 부원장 “레켐비·슈퍼브레인 병용, 치매 진행 지연 효과”[전문가 인사이트]  팜이데일리",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EC%96%91%EB%8F%99%EC%9B%90%20%EC%84%9C%EC%9A%B8%EC%84%B1%EB%AA%A8%EB%B3%91%EC%9B%90%20%EB%B6%80%EC%9B%90%EC%9E%A5%20%E2%80%9C%EB%A0%88%EC%BC%90%EB%B9%84%C2%B7/600/400",
    "url": "https://news.google.com/articles/CBMibkFVX3lxTE5iTzdocGJWdnI4QUpPWHhSVm9DR3d4WTItXy0zZDBnMDF0RVJlc2pUbHhfRXltaXhMTk11UUx0RnhRN1Z2N3paTGhtRGNfNDdVUWNFSjlKUjEyVy1MQzk3SWpYdHFGNkpRVTRLOTlR?oc=5",
    "publishedAt": "2026-02-16T23:10:03.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "서울성모 양동원 교수, 레켐비+디지털치료제 병용 시 치매 진행 지연 효과 확인. 복합치료 트렌드가 AR1001 병용 가능성에도 시사점"
  },
  {
    "id": "26f6548d82ec",
    "title": "경도인지장애 단계서 시작하는 ‘레켐비’ 치료…“병 진행 늦추는 게 중요” - 쿠키뉴스",
    "description": "경도인지장애 단계서 시작하는 ‘레켐비’ 치료…“병 진행 늦추는 게 중요”  쿠키뉴스",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EA%B2%BD%EB%8F%84%EC%9D%B8%EC%A7%80%EC%9E%A5%EC%95%A0%20%EB%8B%A8%EA%B3%84%EC%84%9C%20%EC%8B%9C%EC%9E%91%ED%95%98%EB%8A%94%20%E2%80%98%EB%A0%88%EC%BC%90%EB%B9%84/600/400",
    "url": "https://news.google.com/articles/CBMiY0FVX3lxTE42dWtza0ZmQlFiSTZZUWJ4TGNod0ZrbE5FR0lGR1llQWlUN2kyaUhLSi02bXFtOE1aaVVWb1kwNnNILVRzMV8tUUVpZHNPR1dZRWx6S0pmNXRWdmV6cHRETzVOZw?oc=5",
    "publishedAt": "2026-02-16T21:00:11.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "경도인지장애 단계에서 레켐비 조기 투여가 핵심. 병 진행 속도 늦추는 조기 개입 전략이 치매 신약 시장의 표준 프로토콜로 부상"
  },
  {
    "id": "718b87995b29",
    "title": "Investigational Therapy ALZ-801 Shows Clinical Efficacy in MCI Stage of Alzheimer Disease - Pharmacy Times",
    "description": "Investigational Therapy ALZ-801 Shows Clinical Efficacy in MCI Stage of Alzheimer Disease  Pharmacy Times",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/Investigational%20Ther/600/400",
    "url": "https://news.google.com/articles/CBMiwgFBVV95cUxPa0J4blN2OGlpQmlZaEpkX1R4U3JlTURCTVZpTy1GUnJPaDZLYmJZZm0zQXZoQ0ZsLTZ2NmUxRjhaQ1Y5bXBpUnFBVF9mX05pSmw0b0xEd2tGalNpbzRVTTZPY2txM05KeVNNYzF4OVkxT2dNMGNVcnN5Q0ExaG5HdkI1c2FsV0lfUnE3RFlHV1c0U05sWWZTbm9HNjJCckdvVlQ3bGtaMjIyTVhITFJiWHBVbDFiZmlJTnZ2RG5QOTR5QQ?oc=5",
    "publishedAt": "2026-02-16T17:03:08.000Z",
    "language": "en",
    "importance": 7,
    "summary": "ALZ-801, 경도인지장애 단계에서 임상 유효성 확인. 경구제 강점으로 레켐비 대비 편의성 우위, AR1001과 경쟁 구도 형성"
  },
  {
    "id": "66d7790cb98f",
    "title": "아리바이오, AR1001 美특허 추가 등록... 2040년대 독점권 기반 LO 협상 게임체인저 - MSN",
    "description": "아리바이오, AR1001 美특허 추가 등록... 2040년대 독점권 기반 LO 협상 게임체인저  MSN",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20AR1001%20%E7%BE%8E%ED%8A%B9%ED%97%88%20%EC%B6%94%EA%B0%80/600/400",
    "url": "https://news.google.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?oc=5",
    "publishedAt": "2026-02-16T14:32:13.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오 AR1001 미국 특허 추가 등록, 2040년대까지 독점권 확보. 라이선스아웃 협상에서 강력한 지적재산권 무기 확보"
  },
  {
    "id": "2c1248b4c576",
    "title": "Weight loss jabs do not slow Alzheimer's disease as hoped, causing firm's share prices to plummet - MSN",
    "description": "Weight loss jabs do not slow Alzheimer's disease as hoped, causing firm's share prices to plummet  MSN",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Weight%20loss%20jabs%20do%20/600/400",
    "url": "https://news.google.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?oc=5",
    "publishedAt": "2026-02-16T13:02:28.000Z",
    "language": "en",
    "importance": 5,
    "summary": "GLP-1 체중감량 주사제, 알츠하이머 진행 억제 효과 미달. 세마글루타이드 치매 적응증 실패로 관련 기업 주가 급락"
  },
  {
    "id": "0f756ee1cb2a",
    "title": "Neurophet bags 510(k) for Alzheimer's imaging AI and more briefs - MobiHealthNews",
    "description": "Neurophet bags 510(k) for Alzheimer's imaging AI and more briefs  MobiHealthNews",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Neurophet%20bags%20510(k/600/400",
    "url": "https://news.google.com/articles/CBMinwFBVV95cUxObTlzaV9nTXZQVkI0OWIwSVpQQmlYTHV5aWVSSjlpSnVNTTc5cUVWV3BfSXVWYWUzSG5INkVaY1pSMTYwQzU3c2Fudk9nUXo3SDhmczJSc0VrNHRNZ1RyOGl6Sm5VT3c0TXZ2bDFhTXhOR2VKQ1Z5NUgzVDFBM1ZnYWtMQzFPTDVnZmZsUzZQbVV1RDFWQ2tXQ1A5YXN0dWc?oc=5",
    "publishedAt": "2026-02-16T05:03:34.000Z",
    "language": "en",
    "importance": 4,
    "summary": "뉴로펫, 알츠하이머 영상 AI 솔루션 FDA 510(k) 획득. 진단 보조 AI 시장 확대, 치료제 처방 전 필수 진단 수요 증가 전망"
  },
  {
    "id": "f66aa38486c0",
    "title": "Early diagnosis push meets cost reality in Korea’s dementia overhaul - koreabiomed.com",
    "description": "Early diagnosis push meets cost reality in Korea’s dementia overhaul  koreabiomed.com",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Early%20diagnosis%20push/600/400",
    "url": "https://news.google.com/articles/CBMickFVX3lxTE9qeWtMV3RIRWhoUFd0VWlyVUxCUHBIY1g0Q0VnbTVVdWVGNVpwSThtUk1kUkFMc2xDbDRKek83RFYwd2tGZWpVQzJZWWRHLTAyU1JFQ2stdldsMmloaUpGU05vTDgtNE9KbllvSmpGZjg0d9IBckFVX3lxTE9qeWtMV3RIRWhoUFd0VWlyVUxCUHBIY1g0Q0VnbTVVdWVGNVpwSThtUk1kUkFMc2xDbDRKek83RFYwd2tGZWpVQzJZWWRHLTAyU1JFQ2stdldsMmloaUpGU05vTDgtNE9KbllvSmpGZjg0dw?oc=5",
    "publishedAt": "2026-02-16T01:41:31.000Z",
    "language": "en",
    "importance": 4,
    "summary": "한국 치매 조기진단 확대 정책과 비용 현실 간 괴리 조명. 진단 인프라 구축이 치료제 접근성 확대의 선결 과제로 부각"
  },
  {
    "id": "83898ff79ed7",
    "title": "이미 시작된 위기㊦ 일본, 레켐비·키순라 건강보험 적용…운영 전략 시험대 - Yakup.com",
    "description": "이미 시작된 위기㊦ 일본, 레켐비·키순라 건강보험 적용…운영 전략 시험대  Yakup.com",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EC%9D%B4%EB%AF%B8%20%EC%8B%9C%EC%9E%91%EB%90%9C%20%EC%9C%84%EA%B8%B0%E3%8A%A6%20%EC%9D%BC%EB%B3%B8%2C%20%EB%A0%88%EC%BC%90%EB%B9%84%C2%B7%ED%82%A4/600/400",
    "url": "https://news.google.com/articles/CBMib0FVX3lxTFBzTkg0TkhrVThaN2hjSHhwTWRjR0JiR2pOVXdWdEJKTVJmNGRkRmJ4czk0aDhRdjdieEY2VXZ1Z2dYVjVUcl9QTlhUTHRHUFo1bzNiYkNpLXpvMXpBY2JsdDkzMmhESTFIb0FGUkFYbw?oc=5",
    "publishedAt": "2026-02-15T15:37:31.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "일본, 레켐비·키순라 건강보험 적용 본격화. 아시아 보험 급여 선례가 한국 급여 심사에도 영향 전망, 시장 확대 신호"
  },
  {
    "id": "0499a79268ca",
    "title": "Axsome initiated with Overweight at Wells Fargo on Alzheimer's drug potential - MSN",
    "description": "Axsome initiated with Overweight at Wells Fargo on Alzheimer's drug potential  MSN",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Axsome%20initiated%20wit/600/400",
    "url": "https://news.google.com/articles/CBMi4AJBVV95cUxORTQ2MFVaQ2VSak00ZmpGdk9MMFV1QjJrOGx4Vjc4NUU1dkxmMTZfR3ZZNDJSRmhnd3AwZUgxY0NSTk1QTVRtVEZyeTVFMjZhSFQzZ2wyS0pMZTBhX2pXbjZXZU5qZnBudVlTcExtc1Q3eGZWUXFDRVJjQjZnTWoyX1VsMGZXNGpaTUFsbTNiR1VNVFM5VTVQa2xPR3hsdGFHZUpTbWk4Y2p0c3BWY3Y1SFpnZzZlQzZoRXEtNWRveEQ0NGJ6VmZPWXJYWFg5WHEzd1R2bk1EUjFaUHM5QTE4VWxKamVPX0lCanI0bll5RUkzc3FIemJsQWFYS3RLQ3hsQ3F6R2tzNTlfbm1FRVE2WXZieWVXTEw2NVplSFRWSGt2dl9ET2VjYlNSSDRaZ2JvdHREektMY1l0ZDB4TERfMThIYlN4d3BWaUJtc0RSQVNxTUQ2M09ZbDFpeWg1a1c2?oc=5",
    "publishedAt": "2026-02-15T02:26:27.000Z",
    "language": "en",
    "importance": 3,
    "summary": "웰스파고, Axsome에 비중확대 의견 개시. 알츠하이머 약물 파이프라인 잠재력 평가, 치매 치료제 섹터 전반 관심 증가"
  },
  {
    "id": "f594ce30bafd",
    "title": "치매 치료제, '지연' 아닌 '완치'에 도전…암세포까지 활용한다 - 테크월드뉴스",
    "description": "치매 치료제, '지연' 아닌 '완치'에 도전…암세포까지 활용한다  테크월드뉴스",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EC%B9%98%EB%A7%A4%20%EC%B9%98%EB%A3%8C%EC%A0%9C%2C%20'%EC%A7%80%EC%97%B0'%20%EC%95%84%EB%8B%8C%20'%EC%99%84%EC%B9%98'/600/400",
    "url": "https://news.google.com/articles/CBMiaEFVX3lxTE9wS0p0Q2pyeHlfdFU5M3JGb2ZqdGpJdjJqV2o5SU1zSElvcUdFczVadEc0ZE0yUnZINDNlVFljWmJvc2JheVVBbldLdm1WdmIyN2JxNEtqYVdsZ05rek9aQml5WmlabzMz?oc=5",
    "publishedAt": "2026-02-14T01:00:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "치매 치료 패러다임 전환, 진행 지연에서 완치 도전으로. 암세포 활용한 아밀로이드 제거 등 혁신 기전 연구 가속"
  },
  {
    "id": "9ca12c17a9c4",
    "title": "알츠하이머 시장, 빅파마 시선은 약물→ 기술가치로 전환 - 히트뉴스",
    "description": "알츠하이머 시장, 빅파마 시선은 약물→ 기술가치로 전환  히트뉴스",
    "source": "Google News",
    "category": "market",
    "imageUrl": "https://picsum.photos/seed/%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%20%EC%8B%9C%EC%9E%A5%2C%20%EB%B9%85%ED%8C%8C%EB%A7%88%20%EC%8B%9C%EC%84%A0%EC%9D%80%20%EC%95%BD%EB%AC%BC/600/400",
    "url": "https://news.google.com/articles/CBMia0FVX3lxTE5kcHNCb1pJX1ZLUEJLenBhbE8xME5wUEhFenZ5SUNuTmM1bmNuUjM2Q1BZbW9EMlVvOGNqbklaLWMxX3dJN0YtaTA2S1V5NVd1UUNKUFRZQmR0d3o4a1Q1Rmo2aklPT1ZOTFQ4?oc=5",
    "publishedAt": "2026-02-13T21:05:00.000Z",
    "language": "ko",
    "importance": 5,
    "summary": "알츠하이머 시장 빅파마 전략이 약물 중심에서 기술 가치 평가로 전환. 디지털치료제·진단 플랫폼에 투자 집중 추세"
  },
  {
    "id": "80f657847102",
    "title": "FDA rejects rare disease therapy from Disc Medicine, early recipient of commissioner’s voucher - statnews.com",
    "description": "FDA rejects rare disease therapy from Disc Medicine, early recipient of commissioner’s voucher  statnews.com",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/FDA%20rejects%20rare%20dis/600/400",
    "url": "https://news.google.com/articles/CBMicEFVX3lxTE93NmQxUjJYZzZZX0dYcmhueWZOUmRaVjdPcm80Z1EteElyMUZ5R0poM2twbFdxZkYwVzRmTWxpemxldTE2a0NHQUkwUHl5b3VsRHhSZzVEYXB1OUZjdXVGei1IcW0yVERieFZFRzhqZ3E?oc=5",
    "publishedAt": "2026-02-13T20:33:31.000Z",
    "language": "en",
    "importance": 1,
    "summary": "FDA, Disc Medicine 희귀질환 치료제 거부. 알츠하이머 직접 관련 없으나 FDA 심사 기준 엄격화 동향 참고"
  },
  {
    "id": "4da892ea61f6",
    "title": "2026 장외시장...거래는 아리바이오, 주도주는 삼성메디슨 - 프리스탁뉴스",
    "description": "2026 장외시장...거래는 아리바이오, 주도주는 삼성메디슨  프리스탁뉴스",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/2026%20%EC%9E%A5%EC%99%B8%EC%8B%9C%EC%9E%A5...%EA%B1%B0%EB%9E%98%EB%8A%94%20%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4/600/400",
    "url": "https://news.google.com/articles/CBMib0FVX3lxTE1MNUJaUWw4cC1PS3VVbXZQTV9VMXFfbUwzYnZHc0Jtc3JOLVNlUWx0VmFKWFNVYVZCMUpQTFJodnpXa0EyQmduMXJPTEtWWEZHZjNWNWxhTklaYUlINF9jQ3hET0xjd1lpMTU4VGNWZw?oc=5",
    "publishedAt": "2026-02-13T12:36:05.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "2026년 장외시장 거래량 1위 아리바이오, 주도주는 삼성메디슨. 아리바이오 투자자 관심 지속적으로 높은 수준 유지"
  },
  {
    "id": "3a31e73c0165",
    "title": "Alzheimer's drug INmune Bio co cleared a major regulatory hurdle | Tap to know more | Inshorts - Inshorts",
    "description": "Alzheimer's drug INmune Bio co cleared a major regulatory hurdle | Tap to know more | Inshorts  Inshorts",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Alzheimer's%20drug%20INm/600/400",
    "url": "https://news.google.com/articles/CBMisAFBVV95cUxOYkEwcjY5ejhTenZxVVRYSE9TRlR1aHRjXzhtUDNJTlZKSjE2cjNHLXJNazhrRjd1cXdza29jS09ZVDJoNlBOMTJ6TlhTbnZ6U2ZvOVJSM24xWV9OTVJlVTVleFVGdnhEaFowb3RNV3VUVkY0dE91bkxuQWtSaXI1bWJPS0thaUxVemtfcHNYd0pqT3o5d2l2aUs5SFRKZDJ3am9TbUJmcWNNM01sWVJiMNIBsAFBVV95cUxOYkEwcjY5ejhTenZxVVRYSE9TRlR1aHRjXzhtUDNJTlZKSjE2cjNHLXJNazhrRjd1cXdza29jS09ZVDJoNlBOMTJ6TlhTbnZ6U2ZvOVJSM24xWV9OTVJlVTVleFVGdnhEaFowb3RNV3VUVkY0dE91bkxuQWtSaXI1bWJPS0thaUxVemtfcHNYd0pqT3o5d2l2aUs5SFRKZDJ3am9TbUJmcWNNM01sWVJiMA?oc=5",
    "publishedAt": "2026-02-13T11:21:21.000Z",
    "language": "en",
    "importance": 4,
    "summary": "INmune Bio, 알츠하이머 임상서 주요 규제 허들 통과. 신경염증 타깃 XPro1595 임상 진전으로 대체 기전 치료제 경쟁 확대"
  },
  {
    "id": "70741b962500",
    "title": "Alzheimer’s Detection Test Approved By FDA From Eli Lilly - Indianapolis Monthly",
    "description": "Alzheimer’s Detection Test Approved By FDA From Eli Lilly  Indianapolis Monthly",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Alzheimer%E2%80%99s%20Detectio/600/400",
    "url": "https://news.google.com/articles/CBMilgFBVV95cUxPT0xOY01fbk9WTFBOaVpOVy1oZG9SZTl2RE9yLUtpckxqSmt0SXZlYklBM0JMWVJKSU5JZTBXT2IzSmVVV043dDg4b3RZT05GNjJSZk1TbUNBdHktUWlYYUtmVjJpSHZ6R3dWRmNGTWdZVWx0cXc0UHhTUkRlV1NZeHBSVjVGZXlmRUR5TldJUTFrcmFIQlE?oc=5",
    "publishedAt": "2026-02-13T10:00:40.000Z",
    "language": "en",
    "importance": 7,
    "summary": "릴리 개발 알츠하이머 혈액 진단 검사 FDA 승인. 간편 혈액검사로 조기 진단 확대, 치료제 처방 대상 환자군 증가 기대"
  },
  {
    "id": "c4d4eb2909f1",
    "title": "New Alzheimer’s drug among those not recommended for use in Scotland - thepharmacist.co.uk",
    "description": "New Alzheimer’s drug among those not recommended for use in Scotland  thepharmacist.co.uk",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/New%20Alzheimer%E2%80%99s%20drug/600/400",
    "url": "https://news.google.com/articles/CBMiuwFBVV95cUxOaE1XUFFDakhpTjVYb0kwenE4NWMwX3QzV3VZd3daT3FOTmpXQWdZNjFRdXlCbXkydV9wMVI5d3l5d3NaaHZxMDI3VlBONGJPQzUxNl9zSnZWb09IZHpXejJEbWl5YnNNaFo1VHYyRTdjTDVzWDBJRmtEMTdCWFhCNFgwV0l5WFB0ZnBUdndCNENPd3lWQ21Lc0VQN1o2eURvY0xFRmVEbWFJUE4xMnNjc05zalZKSFpZa1lV?oc=5",
    "publishedAt": "2026-02-13T08:24:59.000Z",
    "language": "en",
    "importance": 3,
    "summary": "스코틀랜드, 일부 알츠하이머 신약 사용 비권고 결정. 유럽 시장 접근성 제한이 글로벌 치료제 매출 전망에 부분적 영향"
  },
  {
    "id": "f9a1d4b6e812",
    "title": "천안 이화병원, 알츠하이머 신약 ‘레켐비’ 치료 접근성 확대 > 뉴스 - 천안신문",
    "description": "천안 이화병원, 알츠하이머 신약 ‘레켐비’ 치료 접근성 확대 > 뉴스  천안신문",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EC%B2%9C%EC%95%88%20%EC%9D%B4%ED%99%94%EB%B3%91%EC%9B%90%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%20%EC%8B%A0%EC%95%BD%20%E2%80%98%EB%A0%88/600/400",
    "url": "https://news.google.com/articles/CBMiakFVX3lxTE5SR0M1UFppdFFuQjNRNXFsMVU2V2hDM3Uwd0VWYjk0UHNvdWtVWTRkd1czaEZldXBKTmZHZXJOTjhxZnZGTHVod3Fya1d4WFV1aHF4aDNwYVdtdVJBQ2FyTG9UYUpfOEMwUlE?oc=5",
    "publishedAt": "2026-02-13T02:33:00.000Z",
    "language": "ko",
    "importance": 7,
    "summary": "천안 이화병원 레켐비 처방 개시, 지방 거점병원까지 치료 접근성 확대. 국내 레켐비 처방 확산세가 시장 성장 가속"
  },
  {
    "id": "3cbb3fc5dec2",
    "title": "Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap - TipRanks",
    "description": "Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap  TipRanks",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Annovis%20Bio%20secures%20/600/400",
    "url": "https://news.google.com/articles/CBMiuAFBVV95cUxQeF9ON3A4enZQTmRXaTZnRHpWcTlwb2J4ZTNValVvMnlZMC1wMXU1QUg3dTV4LUlhS09zZncxa3diNzBPZXhBQUg1VE9QU1p3Qy1LRkZGS0c5ZXRnRk94RURsQzdKb0hORVdnSFplZHNiWS14ZGp2cUxWX0Q3UkNQblI3Wm1CN3hjMFpqTFJUbFZlSzNoTUpWYU9nNFlJbC1hV1VMY2hZbENiblo0MElhb0Uwa21jTzM3?oc=5",
    "publishedAt": "2026-02-13T01:52:47.000Z",
    "language": "en",
    "importance": 8,
    "summary": "애노비스 바이오 분타네탑 3상 DSMB 승인 획득, 임상 계속 진행. 다중 타깃 경구제로 AR1001과 유사 포지션 경쟁"
  },
  {
    "id": "ccd035814184",
    "title": "Beyond amyloid: Emerging drug targets for Alzheimer’s - Chemical & Engineering News",
    "description": "Beyond amyloid: Emerging drug targets for Alzheimer’s  Chemical & Engineering News",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Beyond%20amyloid%3A%20Emer/600/400",
    "url": "https://news.google.com/articles/CBMipgFBVV95cUxNbi1vd1JyOUZnYzFMTkhfMzFIVXpGXzFQLTdBSWczbndnXzIzcUNuRWs0ZXBZNkJ3aXI5ZmNRNVBSWUQtRVMzcFg5XzcwT3NfczR1NFVUNUpVVm5RbGN5ZHpoTUFQNmU1eHZqc0FIUXBqS0FOR1Bac0hLY2s1R0xtR2pzTl9tWnZZU0tQdlVaNElCbXJYTDBhM28zTmtKZXV6WjR3Qlh3?oc=5",
    "publishedAt": "2026-02-12T20:54:01.000Z",
    "language": "en",
    "importance": 5,
    "summary": "아밀로이드 너머 알츠하이머 새 약물 표적 탐색 본격화. TREM2·시냅스·신경염증 등 다양한 기전 후보군 부상"
  },
  {
    "id": "12fd3452de88",
    "title": "Azathioprine Fails to Slow Early Parkinson's Disease Progression - Docwire News",
    "description": "Azathioprine Fails to Slow Early Parkinson's Disease Progression  Docwire News",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Azathioprine%20Fails%20t/600/400",
    "url": "https://news.google.com/articles/CBMikAFBVV95cUxQQkE3ZTdUWWJud19mYTNpMXRHRUFmRnVMeWdBNGZRWWhEdDc5NXVaajFTNlk2cEI1WFRFdDZxSTJxa0V5X2E2NzhNa2pZakk2TkFrUUx6NmhoOTEyQXc4YVhuVW5XRVd0ejIwRThndzFobjFUbEVFelZsNE1aQmUyMzFnRjNjdVlmUjBoeTU0TU8?oc=5",
    "publishedAt": "2026-02-12T20:20:48.000Z",
    "language": "en",
    "importance": 1,
    "summary": "아자티오프린, 초기 파킨슨병 진행 억제 실패. 신경퇴행질환 약물 개발 난이도 확인, 알츠하이머 치료제에 간접 시사점"
  },
  {
    "id": "74e8bfaa1d3b",
    "title": "Reading Books and Writing Is Linked to a 40% Drop in Alzheimer’s Risk - ZME Science",
    "description": "Reading Books and Writing Is Linked to a 40% Drop in Alzheimer’s Risk  ZME Science",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Reading%20Books%20and%20Wr/600/400",
    "url": "https://news.google.com/articles/CBMiuwFBVV95cUxPUV9NV1QtZnNRRGZ2QWE3dndDX3g2QVh3OWwtSGMxNUhLaEVURjF5RDVWaC02bWRIQmwtS1pMSVk1b2VrY05RR1hRWm5kbzlja1N6QkRVbGIwTld1TE5kd3ZFR3FjeEtrSVhrY0trczQ3eVFsMVkyWExoR0lwSk9hczlCRUUxZ2hud2wxek5TaXpTV2UwVUlIZlBSQldIWS1zelJCVFpfTldTd1BGRGtnVTIzUW1tTlBFYnhj?oc=5",
    "publishedAt": "2026-02-12T20:00:30.000Z",
    "language": "en",
    "importance": 2,
    "summary": "독서·글쓰기 습관이 알츠하이머 위험 40% 감소와 연관. 비약물적 예방 접근법 연구로 치료제 시장 직접 영향은 제한적"
  },
  {
    "id": "876f3b355f43",
    "title": "ELI LILLY & Co SEC 10-K Report - TradingView",
    "description": "ELI LILLY & Co SEC 10-K Report  TradingView",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/ELI%20LILLY%20%26%20Co%20SEC%201/600/400",
    "url": "https://news.google.com/articles/CBMilAFBVV95cUxPckV0aEV0Q2xJVWlLV1d4cW5pd2V3VHg3ZGxPYVJHTVE3WW9wRXFpbTJzbGdjdV8weTEzQ1g1WnBLSkl1SE8tQzlKbEgxRXhkWXlBektrNXlmU2hqekppY25DOXM4Q1drejYteV9LcEEwRFNubXNjdVBHZXl0M3l4UzU1QmxpVnNBaDlrQmF1YXFPc2tj?oc=5",
    "publishedAt": "2026-02-12T19:05:01.000Z",
    "language": "en",
    "importance": 6,
    "summary": "릴리 SEC 10-K 보고서 공개, 알츠하이머 사업부 실적 상세 확인 가능. 키순라 매출 추이와 파이프라인 투자 규모 주목"
  },
  {
    "id": "9bd0f19c5bd5",
    "title": "Scientists make huge dementia breakthrough as they reveal new jab which could prevent Alzheimer's - MSN",
    "description": "Scientists make huge dementia breakthrough as they reveal new jab which could prevent Alzheimer's  MSN",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Scientists%20make%20huge/600/400",
    "url": "https://news.google.com/articles/CBMi-AFBVV95cUxQZ3daekhYUGZaWTJvLU0ydUU5UmRTdDF4MjhhZzN5cWV0cGs3Mzh5ZzRsQm51THRDU3k2Q2phNkcyTFQxMWdpa3JBd1JVR1QzZnhqbnc3ZnJQUGtmRVllU3ZKTWpHZ3AtemlwMTF3U2xMampmN0tIWDQ3X1dyQzAzM1ZsZFFYWFR0ckdDRmhBZ041NEs3T2xtZWlBRnU3XzBtSnd1MHFoTXhiZzJRWEdWcVZOOTZFdGZiZVl0UFI3Y1ctbjdFZlVpV3hJNlV2MV8yell4ZUZha0xtQzVEX3dETkJXWGNBblN2aVZWcWxGRlZzRXRrTVc2eQ?oc=5",
    "publishedAt": "2026-02-12T19:02:27.000Z",
    "language": "en",
    "importance": 4,
    "summary": "알츠하이머 예방 백신 후보물질 연구 돌파구. 아밀로이드 축적 방지 주사제 개발 진전, 장기적 시장 판도 변화 가능성"
  },
  {
    "id": "a79eaeae52a8",
    "title": "Decades-old FDA-approved drug can slow progression of Alzheimer’s - New York Post",
    "description": "Decades-old FDA-approved drug can slow progression of Alzheimer’s  New York Post",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Decades-old%20FDA-appr/600/400",
    "url": "https://news.google.com/articles/CBMinAFBVV95cUxNM1E0SGxfVW52SENhZmRqRVAtSXYyUVN3b1VXVjFRdTk0Ykt6VEJsbGxwUThZajI4ZjREODQ2UmhXeFRSQllfdUFrVDcxTEJ1dEEzSXNZdDdvNFBtQjJwS2Mzb0ZPRWt5dWdZRGQwdy11UmdLTE45b003RXdJTFlaRjV2anRYRmpHUUpvSGRUMXBnLWhiTzFEMklPRng?oc=5",
    "publishedAt": "2026-02-12T18:10:00.000Z",
    "language": "en",
    "importance": 4,
    "summary": "수십 년 전 FDA 승인 기존 약물이 알츠하이머 진행 억제 가능성 확인. 약물 재창출 접근법으로 개발 비용·기간 단축 기대"
  },
  {
    "id": "99df9b4dba92",
    "title": "It’s Never Over for Eli Lilly at the 2026 Winter Olympics - MM+M - Medical Marketing and Media - Medical Marketing and Media",
    "description": "It’s Never Over for Eli Lilly at the 2026 Winter Olympics - MM+M - Medical Marketing and Media  Medical Marketing and Media",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/It%E2%80%99s%20Never%20Over%20for%20/600/400",
    "url": "https://news.google.com/articles/CBMikwFBVV95cUxQR3k3TDJBTEoySFpwazYtY3lyd2pranBBQkYxd1JHMDJ4RTJZeXRpT2pWQk4wNnE0Rlk5by1xbXVrek1kUnljTUx0YzhpeEdDa19RVnRseHM0NVkyWEFSelcxRHhHZWRWTUZva0MwMko3SjR2d3QwY3RkV2dLSHk4bWhlZWo3c1VMa3A2NkNUbXNnWFU?oc=5",
    "publishedAt": "2026-02-12T18:01:51.000Z",
    "language": "en",
    "importance": 5,
    "summary": "릴리, 2026 동계올림픽 마케팅 대대적 투자. 알츠하이머·비만 치료제 브랜드 인지도 강화 전략, 시장 지배력 확장 의도"
  },
  {
    "id": "2f2b457ab547",
    "title": "Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance - FinancialContent",
    "description": "Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance  FinancialContent",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Alnylam%20Pharmaceutic/600/400",
    "url": "https://news.google.com/articles/CBMihgJBVV95cUxNRURDeHBOT3R5OU1rN2pHNlpJQ3pkRng1bVNEZDB4dVpoWUZpTFcxUUtpQ25uVjNVYnF2QUk3QnoxcG43aURTakxZNkFUaUZ1LTBBV1BUalFmV0xNMVo4RDMyTUFkMnNzcW9mQ3ZNV09HLWpaYndiaWNlZmVwaTZSNnp0ZDFXelNDQl92eUY5aDNEd1pNUmVMWHBtVE1qSVo2T1Y2NmE1WFZMbkR3TmxSYVdYenI0c09lR1JkNEJiWm9saV9RYTVVeU5CZXFEcjgwc29hUFkyU01mZjVrNHVrZl9mWUdHZW5LWHAzZHBqR0o1Wkt1TTZ1cHc2cDFCTHVTZ002aGVB?oc=5",
    "publishedAt": "2026-02-12T15:20:00.000Z",
    "language": "en",
    "importance": 1,
    "summary": "알닐람, RNAi 기반 심혈관 파이프라인 2026년 성장 기대. 알츠하이머 직접 관련 낮으나 RNA 치료 플랫폼 기술 동향 참고"
  },
  {
    "id": "db4daa769029",
    "title": "애노비스 바이오(ANVS), 알츠하이머병 치료제 임상 3상 시험 진행을 위한 DSMB 승인 확보 - 데이터투자",
    "description": "애노비스 바이오(ANVS), 알츠하이머병 치료제 임상 3상 시험 진행을 위한 DSMB 승인 확보  데이터투자",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%EC%95%A0%EB%85%B8%EB%B9%84%EC%8A%A4%20%EB%B0%94%EC%9D%B4%EC%98%A4(ANVS)%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4/600/400",
    "url": "https://news.google.com/articles/CBMic0FVX3lxTE5wMHVGeHJvM21YdllkSGNtTG1nTzdNODJZOU1CdlN2TXVuZlIzMDRFcmluc1RzbW9lV1JQdC1PVmlHdHR0LVdCdk5qaVJUM0VVaUtVLWltVUh1blRpRjlEMDhQbEszdXp0UW9EZjFreWF1cDA?oc=5",
    "publishedAt": "2026-02-12T14:29:47.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "애노비스 바이오 분타네탑 3상 DSMB 승인, 알츠하이머 임상 지속 결정. 경구 다중표적제로 AR1001 경쟁 포지션 주시 필요"
  },
  {
    "id": "4c865c6219da",
    "title": "INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits",
    "description": "INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial?  Stocktwits",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/INMB%20Stock%20Gained%203%25/600/400",
    "url": "https://news.google.com/articles/CBMirAFBVV95cUxQZkhQNk51UGw5d0ljQ2dkanVacEo1Y2RZdmxiR0V4YmVaRW91TV92aTF0cjBzS2E4cHJ1REo1M1h4ODdaZ0dBbmRhQ0xBZHF5cEhIbkpiYktHYlFtclU2dEJIVU9DcU01WVE4UE1mZ3RmTjVnLVVTRkdrYTQyMzlJSjJjY1dyTXRkemEzTHRPdENNcnFKcXJDeEdnRWN2bC1qbl9rd0NZellnRExO?oc=5",
    "publishedAt": "2026-02-12T12:38:09.000Z",
    "language": "en",
    "importance": 3,
    "summary": "INmune Bio 알츠하이머 임상 관련 FDA 발표 후 주가 3% 상승. 신경염증 타깃 치료제 규제 진전 시그널"
  },
  {
    "id": "e3746f3aa237",
    "title": "Labcorp launches Roche's FDA-cleared Alzheimer's blood test - Fierce Biotech",
    "description": "Labcorp launches Roche's FDA-cleared Alzheimer's blood test  Fierce Biotech",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Labcorp%20launches%20Roc/600/400",
    "url": "https://news.google.com/articles/CBMimwFBVV95cUxORmJoNVNYb18wMk1EMUNfX29GdUtMX19SWEFReGRvVXdEdlQtU1gxeG5vZERuR2xvRTN0Q0t2ZFhOdXJ5U05BMUxTQkY5RHJlbWFlM2VjTFFtS0R3cG9DODlHNUpKMmgyVV9WT00zZGFOckpqb1h5U1lac3JVMVhiVVN0eWR3aHVxYW5UbGplLWJiVE04VjRDYS1wRQ?oc=5",
    "publishedAt": "2026-02-12T12:15:00.000Z",
    "language": "en",
    "importance": 7,
    "summary": "랩코프, 로슈 개발 FDA 승인 알츠하이머 혈액검사 상용 출시. 1차 의료기관 조기 진단 보급 확대로 치료제 수요 증가 기대"
  },
  {
    "id": "a9cb43875c45",
    "title": "FDA Action Update, January 2026: Approvals, Acceptance, and Clearance - NeurologyLive",
    "description": "FDA Action Update, January 2026: Approvals, Acceptance, and Clearance  NeurologyLive",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/FDA%20Action%20Update%2C%20J/600/400",
    "url": "https://news.google.com/articles/CBMiogFBVV95cUxPMVNiRGVYUTlSTzNEVklYRHliOTBVb2hfVG5CWlhzbFBFa1NKX2Y4UUVZaVd3US15OHJxQ2pYWjkyRWktQWNPaGlhYm9EeTE5U0c0a0ZFWnM5cmZ1Z3kyM01SZHNsNkNhci1ZVm5sYlJEbU0zWG1KdmdkenRwVGhlcGpaYU43dENWcHZSQ0hxb1M0ZDVWa2U5a0VDcUpnVktNcUE?oc=5",
    "publishedAt": "2026-02-12T11:02:36.000Z",
    "language": "en",
    "importance": 1,
    "summary": "FDA 2026년 1월 승인·접수 현황 종합. 알츠하이머 관련 직접 신규 승인 없으나 규제 동향 모니터링용 참고 자료"
  },
  {
    "id": "645d3901ada7",
    "title": "한국바이오의약품협회, 알츠하이머 치료제 개발·기술이전 보고서 발간 - 헬스미디어뉴스",
    "description": "한국바이오의약품협회, 알츠하이머 치료제 개발·기술이전 보고서 발간  헬스미디어뉴스",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%ED%95%9C%EA%B5%AD%EB%B0%94%EC%9D%B4%EC%98%A4%EC%9D%98%EC%95%BD%ED%92%88%ED%98%91%ED%9A%8C%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%20%EC%B9%98%EB%A3%8C/600/400",
    "url": "https://news.google.com/articles/CBMickFVX3lxTFB0Qi01aVF5dlc3Wm5ScGlxSlpQMi11MjN6ZHl2RVNkODFvcVFfQjlXS2s2QkJEYk15ZlczRThYRUdubzZKMjN1UUgwYWMwbTFFTzJpRTZNLXNKdjI5c1B2QzcyZjRhSHIyc2JDYy1iWFoxUQ?oc=5",
    "publishedAt": "2026-02-12T07:32:41.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "한국바이오의약품협회, 알츠하이머 치료제 개발·기술이전 보고서 발간. 국내 치매 신약 파이프라인과 글로벌 경쟁력 분석"
  },
  {
    "id": "c03d5e7b3208",
    "title": "알츠하이머병 신약개발, 증상 완화에서 질병조절치료제(DMT)로 전환 - 헬스오",
    "description": "알츠하이머병 신약개발, 증상 완화에서 질병조절치료제(DMT)로 전환  헬스오",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%EB%B3%91%20%EC%8B%A0%EC%95%BD%EA%B0%9C%EB%B0%9C%2C%20%EC%A6%9D%EC%83%81%20%EC%99%84%ED%99%94%EC%97%90%EC%84%9C/600/400",
    "url": "https://news.google.com/articles/CBMiVkFVX3lxTFB6NkJRXzFqTHdxUHo5ZGtQcFM1R3pKSlNGSHNMamZ4UHJ0QmZxSTFLdmdGQ3hrWDlrSy1fU1V2M2ZBVnpZaTJCY1Vac3k3Tk9LMjVVYmF3?oc=5",
    "publishedAt": "2026-02-12T03:00:03.000Z",
    "language": "ko",
    "importance": 5,
    "summary": "알츠하이머 신약개발 패러다임, 증상 완화에서 질병조절치료제(DMT)로 전환. AR1001 포함 DMT 후보물질 가치 재평가 국면"
  },
  {
    "id": "9be2079b63fd",
    "title": "Assessment of Informal Support Provided by Caregivers at Different Stages of Alzheimer's Disease",
    "description": "In France, approximately 1,200,000 people aged 65 and over suffer from Alzheimer's disease or related disorders, of which Alzheimer's disease (AD) accounts for 70% of cases. This prevalence could double by 2050. The cognitive decline and progression to functional dependence that accompany AD are associated with a decline in quality of life, an increased risk of comorbidities, institutionalization, and mortality, as well as high care costs, placing a burden on the patient, their family and friend",
    "source": "Hospices Civils de Lyon",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Assessment%20of%20Inform/600/400",
    "url": "https://clinicaltrials.gov/study/NCT07409506",
    "publishedAt": "2026-02-12",
    "language": "en",
    "importance": 2,
    "summary": "알츠하이머 단계별 비공식 간병인 지원 평가 임상연구. 간병 부담 데이터 축적이 치료제 비용효과 분석에 활용 가능"
  },
  {
    "id": "dd81656b57ad",
    "title": "A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)",
    "description": "Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia.\n\nThe goals of this study are to learn:\n\n* If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo\n* About ",
    "source": "Merck Sharp & Dohme LLC",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/A%20Study%20to%20Evaluate%20/600/400",
    "url": "https://clinicaltrials.gov/study/NCT06721156",
    "publishedAt": "2026-02-12",
    "language": "en",
    "importance": 4,
    "summary": "MK-1167 알츠하이머 임상시험 개시. 머크의 신규 후보물질로 치매 치료제 경쟁 파이프라인에 추가, 시장 경쟁 심화"
  },
  {
    "id": "c85ff40ce6fa",
    "title": "Validation of a Digital Intervention to Rehabilitate Cognitive Resources",
    "description": "The goal of this clinical trial is to learn if the use of a digital cognitive rehabilitation system named RICORDO, that is flexible and capable of adapting the rehabilitation pathway according to the needs and capacity of the patients will prove effective for subjects with Subjective Memory Complaint or with Mild Cognitive Impairment or with Mild Dementia.\n\nThe main questions it aims to answer are:\n\nWill the RICORDO rehabilitation treatment, lead to an improvement in the global cognitive level? ",
    "source": "Fondazione Don Carlo Gnocchi Onlus",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Validation%20of%20a%20Digi/600/400",
    "url": "https://clinicaltrials.gov/study/NCT07064226",
    "publishedAt": "2026-02-12",
    "language": "en",
    "importance": 5,
    "summary": "디지털 인지재활 중재 프로그램 임상 검증 연구. 디지털치료제 유효성 입증 추세가 아리바이오 GVD-01 개발에 긍정적 참고"
  },
  {
    "id": "172a2fb09ebf",
    "title": "Alzheimer's: Anti-seizure drug helps reduce amyloid buildup in brain - Medical News Today",
    "description": "Alzheimer's: Anti-seizure drug helps reduce amyloid buildup in brain  Medical News Today",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Alzheimer's%3A%20Anti-se/600/400",
    "url": "https://news.google.com/articles/CBMirAFBVV95cUxOQy1SRUZBSEFrQ1cyMmNUbGpjWWg1V3d3bmhLTVZFZkdaY0djWmJhMWpmeUotdmxjTUJadEVWMTVBY0NYTXFTRWt6MjVhOEdsSEVnY0FHbkprMXpkZzBYMURLbWdzNG9aZTZtckdzU0VycWRlWFUxZldIaldQaW40VnlvdFBra1VHMHFUYVMtVGtJV09YRnY5Z1F4WlNNRWtaeF9sRE91RTB3cVNz?oc=5",
    "publishedAt": "2026-02-11T19:50:02.000Z",
    "language": "en",
    "importance": 5,
    "summary": "항경련제가 뇌 아밀로이드 축적 감소 효과 확인. 기존 약물 재창출 연구로 알츠하이머 치료 옵션 다양화 가능성 제시"
  },
  {
    "id": "cd56a0084443",
    "title": "Quest Diagnostics (DGX): Navigating the New Frontier of Advanced Diagnostics and AI Efficiency - FinancialContent",
    "description": "Quest Diagnostics (DGX): Navigating the New Frontier of Advanced Diagnostics and AI Efficiency  FinancialContent",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Quest%20Diagnostics%20(D/600/400",
    "url": "https://news.google.com/articles/CBMi9AFBVV95cUxQY2pkcDdRekFtOU9ZS0lFellUcVBTaGRubXJibVZCTmxwS09ybGpQUjF4UFhVb21kSzhHZmsydV8zbEF0YlphMjk2T3ZiRUVWdXBwS2l0QWl1dS1RSnNWWkFrUFBjWFp1SWppQ3ZvSW9jV3N6N2phcjJUQVB2cGRGR2FUVm5GTF9PYzlwU1M5d0lOMGdzLU9DOExYQ1Y4aVVUYmJfR2NQZDRyR1ZQdW9BWkxGeGR1RHFlaEl2c1VFVmVIWDZQbmg3SUJOcHVSTVdVSHVGNUJYZHdDcHF5TjlzWENEbXhqT1JZZGVWYlZpRmZlazhj?oc=5",
    "publishedAt": "2026-02-11T14:52:00.000Z",
    "language": "en",
    "importance": 2,
    "summary": "퀘스트 다이어그노스틱스, AI 기반 첨단 진단 사업 확장. 알츠하이머 진단 시장 성장에 간접 수혜 가능 기업으로 주목"
  },
  {
    "id": "f75f58c712ea",
    "title": "TIME100 Health: David Ricks - Time Magazine",
    "description": "TIME100 Health: David Ricks  Time Magazine",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/TIME100%20Health%3A%20Davi/600/400",
    "url": "https://news.google.com/articles/CBMiggFBVV95cUxOSEZzTjlFYUxQdzlDNkN2VW9CZ1Itd3JkVUtjUHBIcU5LaHdLZXg1UDNxa1FnbFZkR3hKYzZWYXVKNFhHRVA4LUVuMHcwcmZXdXlESHNLcGZ1T1BicWx2LXJwTDNCbUpjNVhyV0hoQ3hKTXFhMlFzQnRhS0NoakRTeTVB?oc=5",
    "publishedAt": "2026-02-11T13:05:46.000Z",
    "language": "en",
    "importance": 2,
    "summary": "릴리 CEO 데이비드 릭스 TIME100 Health 선정. 알츠하이머·비만 치료제 혁신으로 글로벌 헬스케어 리더십 인정"
  },
  {
    "id": "ab889235a342",
    "title": "Goki Ishikawa - Time Magazine",
    "description": "Goki Ishikawa  Time Magazine",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Goki%20Ishikawa%20-%20Time/600/400",
    "url": "https://news.google.com/articles/CBMie0FVX3lxTFBwVFRzeDBuMUlILXpzYU9vX1oteUhKUlhiQW1YNG80NTZpclYtcmY2MkplTkJSLUdxUWswa05CZVoyeUM2cThBSXVKdFg1UnJwRkJLa0JWeXhXREZfVHpKeHlkdDV6aER2ZTVKamFYcU5HbXhyZ1hrdHl3bw?oc=5",
    "publishedAt": "2026-02-11T13:04:06.000Z",
    "language": "en",
    "importance": 1,
    "summary": "TIME100 Health 인물 소개 기사. 알츠하이머 치료제 시장과 직접 관련성 낮은 일반 의료계 인물 조명"
  },
  {
    "id": "7e8beb77bf0e",
    "title": "New Alzheimer's blood test lets family doctors rule out disease - Stock Titan",
    "description": "New Alzheimer's blood test lets family doctors rule out disease  Stock Titan",
    "source": "Google News",
    "category": "market",
    "imageUrl": "https://picsum.photos/seed/New%20Alzheimer's%20bloo/600/400",
    "url": "https://news.google.com/articles/CBMitAFBVV95cUxNakRmSzdQRFc5cjRtT3ktOTdPVlJJX3loX0ZKcWxZX2hoTnZQRWczd0NMVm1tNUN2YzVfcGNQeDdGb1ducU91NnBYMVp0d3F5a3JlOEgzaFBQUmpfMm5hOUtYenNlR1ZoOUNlZ01wSnhzMFc5Qmkyd2k4ZXlPRFlaenVjMUsxaXFka2s1OTVIdUNRQzhHQmpDOEhmWlVuYzlodERlTUNyNTRLbDNRemlfcVdpd0Q?oc=5",
    "publishedAt": "2026-02-11T12:00:00.000Z",
    "language": "en",
    "importance": 5,
    "summary": "신규 알츠하이머 혈액검사로 1차 의료진이 질병 배제 가능. 간편 진단 보급이 치료제 처방 파이프라인 확대의 핵심 인프라"
  },
  {
    "id": "5a1599a93637",
    "title": "[인터뷰] 김상윤, 치매 연구 30년의 끝에서 ‘즐거움’을 말하다 - 디멘시아뉴스",
    "description": "[인터뷰] 김상윤, 치매 연구 30년의 끝에서 ‘즐거움’을 말하다  디멘시아뉴스",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%5B%EC%9D%B8%ED%84%B0%EB%B7%B0%5D%20%EA%B9%80%EC%83%81%EC%9C%A4%2C%20%EC%B9%98%EB%A7%A4%20%EC%97%B0%EA%B5%AC%2030%EB%85%84/600/400",
    "url": "https://news.google.com/articles/CBMickFVX3lxTE9KNmdBVEEyRmZ4QzFlN3NEQ0prSlRMTDB4QXNkSkEwc3lCYVVSSHZ4ekZ0WVNUalRMYjZnQk9DWE5YbWZoUXFFYm1tOGNOMTFUY1BjOUg0QkFrS1lMdXAxNmVjd2VHeVBlY1I0MkZ0dFE3Zw?oc=5",
    "publishedAt": "2026-02-11T06:39:37.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "치매 연구 30년 김상윤 교수 인터뷰, 한국 치매 연구의 과거와 미래 조망. 국내 임상 인프라 발전이 신약 개발에 기여"
  },
  {
    "id": "97de60b054f4",
    "title": "FDA refuses to review Moderna’s influenza vaccine - statnews.com",
    "description": "FDA refuses to review Moderna’s influenza vaccine  statnews.com",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/FDA%20refuses%20to%20revie/600/400",
    "url": "https://news.google.com/articles/CBMikAFBVV95cUxQTzgxTE9iSXRKQ0hucHQxd2FaWXJ4MzR2dFJVSkVFTUlZbmZnNm9JXzF4QVFSSV9LZmdQVXdxYmlaeG1zRWxFRjloWElyVzY1QWFGVlFTVnA3SHo0enNEZHN6cWhwMmVJUXgxeWdad2dyY2dVZm1xZmozNXZxQVQ2RG5wV3RVZXJfLXdxalVPZ2s?oc=5",
    "publishedAt": "2026-02-10T23:02:08.000Z",
    "language": "en",
    "importance": 1,
    "summary": "FDA, 모더나 인플루엔자 백신 심사 거부. 알츠하이머 분야와 무관하나 FDA 심사 기조 참고용"
  },
  {
    "id": "fa610b9c8b6a",
    "title": "MNA-001",
    "description": "Muna Therapeutics              MTX46943              Small Molecule              Inflammation              \nIn September 2025, a Phase 1 trial began testing MNA-001’s safety, tolerability, and pharmacokinetics in 112 healthy young and older men and women. This open-label, single- and multiple-ascending-dose study will collect CSF and plasma to monitor TREM2 activation and changes in candidate biomarkers. The study, in the Netherlands, is expected to finish in July 2026.\nMNA-001 is an oral, small",
    "fullContent": "Muna Therapeutics              MTX46943              Small Molecule              Inflammation              \nIn September 2025, a Phase 1 trial began testing MNA-001’s safety, tolerability, and pharmacokinetics in 112 healthy young and older men and women. This open-label, single- and multiple-ascending-dose study will collect CSF and plasma to monitor TREM2 activation and changes in candidate biomarkers. The study, in the Netherlands, is expected to finish in July 2026.\nMNA-001 is an oral, small molecule agonist of the immune receptor TREM2 on microglia. The company claims that it is brain-penetrant. TREM2 activation stimulates proliferation and phagocytic function of microglia, which play a central role in Alzheimer's disease pathology. Genetic variation in TREM2 is linked to AD (see TREM2 Mutations), whereby reductions in receptor activity increase risk. Multiple TREM2 agonist antibodies and small molecules are being tested for their ability to spur phagocytosis and clearance of Aβ and treat Alzheimer's disease.\nNo preclinical work is published for MNA-001, but data was presented at the 2025 CTAD conference (Dec 2025 news). In human iPSC-derived microglia, MNA-001 activated TREM2 signaling at nanomolar concentrations, and induced a phagocytic phenotype. Activation occurred by incuding TREM2/DAP12 receptor dimerization and stabilization, without receptor cleavage or internalization. MNA-001 did not bind to the soluble TREM2 receptor fragment. In 5xFAD/hTREM2 knock-in mice MNA-001 significantly decreased brain amyloid, plasma soluble TREM2, and the inflammation marker GFAP.\n          \n          Alzheimer's Disease              Phase 1    \n    \n          Breaking News    \nReferences\nMutation Interactive Images Citations\nTREM2 6 Feb 2018\n              \n    \n                    \nNews Citations\nInflammatory Targets at CTAD: Some Old, Some New 23 Dec 2025\n              \n    \n                    \nResearch Models Citations\nTREM2, humanized (common variant) X 5XFAD              \n    \n                    \nExternal Citations\nPhase 1 trial\n              \n    \n            \n          10 Feb 2026",
    "source": "Alzforum",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/MNA-001/600/400",
    "url": "https://www.alzforum.org/therapeutics/mna-001",
    "publishedAt": "2026-02-10T20:51:39.000Z",
    "language": "en",
    "importance": 1,
    "summary": "MNA-001 임상시험 등록 정보. 알츠하이머 관련 구체적 내용 미확인, 초기 단계 파이프라인 모니터링 대상"
  },
  {
    "id": "433aaea6dc70",
    "title": "Houston biotech co. raises $11M to advance ALS drug development - InnovationMap",
    "description": "Houston biotech co. raises $11M to advance ALS drug development  InnovationMap",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Houston%20biotech%20co.%20/600/400",
    "url": "https://news.google.com/articles/CBMihgFBVV95cUxPb1dLUmxDWkhVTW5hLV9UNDFyRGJaQWtRYTNmUk1NY1g4cW85NDlLalhWRUhCakdNXzR5NjgyRlkycG5ybzBDUXhXa21vTHNzcTlVTFVRRUcwazZpa2pBaFV2YTJnRDd5aVNzaG4yMEJoMFozZmVxeXdrV1AyVURhdGVhSDBYdw?oc=5",
    "publishedAt": "2026-02-10T14:36:49.000Z",
    "language": "en",
    "importance": 1,
    "summary": "휴스턴 바이오텍, ALS 신약 개발 위해 1100만 달러 자금 조달. 신경퇴행질환 투자 심리 건재, 알츠하이머와 간접 연관"
  },
  {
    "id": "17a4b21147dc",
    "title": "치매 관련주 TOP15 | 알츠하이머 치료제 대장주 - 브런치",
    "description": "치매 관련주 TOP15 | 알츠하이머 치료제 대장주  브런치",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EC%B9%98%EB%A7%A4%20%EA%B4%80%EB%A0%A8%EC%A3%BC%20TOP15%20%7C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8/600/400",
    "url": "https://news.google.com/articles/CBMiSkFVX3lxTE5RWEN0bFptOWJ1RW00MTdkanJfYlZLWF80OHktZU5kNlBvRmtrUFBaYVJhQkxqMFk1V25ZYjVyemtieDhDNENQY19B?oc=5",
    "publishedAt": "2026-02-10T14:02:03.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "치매 관련주 TOP15 정리, 알츠하이머 치료제 시장 테마 투자 종목 분석. 아리바이오 포함 국내 치매 관련 투자처 조망"
  },
  {
    "id": "4a4b2efba09d",
    "title": "에자이·바이오젠, 레켐비 피하주사 中 NMPA 우선심사 지정 - 메디코파마",
    "description": "에자이·바이오젠, 레켐비 피하주사 中 NMPA 우선심사 지정  메디코파마",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EC%97%90%EC%9E%90%EC%9D%B4%C2%B7%EB%B0%94%EC%9D%B4%EC%98%A4%EC%A0%A0%2C%20%EB%A0%88%EC%BC%90%EB%B9%84%20%ED%94%BC%ED%95%98%EC%A3%BC%EC%82%AC%20%E4%B8%AD/600/400",
    "url": "https://news.google.com/articles/CBMickFVX3lxTFB2MlVseEVJeUJsV0c4MmdTV0xCSnJTYlcwOUlqcmlJQWFXVlpCcDZkVERQanRKTm9iX21IbkZJODJaZk9VRllxM3I4X3FNVWM3d0doNDB1dzlOQmNwUWw5RC1IaDZfa2xTNkFFNzFWcDNhQQ?oc=5",
    "publishedAt": "2026-02-10T07:31:05.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "에자이·바이오젠, 레켐비 피하주사 중국 NMPA 우선심사 지정. 중국 시장 진입 가속으로 글로벌 매출 성장 동력 확보"
  },
  {
    "id": "7a306b0a9fc9",
    "title": "FDA 승인 받았다더니, 알고 보니 클리어런스? - 디멘시아뉴스",
    "description": "FDA 승인 받았다더니, 알고 보니 클리어런스?  디멘시아뉴스",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/FDA%20%EC%8A%B9%EC%9D%B8%20%EB%B0%9B%EC%95%98%EB%8B%A4%EB%8D%94%EB%8B%88%2C%20%EC%95%8C%EA%B3%A0%20%EB%B3%B4%EB%8B%88%20/600/400",
    "url": "https://news.google.com/articles/CBMickFVX3lxTE1yeXBEMlhuWWoydzk3RF9HR3FMamZ1M3RFdGZIZE16aVVMMEE1UEM2WHZyd2J1YlhzODNCMlp0TUFqamxtX2RJaTFaNFQ4VEU1ZDR5OW02OEpKY2dLbGpEV1ptYVhMZXBPNmZFTTg1NWNGZw?oc=5",
    "publishedAt": "2026-02-10T01:24:50.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "FDA 승인과 510(k) 클리어런스 차이 해설. 알츠하이머 관련 의료기기·진단 제품의 정확한 규제 경로 이해에 필수"
  },
  {
    "id": "699902148712",
    "title": "Key facts: Analysts Boost Biogen Price Targets; Profit Outlook Improves; Leqembi Review Accelerated - TradingView",
    "description": "Key facts: Analysts Boost Biogen Price Targets; Profit Outlook Improves; Leqembi Review Accelerated  TradingView",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/Key%20facts%3A%20Analysts%20/600/400",
    "url": "https://news.google.com/articles/CBMi7wFBVV95cUxPbzBxekw0RURscG8yMFp6MXRFMXQ4SUFMX3gwa0hOU3VvZDhrbTBPVG1xSmhxd0JtZWkxV3dYNGxIMmFnUF9IbFk5WUp0d1VrWkwtQkZFSmNwUGNYRFdVVmlRQlJySlFGd1MzM1BwOTNuV0dVZkVlRWFSWTBjOHFTYlE5V3NqZ0FJbDNOLW5tSjBhMk40Y3NTWFJrTEFxVWZCRGtYUm1ZMmpxZHJsUzJOeHpDemZGLWx6ZEZTQlJtenY2RlRKR3Z2aXVNODRfM2VGbWFoeFVTRnE4bmRyRmpaaV8xb2tMUFN3bVRFaF9Bdw?oc=5",
    "publishedAt": "2026-02-09T20:03:45.000Z",
    "language": "en",
    "importance": 8,
    "summary": "바이오젠 목표가 상향, 레켐비 매출 성장·연간 이익 전망 개선. 알츠하이머 치료제 시장 기대감이 주가에 본격 반영"
  },
  {
    "id": "bfae4a033020",
    "title": "에자이 2025 회계연도 3분기, 레켐비 매출 109% 성장, 전략적 항암 투자 By Investing.com - Investing.com 한국어",
    "description": "에자이 2025 회계연도 3분기, 레켐비 매출 109% 성장, 전략적 항암 투자 By Investing.com  Investing.com 한국어",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EC%97%90%EC%9E%90%EC%9D%B4%202025%20%ED%9A%8C%EA%B3%84%EC%97%B0%EB%8F%84%203%EB%B6%84%EA%B8%B0%2C%20%EB%A0%88/600/400",
    "url": "https://news.google.com/articles/CBMicEFVX3lxTFBOVXZvc3hWSkE4Sk5iUlQ1SXVrUEVXZFdCeXNyeUVxUXg3Mm15c1JaR3ZELTBHcXFYUDBfWks0Zll1T2l3VE1La1VHazlzRXNDWFRVd05DcFVNSVM1eHViY2hpTWFYRHhHY21rQkRLc3M?oc=5",
    "publishedAt": "2026-02-09T14:29:00.000Z",
    "language": "ko",
    "importance": 9,
    "summary": "에자이 3분기 레켐비 매출 109% 성장 기록, 분기 매출 역대 최고. 글로벌 알츠하이머 치료제 시장 급성장 입증"
  },
  {
    "id": "3fdc42f02cc3",
    "title": "Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions - BioSpace",
    "description": "Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions  BioSpace",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/Biogen%E2%80%99s%20Much%20Antici/600/400",
    "url": "https://news.google.com/articles/CBMiuAFBVV95cUxNS19VdHBSbUR0MWFKQjYycUROYi1nMDZmZVk0N3NCNXJiVzg5d1YzQkpoaWhPWE9YZGJvWlJKajNSRFNNMFZ0aE5ZS2dFY182WUh4VjNxdHkyb19FeGU5amhNT1pJXzFYSDdsS0lNRlN6Zk1iWm8xeHhtcVFNTFVPTXVuNjBEcWVIMmhNRlg0RGxrQ2czUFpOcXRFb3ZFM0pLN1pGRkx0TEdfZ0NZa2xqNkMwdUVKQWdW?oc=5",
    "publishedAt": "2026-02-09T13:24:20.000Z",
    "language": "en",
    "importance": 7,
    "summary": "바이오젠 타우 표적 알츠하이머 임상 데이터 발표 예정, 시장 주목. 아밀로이드 이후 차세대 기전 경쟁의 분수령"
  },
  {
    "id": "9302069055c2",
    "title": "2025's top 10 clinical trial flops - Fierce Biotech",
    "description": "2025's top 10 clinical trial flops  Fierce Biotech",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/2025's%20top%2010%20clinic/600/400",
    "url": "https://news.google.com/articles/CBMie0FVX3lxTE56ZW4wOThDQmJaMVYwN3F0NG9Mcm9JdkNkZFhBcjF1SnVEMWllYUNmUHlsLVJYeTRvZllPaDNVNmZ0QWtTOXdhdHJnM1dXN3Zfd3BodkV1dG82SEtNdWhNbFFUX1dhMzJtLUpXNVZCeHhvM3ZrVFlWcDF2MA?oc=5",
    "publishedAt": "2026-02-09T08:00:00.000Z",
    "language": "en",
    "importance": 5,
    "summary": "2025년 임상시험 실패 Top 10 분석. 알츠하이머 포함 다수 뇌질환 임상 좌초로 성공 후보물질 희소가치 상승"
  },
  {
    "id": "310188c1a9ca",
    "title": "\"올 신약 최대 격전지는 뇌질환 치료제\" - 한국경제",
    "description": "\"올 신약 최대 격전지는 뇌질환 치료제\"  한국경제",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%22%EC%98%AC%20%EC%8B%A0%EC%95%BD%20%EC%B5%9C%EB%8C%80%20%EA%B2%A9%EC%A0%84%EC%A7%80%EB%8A%94%20%EB%87%8C%EC%A7%88%ED%99%98%20%EC%B9%98%EB%A3%8C/600/400",
    "url": "https://news.google.com/articles/CBMiWkFVX3lxTE9zQ0FuaDFrMXk5XzY2X2FhM1lNWGJhRDF5WWdDUFFlZXhfLVpxdF80Z3k3ZVU5SnBWR0ZvRldhN1dfOVlja0wxbzU1MmtvdTI5M3M1SHlUaXoyZ9IBVEFVX3lxTE9mSzNOSUtiUjEtZkwwOE96Mnc5WTJoZVhpNkdLeEgzQ3ZCYm9Mbm95Z1Q2ZllrNzdxQ0dmOG9pSW1MclFmeDN5NmFhM2htaG5TNGNGMQ?oc=5",
    "publishedAt": "2026-02-09T08:00:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "2026년 신약 최대 격전지로 뇌질환 치료제 부상. 알츠하이머·파킨슨 등 CNS 분야 글로벌 경쟁 격화 전망"
  },
  {
    "id": "e3bc888b8e80",
    "title": "온병원 “디지털 PET-CT로 암부터 치매·파킨슨까지” - 일요신문",
    "description": "온병원 “디지털 PET-CT로 암부터 치매·파킨슨까지”  일요신문",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EC%98%A8%EB%B3%91%EC%9B%90%20%E2%80%9C%EB%94%94%EC%A7%80%ED%84%B8%20PET-CT%EB%A1%9C%20%EC%95%94%EB%B6%80%ED%84%B0/600/400",
    "url": "https://news.google.com/articles/CBMiZkFVX3lxTE5ZeXlnVkJYOE5XRVh6OXpZdEpGQjlVZWk0aXUwYlByek4zU3VhNGkwQUdZQ2V6SHlGeXhvR04xbFFmdHFxRXBrenBEcE1Eb2V4RjU2cVJVTEgyUVRXeExDeGktNkNkQQ?oc=5",
    "publishedAt": "2026-02-09T07:08:11.000Z",
    "language": "ko",
    "importance": 2,
    "summary": "온병원, 디지털 PET-CT로 암·치매·파킨슨 정밀진단 시행. 국내 치매 영상진단 인프라 확대, 치료제 접근성 개선 기여"
  },
  {
    "id": "795894c722d3",
    "title": "BioArctic’s Partner Eisai Wins Priority Review in China for At-Home Leqembi Alzheimer’s Injection - TipRanks",
    "description": "BioArctic’s Partner Eisai Wins Priority Review in China for At-Home Leqembi Alzheimer’s Injection  TipRanks",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/BioArctic%E2%80%99s%20Partner%20/600/400",
    "url": "https://news.google.com/articles/CBMi4AFBVV95cUxQNHNwM3lSWUtwTGNDaTF4OTJ4dlFObnRia09nOFNEMXV6LWR5bURFWEZ2cTJicU5kNkJqVkFiRVBoNFRGSDJTOGFxMjA0VzlXSHo4Q3dJWEQ5d0thM2ZGT3Z1amNQbEV1T3ZQXzhIME9OX0xoQTV4bkM1VTZNU0VESktKbWhkWmloR1hXampTOTJTS0loSzh6Y2VQUlhkWFBuNUFfN19JZGxNRVhsODlmemwzcU9mNjRqU3ZtZmZUVlJ5VEoxcUE4ZnBIU29jS2JWTUxydjBfR1lfTVl1ekV4UQ?oc=5",
    "publishedAt": "2026-02-09T06:06:37.000Z",
    "language": "en",
    "importance": 8,
    "summary": "에자이 파트너 바이오아크틱, 레켐비 자가주사제 중국 우선심사 획득. 자가투여 편의성이 시장 확대의 핵심 동력"
  },
  {
    "id": "266103cc658a",
    "title": "Commissioner's National Priority Voucher (CNPV) Pilot Program - fda.gov",
    "description": "Commissioner's National Priority Voucher (CNPV) Pilot Program  fda.gov",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Commissioner's%20Natio/600/400",
    "url": "https://news.google.com/articles/CBMikAFBVV95cUxQUWk0TnM5QUY4aEM2SlItbjczWDRQRGQ0c1dMTmNRdnZxSGdmZk9oRk9DRG9TQkx0d3lzZWQtbngzWGlTcnRYbDZQeS0tSXFieHhFQzZ5LVRzN2xiMFV5akl4Ymh5aVpMWmQxbTRXVE5Lbk1nd0d5QS1KTEtTQlN2YWl6Tk1oeEtuSVRSM0lCLUY?oc=5",
    "publishedAt": "2026-02-09T00:00:00.000Z",
    "language": "en",
    "importance": 2,
    "summary": "FDA 커미셔너 국가우선 바우처(CNPV) 시범 프로그램 공개. 신약 개발 인센티브 제도로 치매 치료제 개발 촉진 가능"
  },
  {
    "id": "f3eeba78e398",
    "title": "Use of Socially Assistive Robots for Long Term Care Older Adults With Cognitive Impairment and Apathy",
    "description": "The objective of this study is to demonstrate the impact of a socially assistive robot system on reducing apathy among cognitively impaired older adults residing in long term care facilities. Earlier phases of this project demonstrated the feasibility and acceptability of the robotic system. First, investigators will improve the social robotic interaction architecture through additional software development, enhance its versatility, and make it easy for non-experts to run. Second, 188 participan",
    "source": "Vanderbilt University",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Use%20of%20Socially%20Assi/600/400",
    "url": "https://clinicaltrials.gov/study/NCT05178992",
    "publishedAt": "2026-02-09",
    "language": "en",
    "importance": 1,
    "summary": "인지장애 노인 장기요양에 사회보조 로봇 활용 임상연구. 비약물적 개입 연구로 치료제 시장 직접 영향은 제한적"
  },
  {
    "id": "865536f447ab",
    "title": "Biologics License Application for Subcutaneous Formulation - GlobeNewswire",
    "description": "Biologics License Application for Subcutaneous Formulation  GlobeNewswire",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Biologics%20License%20Ap/600/400",
    "url": "https://news.google.com/articles/CBMi2gJBVV95cUxOTEpMZGxtNTRrS2w2SFhhbjk1WnRyM01yb3c2aURaQWowdDk2YVBZUy1EblJEUXVGNkRmbXVsY3hYWGYwN0J5R1NROHZ0cU1XcHYyUHFpX01kUFZmZW1aU09UV2RMSDd1WVBNOEJZQUxIX1dkeTlDU2ZfbzBCTnRKWkxIYnhtWjFOU05jaV9kLTJsRFQwTmhNbnFKNmVtYjQ2RnpTZXg3eXZPN3NVRGlITWRob09ILV81eHkxZFJqMUxCTmVRSExNdVlERmFzeTVmSWRrRXJwdXFsd3NBRWR1S29taDNmOUpfSnZYa3o4OVM5SmFxdk5IbDk1alFvZGVrWW5KV09pV1ZlWFFiVWs0TmtjbU83eEk5V1BsR0FBdEUyWUdrM3dGVG9PMzU2dW52WTgybDZVTVdDYllERFlBV3ZYY0lsMGk1Wmszcl8tNmRzVzR1M3R4c2V3?oc=5",
    "publishedAt": "2026-02-08T08:00:00.000Z",
    "language": "en",
    "importance": 5,
    "summary": "레켐비 피하주사 제형 생물학적 제제 허가 신청(BLA) 관련 보도. 투여 편의성 향상으로 환자 접근성 대폭 개선 기대"
  },
  {
    "id": "64a5945488b2",
    "title": "Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump - Yahoo Finance",
    "description": "Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump  Yahoo Finance",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/Biogen%20Hits%2052-Week%20/600/400",
    "url": "https://news.google.com/articles/CBMiekFVX3lxTE9EY2FEbUFseXJuNWtFNWRpMEcxVDlNNlRnSExYRTlOaEctMVVVV3d1OTJWcEJWQ1NKRUo2eDV0a1BfeVctYThlMVBWQWpaX2tpMmJucTJYemFhbV9uV2pKV1FNbDdhTWlUcGR1LTdiQjVpbFZFT2ZRN0VB?oc=5",
    "publishedAt": "2026-02-08T08:00:00.000Z",
    "language": "en",
    "importance": 7,
    "summary": "바이오젠 주가 52주 최고가 경신, 알츠하이머 약 매출 급증 견인. 레켐비 상업적 성공이 치매 치료제 섹터 전반 상승 유도"
  },
  {
    "id": "d1336ff2cce2",
    "title": "온병원, ‘디지털 PET-CT’로 노인 3대 질환 정밀 진단 시대 연다 - sports.donga.com",
    "description": "온병원, ‘디지털 PET-CT’로 노인 3대 질환 정밀 진단 시대 연다  sports.donga.com",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EC%98%A8%EB%B3%91%EC%9B%90%2C%20%E2%80%98%EB%94%94%EC%A7%80%ED%84%B8%20PET-CT%E2%80%99%EB%A1%9C%20%EB%85%B8/600/400",
    "url": "https://news.google.com/articles/CBMickFVX3lxTE91WVQ3Yk9EcXhPM2JkZmlHa3VSVlBGWEFrdjdHdF90NlZEZTlUZ29RRlJORWZXNU12N0YzbFNNQ193Rm5wT25QTi1iMkVRZFJOV0lEYVdfSDE1RHIxaWNaTnBoamxVRnJxbmZtN0doVmhFQQ?oc=5",
    "publishedAt": "2026-02-08T05:29:06.000Z",
    "language": "ko",
    "importance": 2,
    "summary": "온병원 디지털 PET-CT 도입, 노인 3대 질환 정밀진단. 치매 진단 기술 고도화가 치료제 조기 처방 확대에 기여"
  },
  {
    "id": "fc1684fc7af0",
    "title": "“우린 치료비 3600만원, 우린 1억원까지” 100만 치매 시대 보험경쟁 점입가경 - v.daum.net",
    "description": "“우린 치료비 3600만원, 우린 1억원까지” 100만 치매 시대 보험경쟁 점입가경  v.daum.net",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%E2%80%9C%EC%9A%B0%EB%A6%B0%20%EC%B9%98%EB%A3%8C%EB%B9%84%203600%EB%A7%8C%EC%9B%90%2C%20%EC%9A%B0%EB%A6%B0%201/600/400",
    "url": "https://news.google.com/articles/CBMiVEFVX3lxTFBpZk5DdThZVWFCaFhXWXgxTGw4YnlkY29PUl9xdGFjYmZIUjZXSEd5OUl1eDlGWEg2aE5jaXRZR3B2ZmJuX0JnZ2xBMi1LNy00TTVFZQ?oc=5",
    "publishedAt": "2026-02-07T02:01:32.000Z",
    "language": "ko",
    "importance": 5,
    "summary": "치매 치료비 보험 경쟁 심화, 보장액 3600만~1억 원 수준. 보험 보장 확대가 고가 치료제 처방 장벽 낮춰 시장 성장 촉진"
  },
  {
    "id": "81876421bed9",
    "title": "Tackling the brain: Why GLP-1s may be the MVP for CTE - MDLinx",
    "description": "Tackling the brain: Why GLP-1s may be the MVP for CTE  MDLinx",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Tackling%20the%20brain%3A%20/600/400",
    "url": "https://news.google.com/articles/CBMiqAFBVV95cUxPTUFCR2UydjB2T3QxVVJQV0tlbmV0X1JheW1WWmRGUVVDSDZqSFJod0dxb241c0pSb3ZNaGR1WWMyUDJmQ2VrQnB6Mkl4Ym0tZE1oYlJRNWIzQVJZbUFWZVhNd3YwTF9BUU4temh3MjVRWmV1R3REUWQ5MC1pM0I3WWhhYW9UeU4yV3BINWRTX3FZOEFmYW85WDB0R1JXcGQzRnRBdjg1WkE?oc=5",
    "publishedAt": "2026-02-06T19:37:34.000Z",
    "language": "en",
    "importance": 2,
    "summary": "GLP-1 수용체 작용제의 만성외상성뇌병증(CTE) 치료 가능성 탐색. 알츠하이머 적용 가능성도 연구 중이나 초기 단계"
  },
  {
    "id": "1cc8ad2e8109",
    "title": "바이오젠, 알츠하이머 치료제 고성장·연간 가이던스 상향…주가 5%↑ - 마켓인",
    "description": "바이오젠, 알츠하이머 치료제 고성장·연간 가이던스 상향…주가 5%↑  마켓인",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EB%B0%94%EC%9D%B4%EC%98%A4%EC%A0%A0%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%20%EC%B9%98%EB%A3%8C%EC%A0%9C%20%EA%B3%A0%EC%84%B1%EC%9E%A5%C2%B7/600/400",
    "url": "https://news.google.com/articles/CBMic0FVX3lxTE9QMENCTjFmak1xWnlLWnJ0VndaVHRiSldjb0JRZUVNcGk2Z2R3SjM1SE1WMFlnaEc0aFhYRkYzRlE2MXRmSTh4YWh0d2NtcV8xU0p2MHhuRVM4LVgtWE5MamV0cExJN2QwZk5rV3NKWnlSWTQ?oc=5",
    "publishedAt": "2026-02-06T17:27:24.000Z",
    "language": "ko",
    "importance": 7,
    "summary": "바이오젠, 알츠하이머 치료제 고성장·연간 가이던스 상향. 레켐비 매출 호조로 주가 5% 상승, 시장 기대 충족"
  },
  {
    "id": "86d227a5cc2e",
    "title": "뉴로펫, 알츠하이머 영상 소프트웨어 FDA 승인 획득 By Investing.com - Investing.com 한국어",
    "description": "뉴로펫, 알츠하이머 영상 소프트웨어 FDA 승인 획득 By Investing.com  Investing.com 한국어",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%EB%89%B4%EB%A1%9C%ED%8E%AB%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%20%EC%98%81%EC%83%81%20%EC%86%8C%ED%94%84%ED%8A%B8%EC%9B%A8%EC%96%B4%20/600/400",
    "url": "https://news.google.com/articles/CBMicEFVX3lxTE5zekl4QnR3Z3I3SHRyWThfOHFtYWhVYlNvUU1kTlZPQXAwSk9seDZOeEpDdm90ZDlwMERmT2hnaDZqUkNZNjFqMmNPaVNlUDdsdkNmR3VGa2YzLW9TM1FRRmp0eWtXcjhPYU5DTFltUGw?oc=5",
    "publishedAt": "2026-02-06T14:06:00.000Z",
    "language": "ko",
    "importance": 7,
    "summary": "뉴로펫 알츠하이머 영상 AI 소프트웨어 FDA 승인 획득. 치매 진단 AI 국내 기업 글로벌 시장 진출 성과"
  },
  {
    "id": "b221ea1d35f5",
    "title": "바이오젠, 레켐비 매출 증가로 예상치를 상회하는 연간 이익 전망 - TradingView",
    "description": "바이오젠, 레켐비 매출 증가로 예상치를 상회하는 연간 이익 전망  TradingView",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EB%B0%94%EC%9D%B4%EC%98%A4%EC%A0%A0%2C%20%EB%A0%88%EC%BC%90%EB%B9%84%20%EB%A7%A4%EC%B6%9C%20%EC%A6%9D%EA%B0%80%EB%A1%9C%20%EC%98%88%EC%83%81%EC%B9%98/600/400",
    "url": "https://news.google.com/articles/CBMif0FVX3lxTE52VHJIY0Y1RlY4TER6NWFoTzRmNG43UEJOelNPT29HamZBbmtuVkViOWpXMGlMVUZsSnQtRlM2NXVrSThKSHQ1S29HemxPb3UyaGRULUNvbnpYcjhkOEVOa1ZRdzdJaGV2Q1FFOURnTnpWNHhvWnYtUk14bHpZRmM?oc=5",
    "publishedAt": "2026-02-06T11:02:44.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "바이오젠, 레켐비 매출 증가로 연간 이익 전망 시장 예상 상회. 알츠하이머 치료제 상업화 궤도 안착 확인"
  },
  {
    "id": "a4ef2e46ca56",
    "title": "BioArctic: Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 - Finansavisen",
    "description": "BioArctic: Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025  Finansavisen",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/BioArctic%3A%20Sales%20of%20/600/400",
    "url": "https://news.google.com/articles/CBMi_wFBVV95cUxNUmw3aGlCWkp5X3piVFpFQk81eVl3YXo3dTd3Zl81WkRVZGNFWmJGb0xBdktPSXVBM0trZ2RnZkQxSzhkbkdoT1ZSa3FiTElSbkhYem56ZlZ6d1htNXU4Y3l2RkNpUWJxa1N2b0k3REJiei1zdW5jT0EtY2tvbWRfeFVveGtjY2kydENCeHpIcWlzclgxblVwUXhZNXkwWGFydVNPRzV5TmNfbTduUFhuY2dRZ05IWWhwSU4ybV92V21SZXVXWkx2Q3N6QjBubS1QWXJibUtiRVNmckIwMU5qS1dzZFBzTnJyQ1BIb0RVLTN6bTNaWXZQUDVpWjBUVTg?oc=5",
    "publishedAt": "2026-02-06T08:00:00.000Z",
    "language": "en",
    "importance": 8,
    "summary": "바이오아크틱, 레켐비 4분기 매출 207억 엔 달성. 글로벌 누적 매출 급성장으로 알츠하이머 블록버스터 입증"
  },
  {
    "id": "5ad013f2730f",
    "title": "‘레켐비’ 치료 시대...손보사 ‘표적치매약물 허가치료비’ 보장 흐름 변화 (영상+) - 보험저널",
    "description": "‘레켐비’ 치료 시대...손보사 ‘표적치매약물 허가치료비’ 보장 흐름 변화 (영상+)  보험저널",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%E2%80%98%EB%A0%88%EC%BC%90%EB%B9%84%E2%80%99%20%EC%B9%98%EB%A3%8C%20%EC%8B%9C%EB%8C%80...%EC%86%90%EB%B3%B4%EC%82%AC%20%E2%80%98%ED%91%9C/600/400",
    "url": "https://news.google.com/articles/CBMib0FVX3lxTE5DOC1ZSFFzaWN4T0lFTHFjMUUyamNYeGVuRWx3eGY1VUJvUjdfQVg1OVNJVjZ0SmpQQ2pFZS01SXJxUXd4TUl4Y25DVDdKcFhDZWJGbk5STEJ6RW1LbHBvTHRBenZxaVpzZEpLNlo5dw?oc=5",
    "publishedAt": "2026-02-06T08:00:00.000Z",
    "language": "ko",
    "importance": 7,
    "summary": "레켐비 치료 시대 개막에 손보사 표적치매 약물치료비 보장 상품 속속 출시. 보험 급여가 치료제 접근성 핵심 변수"
  },
  {
    "id": "d9bda7f84b11",
    "title": "\"오래 살수록 수십조 증발\"…금융시장 뒤흔든 '장수 리스크' [글로벌 머니 X파일] - 한국경제",
    "description": "\"오래 살수록 수십조 증발\"…금융시장 뒤흔든 '장수 리스크' [글로벌 머니 X파일]  한국경제",
    "source": "Google News",
    "category": "market",
    "imageUrl": "https://picsum.photos/seed/%22%EC%98%A4%EB%9E%98%20%EC%82%B4%EC%88%98%EB%A1%9D%20%EC%88%98%EC%8B%AD%EC%A1%B0%20%EC%A6%9D%EB%B0%9C%22%E2%80%A6%EA%B8%88%EC%9C%B5%EC%8B%9C%EC%9E%A5/600/400",
    "url": "https://news.google.com/articles/CBMiWkFVX3lxTE5BMEl0VVV1M1pLd2xDcW1fcE45TzBEM1FjYkRUZ2NsZ1k5MkF0Y1o1QjFJT3lfdUVZZUFGMWhNY0xyeFlwazV5WXFnXzllc1MyYXo3OGhNOHpjUdIBVEFVX3lxTFBuWUoyTFdCTmRnNmFnczBzQjBVNmtnNEpZRDR6eWYtR2JtRUtBenNEbXhHLVJSR3BlWXNxSnhtUzBGYVN4VURLbXpNcEdPYlBJSzZnYg?oc=5",
    "publishedAt": "2026-02-06T08:00:00.000Z",
    "language": "ko",
    "importance": 2,
    "summary": "금융시장 '장수 리스크' 조명, 치매 등 노인질환 비용 증가가 재정 부담. 치료제 시장 장기 성장 동인 확인"
  },
  {
    "id": "0c0481a95701",
    "title": "Wins and losses: Mapping the GLP-1 receptor’s path - MDLinx",
    "description": "Wins and losses: Mapping the GLP-1 receptor’s path  MDLinx",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Wins%20and%20losses%3A%20Map/600/400",
    "url": "https://news.google.com/articles/CBMipgFBVV95cUxQeXV5VnpvRV9qamIyOFprRjhsaHdUMmYzTThlQWV0WkExMm10cFhEd1Zjb1UxZ2sybVA0QUpmWExXNGpMNUhDU3d2blk0elU2Yl9kS3BmZWRUdWpxOTBZUVJac2lEVlY2b0sxSm9RMUdRa2NpT2pDaVFXUHd6aW5qM3FlVkZSVWVQRjZZdl9heFpxQU1CeVh3Nm5ieVFkUjJmQnBwY1lR?oc=5",
    "publishedAt": "2026-02-06T08:00:00.000Z",
    "language": "en",
    "importance": 2,
    "summary": "GLP-1 수용체 작용제 성과와 한계 종합 분석. 체중감량 이후 알츠하이머 등 적응증 확장 시도 결과 혼재"
  },
  {
    "id": "df20e367589d",
    "title": "Upstate experts celebrate milestone in Alzheimer's, dementia research - WYFF News 4",
    "description": "Upstate experts celebrate milestone in Alzheimer's, dementia research  WYFF News 4",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Upstate%20experts%20cele/600/400",
    "url": "https://news.google.com/articles/CBMijgFBVV95cUxOdHVQVGZ3dFNubWlCRXcwNEFXdWRfOE9WbUlWdXczUHNySXU3RV9kQTUxdWFZSjlTOW9TUi1SamR1MlRmUlljSlNLMmNWN281dDNZY08wQjhuTG5UTUlNMzlZcnBCdkd1MEFxWDU5SzR1RXNVSzVvaFhjdmZMOW1mVUlZbG5ETHo4UTh6aFZ3?oc=5",
    "publishedAt": "2026-02-06T08:00:00.000Z",
    "language": "en",
    "importance": 3,
    "summary": "미국 연구진, 알츠하이머·치매 연구 주요 이정표 달성 축하. 기초연구 진전이 신약 개발 파이프라인에 장기적 기여"
  },
  {
    "id": "e640f2a5d7c1",
    "title": "“알츠하이머병 신약개발 성공 답은 ‘언제·무엇을·누구에게’에 있다” - Yakup.com",
    "description": "“알츠하이머병 신약개발 성공 답은 ‘언제·무엇을·누구에게’에 있다”  Yakup.com",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%E2%80%9C%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%EB%B3%91%20%EC%8B%A0%EC%95%BD%EA%B0%9C%EB%B0%9C%20%EC%84%B1%EA%B3%B5%20%EB%8B%B5%EC%9D%80%20%E2%80%98/600/400",
    "url": "https://news.google.com/articles/CBMiZkFVX3lxTE1Kb0ZfYk92TUJ1OWhhaDZSTHFyZEdMcGFweWJzLVdHWExpMzZkN2cyUlZQMXp3eVI0MV9tX19YRE5XQVYyQklEWkNaZ0k0UW10ZkZsMFR3alZ4V0dPR3VpcmREZVYxQQ?oc=5",
    "publishedAt": "2026-02-06T08:00:00.000Z",
    "language": "ko",
    "importance": 5,
    "summary": "알츠하이머 신약개발 성공 열쇠는 '투여 시기·표적·환자 선별'. 정밀의료 기반 임상 설계가 AR1001 전략에도 시사점"
  },
  {
    "id": "b7e9870b8b86",
    "title": "How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat - Investor's Business Daily",
    "description": "How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat  Investor's Business Daily",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/How%20One%20Drug%20Heavy-L/600/400",
    "url": "https://news.google.com/articles/CBMihgFBVV95cUxQTzF1dDhYM1R5NFNpZ2huRzhvV3RpOTBQY0VJbXZEelhMZnNNYmVUaExrbWd4OHBoXzFkMFJxZnRxbmNlVjlQV2JialozRjdqMXRDT2RHYW9CT0hrYVBhU1BBTElOVnhzNEJQRkJObzZqMlo0ZXREckR4YmgtMWZCTFB0R0hWQQ?oc=5",
    "publishedAt": "2026-02-06T08:00:00.000Z",
    "language": "en",
    "importance": 7,
    "summary": "바이오젠 4분기 실적 어닝서프라이즈, 레켐비 단일 약물이 성장 견인. 알츠하이머 치료제 상업적 가치 재확인"
  },
  {
    "id": "6ffc11249bc0",
    "title": "아리바이오 “디지털치료제 오스트리아서 임상 시작” - 코메디닷컴",
    "description": "아리바이오 “디지털치료제 오스트리아서 임상 시작”  코메디닷컴",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%20%E2%80%9C%EB%94%94%EC%A7%80%ED%84%B8%EC%B9%98%EB%A3%8C%EC%A0%9C%20%EC%98%A4%EC%8A%A4%ED%8A%B8%EB%A6%AC%EC%95%84%EC%84%9C/600/400",
    "url": "https://news.google.com/articles/CBMiQkFVX3lxTE9fQ2d0RThFdGlCczktWVhZOGJxSkdrc2FLN2NaWWxEc2ZvdW9MdFVHdzBJV2hsMzhmaEEtZmt6dnJBQQ?oc=5",
    "publishedAt": "2026-02-05T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, 디지털치료제 GVD-01 오스트리아 국제임상 시작. 뇌 자극 전자약 파이프라인 본격 가동으로 포트폴리오 다각화"
  },
  {
    "id": "b4d3ce756e75",
    "title": "아리바이오, 뇌 자극 전자약 'GVD-01' 오스트리아 임상 착수 - 히트뉴스",
    "description": "아리바이오, 뇌 자극 전자약 'GVD-01' 오스트리아 임상 착수  히트뉴스",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EB%87%8C%20%EC%9E%90%EA%B7%B9%20%EC%A0%84%EC%9E%90%EC%95%BD%20'GVD/600/400",
    "url": "https://news.google.com/articles/CBMia0FVX3lxTE1tVFR2TUFPLU53ejV1WWpiTDJvTXQzMnJwWlJBdEYtcXE3TDRiS1g5NWpEWWhDQWQ2SHNlcllWbEZYQ0ozSjdSTFJXWDR0SHk2VlRvVVlNbU1TVVo1YWNFTkVSdERJSzAtckRn?oc=5",
    "publishedAt": "2026-02-05T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오 뇌 자극 전자약 GVD-01 오스트리아 임상 착수. AR1001 외 디지털치료제로 파이프라인 확장 본격화"
  },
  {
    "id": "8136b438e15d",
    "title": "아리바이오, ‘전자약 GVD-01’ 국제 공동 임상시험 착수 - 톱데일리",
    "description": "아리바이오, ‘전자약 GVD-01’ 국제 공동 임상시험 착수  톱데일리",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%E2%80%98%EC%A0%84%EC%9E%90%EC%95%BD%20GVD-01%E2%80%99%20/600/400",
    "url": "https://news.google.com/articles/CBMiUEFVX3lxTE01NjBubUZxR0RvNFhTQXd0Z2NJZUd1anp6R2hKMzlNVDBqRnBzRkdqWGc2MVdUVXo2Mk1YZk4tQ0JJWm1MNHRGMEdSWWpfM09U?oc=5",
    "publishedAt": "2026-02-05T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오 GVD-01 국제 공동 임상시험 착수. 뇌전기자극 기반 인지기능 개선 전자약으로 기존 약물과 차별화된 접근"
  },
  {
    "id": "b5410e10ab01",
    "title": "Kisunla (donanemab-azbt) for the Treatment of Early Alzheimer’s Disease, US - Clinical Trials Arena",
    "description": "Kisunla (donanemab-azbt) for the Treatment of Early Alzheimer’s Disease, US  Clinical Trials Arena",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Kisunla%20(donanemab-a/600/400",
    "url": "https://news.google.com/articles/CBMikwFBVV95cUxOZTlEZ0IxWm1KY1VRV1pYT3dKclBVZzhRSjJDRzlpa0pKN1N1TlJ5c3hKVkRwUlZVVjdWb3BITk5XUlp3NFVxa1otQkZ6RUNfMmNhYm5rQV9YTGw1MThndFh4aW5aRDlwQkQyQ1FKQ3g5cGlFRGlzeXhEMkdXREZYdVpZVVZOUmF3eUhFRzFiMWcweEk?oc=5",
    "publishedAt": "2026-02-05T08:00:00.000Z",
    "language": "en",
    "importance": 7,
    "summary": "키순라(도나네맙) 초기 알츠하이머 미국 임상시험 리뷰. 릴리의 항아밀로이드 치료제 시장 지위와 AR1001 경쟁 분석 자료"
  },
  {
    "id": "b122c6fe349d",
    "title": "Eli Lilly Reclaims $1 Trillion Market Cap - 조선일보",
    "description": "Eli Lilly Reclaims $1 Trillion Market Cap  조선일보",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/Eli%20Lilly%20Reclaims%20%24/600/400",
    "url": "https://news.google.com/articles/CBMiiAFBVV95cUxPVjZwRXBJVkVfUllFN29leFE1cExVNzlSeGJZR3o0TUZvRndPMnlSYnp6a0dfNDhlV3J0aG5jVEtPS204aU1qVVVGRzdBWVhmYjF0ZkRya2xXcnZqRzFPYlJuVTlhZllYVTNfT3RzVFRVc0NYX1hIWDhydXpqdTV3TjhSMkFNZUlN?oc=5",
    "publishedAt": "2026-02-05T08:00:00.000Z",
    "language": "ko",
    "importance": 6,
    "summary": "릴리, 시가총액 1조 달러 재탈환. 알츠하이머·비만 치료제 파이프라인 가치로 글로벌 제약사 시총 경쟁 선두 복귀"
  },
  {
    "id": "a8a5d5c1271e",
    "title": "Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool",
    "description": "Best Biotech Stocks of 2026 and How to Invest in Them  The Motley Fool",
    "source": "Google News",
    "category": "market",
    "imageUrl": "https://picsum.photos/seed/Best%20Biotech%20Stocks%20/600/400",
    "url": "https://news.google.com/articles/CBMijgFBVV95cUxQUzJDQTRnQ2pOU0JoUUJRT2YxYm9Qc3hIaFY4WktwR09HeDFLaVRCQ0dRRzF4RHJ1RnN3cTFVUFUyVzVjVFJjZmpuS3VCbTlpQ1RTQi1OcnhPWFZ1ZUJWTHpDN1hwbW51UGlBdUlFU3NrYzdXSWRob1Y0Q3F1QUs3c3dNcl9sNU16amtjT2lB?oc=5",
    "publishedAt": "2026-02-05T08:00:00.000Z",
    "language": "en",
    "importance": 2,
    "summary": "2026년 유망 바이오텍 주식 투자 가이드. 알츠하이머 치료제 기업 포함 바이오 섹터 투자 전반 트렌드 분석"
  },
  {
    "id": "286961376fcc",
    "title": "[바이오스냅] 메드트로닉, 수술용 에너지 기구 '리가슈어 RAS' 출시 - 연합뉴스 한민족센터",
    "description": "[바이오스냅] 메드트로닉, 수술용 에너지 기구 '리가슈어 RAS' 출시  연합뉴스 한민족센터",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%5B%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%EB%83%85%5D%20%EB%A9%94%EB%93%9C%ED%8A%B8%EB%A1%9C%EB%8B%89%2C%20%EC%88%98%EC%88%A0%EC%9A%A9%20%EC%97%90/600/400",
    "url": "https://news.google.com/articles/CBMidEFVX3lxTFBYQUlHYWVlR056YkhlZkhvX2dYWU1NaUVFUmdIMjE0TzBaUFV5T0NSOWVMTU9fLXlYc2RKcVhJcDNvVjNlam5pUkFDaXBRWXBaeGpULWtobjVBdEtOZVR4YXhWMl9ET0xCMDRFbE9GTFBRc0Jz?oc=5",
    "publishedAt": "2026-02-05T06:30:14.000Z",
    "language": "ko",
    "importance": 1,
    "summary": "메드트로닉 수술용 에너지 기구 출시. 알츠하이머 치료제와 직접 관련 없는 의료기기 뉴스"
  },
  {
    "id": "55a6e4e83581",
    "title": "뉴로핏 아쿠아 AD 플러스, '美FDA 510(k)' 획득 - 데일리메디",
    "description": "뉴로핏 아쿠아 AD 플러스, '美FDA 510(k)' 획득  데일리메디",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%EB%89%B4%EB%A1%9C%ED%95%8F%20%EC%95%84%EC%BF%A0%EC%95%84%20AD%20%ED%94%8C%EB%9F%AC%EC%8A%A4%2C%20'%E7%BE%8EFD/600/400",
    "url": "https://news.google.com/articles/CBMiaEFVX3lxTE9raFdBX2ZCRGZuNE1lcjlOcDY1T2pOZWgyS3F5dTc4NmVQcEtTYW1KVGhBaHNKTzV2NzV2SFdZMVkwWXZrNEs0T0xEWFBRVnhweFBEQkg0YXk0dEZ3TVlKTkpwMVAzRl93?oc=5",
    "publishedAt": "2026-02-05T00:19:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "뉴로핏, 알츠하이머 진단 AI '아쿠아 AD 플러스' FDA 510(k) 획득. 국내 AI 진단 기업의 미국 시장 진출 성과"
  },
  {
    "id": "3325170f9057",
    "title": "Marijuana compound may help prevent dementia when paired with common drug - WFIN",
    "description": "Marijuana compound may help prevent dementia when paired with common drug  WFIN",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Marijuana%20compound%20m/600/400",
    "url": "https://news.google.com/articles/CBMiqwFBVV95cUxPTDdWYzFteFMtOXo0ck1hNEpVZ2pSeWtqYUdQSDFVWjZHRFZ3YnNpZVAzOXljYjVFTkhVejhDNUota01Jc3pmbU9obWg4dDFGd1NfQmFDUlpYeFZfMlhYaFJ5Mkt3N3ZvMnduZnB4dnFxNGF5MWloTF9iZFI3RUxlQkN1bVJTMy1CLW43T3duNy1QS0o4Umd6YVJaZ3Q0clBjYWhjMlFrSVpzTDA?oc=5",
    "publishedAt": "2026-02-04T20:43:14.000Z",
    "language": "en",
    "importance": 2,
    "summary": "대마 화합물+기존 약물 조합이 치매 예방 효과 가능성 확인. 전임상 단계 연구로 상용화까지 먼 거리, 참고 수준"
  },
  {
    "id": "f65cb8e175c8",
    "title": "Gold Coast grandmother's remarkable recovery with groundbreaking Alzheimer's drug donanemab - 7NEWS",
    "description": "Gold Coast grandmother's remarkable recovery with groundbreaking Alzheimer's drug donanemab  7NEWS",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Gold%20Coast%20grandmoth/600/400",
    "url": "https://news.google.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?oc=5",
    "publishedAt": "2026-02-04T08:00:00.000Z",
    "language": "en",
    "importance": 7,
    "summary": "호주 할머니, 키순라(도나네맙) 투여 후 극적 인지기능 회복 사례 보도. 실사용 효과 입증으로 치료제 신뢰도 강화"
  },
  {
    "id": "13eb6cbedac8",
    "title": "DUVAX",
    "description": "Nuravax              Immunotherapy (active)              Amyloid-Related          Tau              \nIn November 2025, an NIH-funded Phase 1 trial began to test the safety and immunogenicity of DUVAX in 24 healthy adults. The study calls for three intramuscular injections of 200 or 400 micrograms or placebo, at baseline, four weeks, and 22 weeks. The primary outcome is safety. Other endpoints are Aβ and tau antibody titers, and antibodies to the MultiTEP antigens. The study is running at one site",
    "fullContent": "Nuravax              Immunotherapy (active)              Amyloid-Related          Tau              \nIn November 2025, an NIH-funded Phase 1 trial began to test the safety and immunogenicity of DUVAX in 24 healthy adults. The study calls for three intramuscular injections of 200 or 400 micrograms or placebo, at baseline, four weeks, and 22 weeks. The primary outcome is safety. Other endpoints are Aβ and tau antibody titers, and antibodies to the MultiTEP antigens. The study is running at one site in Florida until July 2027.\nFor details on DUVAX trials, see clinicaltrials.gov\nDUVAX is a combination vaccine designed to elicit antibodies to Aβ peptides and tau protein. It is a mixture of the recombinant-protein-based Aβ and tau vaccines AV-1959R and AV-1980R/A. It uses the Advax-CpG adjuvant, a combination of polysaccharides and CpG oligonucleotides.\nBoth vaccines are built on the MultiTEP platform, which aims to maximize B cell production of antibodies without activating potentially harmful autoreactive T cells. Three copies of a recombinant Aβ1-11 peptide or three copies of a tau2-18 peptide are fused to DNA encoding a string of 12 T-cell-activating epitopes. These include a synthetic pan-T cell antigen, antigens derived from Tetanus toxin, and from the hepatitis B and influenza viruses. The foreign antigens function to boost antibody responses by activating memory and helper T cells. This is important in old people, who tend to mount weaker responses to vaccines.\nIn preclinical work in mice, dual vaccination with AV-1959R and AV-1980R elicited high titer Aβ- and tau-specific antibodies (Davytan et al., 2016). In the Tau22/5xFAD (T5x) mouse model of Alzheimer’s, vaccination with AV-1959R and AV-1980R together led to significant reduction of insoluble Aβ42, total tau, and hyperphosphorylated tau in brain (Davtyan et al., 2019).\n          \n          Alzheimer's Disease              Phase 1    \n    \n          Breaking News    \nReferences\nTherapeutics Citations\nAV-1959R              \nAV-1980R/A              \n    \n                    \nPaper Citations\nDavtyan H, Zagorski K, Rajapaksha H, Hovakimyan A, Davtyan A, Petrushina I, Kazarian K, Cribbs DH, Petrovsky N, Agadjanyan MG, Ghochikyan A.\nAlzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules.\n  Sci Rep. 2016 Jul 1;6:28912. \n    PubMed.\n              \nDavtyan H, Hovakimyan A, Kiani Shabestari S, Antonyan T, Coburn MA, Zagorski K, Chailyan G, Petrushina I, Svystun O, Danhash E, Petrovsky N, Cribbs DH, Agadjanyan MG, Blurton-Jones M, Ghochikyan A.\nTesting a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice.\n  Alzheimers Res Ther. 2019 Dec 17;11(1):107. \n    PubMed.\n              \n    \n                    \nExternal Citations\nclinicaltrials.gov\n              \n    \n            \n          03 Feb 2026",
    "source": "Alzforum",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/DUVAX/600/400",
    "url": "https://www.alzforum.org/therapeutics/duvax",
    "publishedAt": "2026-02-03T17:20:49.000Z",
    "language": "en",
    "importance": 4,
    "summary": "DUVAX 알츠하이머 백신 후보물질 임상시험 등록. 예방 백신 접근법으로 치료제 시장에 장기적 판도 변화 가능성"
  },
  {
    "id": "eb00ae690d2e",
    "title": "AV-1959R",
    "description": "Nuravax              Immunotherapy (active)              Amyloid-Related              \nIn June 2024, Phase 1 began testing the vaccine in 16 healthy adults in Australia. The active treatment arm consisted of 12 participants, who received three intramuscular injections of 100 or 300 micrograms AV-1959R in adjuvant over three months; four received adjuvanted placebo. The study was completed in October 2025, and results were presented at the December CTAD conference (news). The most common adverse ",
    "fullContent": "Nuravax              Immunotherapy (active)              Amyloid-Related              \nIn June 2024, Phase 1 began testing the vaccine in 16 healthy adults in Australia. The active treatment arm consisted of 12 participants, who received three intramuscular injections of 100 or 300 micrograms AV-1959R in adjuvant over three months; four received adjuvanted placebo. The study was completed in October 2025, and results were presented at the December CTAD conference (news). The most common adverse event was injection site pain or swelling, in 83 percent of participants. No serious adverse events occurred. The vaccine produced high titers of anti-Aβ gG in all participants. The company claimed that the blood concentration of anti-Aβ antibodies was similar to steady-state levels reached after infusion of monoclonal antibodies lecanemab and donanemab. The elicited antibodies bound strongly to protofibrils and fibrils, moderately to oligomers, and only weakly to monomers. They reacted with AD plaques in mouse or human brain tissue. A booster shot at three months was less effective than expected, presumably because existing antibodies were binding up available antigen. A model predicted yearly boosting would be more effective.\nA Phase 2 trial is planned to begin in 2026.\nA combination of AV-1959R with the tau vaccine AV-1980R called DUVAX was to begin Phase 1 in 2025.\nFor details on AV-1959R trials, see clinicaltrials.gov.\nAV-1959R is a vaccine designed to elicit antibodies to Aβ peptides without activating potentially harmful autoreactive T cells. It is administered with the Advax-CpG adjuvant, a combination of polysaccharides and CpG oligonucleotides.\nThis vaccine fuses three copies of a recombinant Aβ1-11 N-terminal peptide to DNA encoding a string of 12 T-cell-activating epitopes. The MultiTEP platform includes a synthetic pan-T cell antigen, antigens derived from Tetanus toxin, and from the hepatitis B and influenza viruses. The foreign antigens function to boost antibody responses by activating memory and helper T cells. This is important in old people who tend to mount weaker responses to vaccination.\nAV-1959R grew out of a multiyear optimization process that began with identification of Aβ1-11 as the dominant B-cell epitope in Aβ peptides, followed by preclinical testing of peptide and DNA vaccines combining this epitope with increasing numbers of T-cell epitopes. Other versions of this vaccine include AV-1959D, a DNA vaccine encoding Aβ1-11 (e.g., Petrushina et al., 2020) currently in Phase 1. AV-1959LR is an mRNA version of the vaccine encapsulated in lipid-based nanoparticles; it generated high-titer Aβ antibodies in mice and nonhuman primates (Hovakimyan et al., 2024).\nIn preclinical work, AV-1959R elicited high-titer Aβ antibodies in mice, with Advax(CpG) being the most effective adjuvant. Dual vaccination with AV-1959R and the MultiTEP tau vaccine AV-1980R/A elicited high titer Aβ and tau-specific antibodies in the mice, while a dual epitope Aβ/tau vaccine was less effective at raising tau antibodies (Davtyan et al., 2016). In the Tau22/5xFAD (T5x) mouse model of Alzheimer’s, vaccination with AV-1959R and AV-1980R together led to significant reduction of insoluble Aβ42, total tau, and hyperphosphorylated tau in brain (Davtyan et al., 2019).\n          \n          Alzheimer's Disease              Phase 1    \n    \n          Breaking News    \nReferences\nNews Citations\nIn Early Trial, Vaccine Spurs Glut of Antibodies Against Aβ Aggregates 10 Dec 2025\n              \n    \n                    \nTherapeutics Citations\nDUVAX              \nAV-1959D               \nAV-1980R/A              \n    \n                    \nPaper Citations\nPetrushina I, Hovakimyan A, Harahap-Carrillo IS, Davtyan H, Antonyan T, Chailyan G, Kazarian K, Antonenko M, Jullienne A, Hamer MM, Obenaus A, King O, Zagorski K, Blurton-Jones M, Cribbs DH, Lander H, Ghochikyan A, Agadjanyan MG.\nCharacterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials.\n  Neurobiol Dis. 2020 Jun;139:104823.  Epub 2020 Feb 28\n    PubMed.\n              \nHovakimyan A, Chilingaryan G, King O, Capocchi JK, Chadarevian JP, Davtyan H, Kniazev R, Agadjanyan MG, Ghochikyan A.\nmRNA Vaccine for Alzheimer's Disease: Pilot Study.\n  Vaccines (Basel). 2024 Jun 14;12(6)\n    PubMed.\n              \nDavtyan H, Zagorski K, Rajapaksha H, Hovakimyan A, Davtyan A, Petrushina I, Kazarian K, Cribbs DH, Petrovsky N, Agadjanyan MG, Ghochikyan A.\nAlzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules.\n  Sci Rep. 2016 Jul 1;6:28912. \n    PubMed.\n              \nDavtyan H, Hovakimyan A, Kiani Shabestari S, Antonyan T, Coburn MA, Zagorski K, Chailyan G, Petrushina I, Svystun O, Danhash E, Petrovsky N, Cribbs DH, Agadjanyan MG, Blurton-Jones M, Ghochikyan A.\nTesting a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice.\n  Alzheimers Res Ther. 2019 Dec 17;11(1):107. \n    PubMed.\n              \n    \n                    \nExternal Citations\nclinicaltrials.gov\n              \n    \n            \n          03 Feb 2026",
    "source": "Alzforum",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/AV-1959R/600/400",
    "url": "https://www.alzforum.org/therapeutics/av-1959r",
    "publishedAt": "2026-02-03T17:08:25.000Z",
    "language": "en",
    "importance": 4,
    "summary": "AV-1959R 알츠하이머 백신 임상시험 정보. 아밀로이드 타깃 능동면역 치료 접근법으로 장기적 경쟁 파이프라인 모니터링 대상"
  },
  {
    "id": "92e871643871",
    "title": "레켐비, 기억력 되찾아줬다 … 藥 언제 투여하느냐가 관건 - v.daum.net",
    "description": "레켐비, 기억력 되찾아줬다 … 藥 언제 투여하느냐가 관건  v.daum.net",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EB%A0%88%EC%BC%90%EB%B9%84%2C%20%EA%B8%B0%EC%96%B5%EB%A0%A5%20%EB%90%98%EC%B0%BE%EC%95%84%EC%A4%AC%EB%8B%A4%20%E2%80%A6%20%E8%97%A5%20%EC%96%B8/600/400",
    "url": "https://news.google.com/articles/CBMiS0FVX3lxTE54MVNJXzViYTFodGtvNG1FOXpEZFRYNTdBYUZBdFpTRmp6LTNfR2tCdW5OTUtPNzRCZURuUlM3YkhPX1d6eUFqOTk3MA?oc=5",
    "publishedAt": "2026-02-03T08:33:00.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "레켐비 투여 환자 기억력 회복 사례 보도, 투여 시기가 핵심 변수. 조기 투여 효과 데이터가 치료 프로토콜 표준화 주도"
  },
  {
    "id": "fdadb11d4908",
    "title": "138 new drugs for dementia are currently being developed by humans. Domestic and foreign pharmaceuti.. - 매일경제",
    "description": "138 new drugs for dementia are currently being developed by humans. Domestic and foreign pharmaceuti..  매일경제",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/138%20new%20drugs%20for%20de/600/400",
    "url": "https://news.google.com/articles/CBMiS0FVX3lxTFBjLVpXdjJsZlJWcXA1RmJDQllZRkxxVFpuZXdyOHVDU016RVkwbzhHUkFHRGNMVGRYMERKT2VSV0xaYjFENnZTdkVfcw?oc=5",
    "publishedAt": "2026-02-03T08:00:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "현재 글로벌 치매 신약 138종 개발 중. 국내외 파이프라인 현황으로 AR1001 포함 경쟁 환경 전체 조망 가능"
  },
  {
    "id": "70b400573e98",
    "title": "Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma - PMLiVE",
    "description": "Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma  PMLiVE",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Johnson%20%26%20Johnson%E2%80%99s%20/600/400",
    "url": "https://news.google.com/articles/CBMitgFBVV95cUxNbG5TTFZEeXhLRTVRcjg4QlZnSUxKSFAyNEp0ZmxlNkhpTnAyWTN2Z0lDcHFXOTl0RmVBSlJ5V0RPWHpHX1BMNlFuZl9qVElaR2xGeHktZXVYZ2JqX0FBQ3d4OEo2VHBVei1iaXFvTXhvSGFvaVE1QnhUX2JnM09rLWNCV2lXVmhSUml5VVljZEgtUUp3ODJMWGVBR1hfT3R6Q0ZCYldscXZ2TWI1RGptY1VBWmYyQQ?oc=5",
    "publishedAt": "2026-02-03T08:00:00.000Z",
    "language": "en",
    "importance": 1,
    "summary": "J&J 다잘렉스 파스프로 복합요법 다발성골수종 FDA 승인. 알츠하이머 직접 관련 없으나 FDA 승인 동향 참고"
  },
  {
    "id": "d623be700b00",
    "title": "뉴로핏, 알츠하이머병 영상 설루션 미국 허가 - 연합뉴스",
    "description": "뉴로핏, 알츠하이머병 영상 설루션 미국 허가  연합뉴스",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%EB%89%B4%EB%A1%9C%ED%95%8F%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%EB%B3%91%20%EC%98%81%EC%83%81%20%EC%84%A4%EB%A3%A8%EC%85%98%20%EB%AF%B8/600/400",
    "url": "https://news.google.com/articles/CBMiW0FVX3lxTE56Mm9QNXFVTDNxV0RZbjk4SmxTUFZWdkh1MnB4VlRVV3lQWFFsVVR5c3RRdDk5Z2NsajB0anlKRGtaWHVLRkdKd294a1dfUW5wM0FuaE45NG8zX0nSAWBBVV95cUxOejJNQ0ZkcnRRek9NSmNXN1Y2LWRrZGxmbXM1endZY3hVSjN6Z0dfUzBlNGNrYm5FaUszWVY3bE1YWFRWMDg2RXlIMmRraFFBYzdNRnR5UTd1UGZvOEhfeEU?oc=5",
    "publishedAt": "2026-02-03T08:00:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "뉴로핏 알츠하이머 AI 영상 솔루션 미국 FDA 시판 전 승인. 치매 진단 AI 기술 글로벌 인허가 확보 성과"
  },
  {
    "id": "698230be50db",
    "title": "뉴로핏 알츠하이머병 영상 분석 AI, 美 FDA 시판 전 신고 승인 - 조선비즈 - Chosunbiz",
    "description": "뉴로핏 알츠하이머병 영상 분석 AI, 美 FDA 시판 전 신고 승인 - 조선비즈  Chosunbiz",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%EB%89%B4%EB%A1%9C%ED%95%8F%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%EB%B3%91%20%EC%98%81%EC%83%81%20%EB%B6%84%EC%84%9D%20AI%2C/600/400",
    "url": "https://news.google.com/articles/CBMilwFBVV95cUxOTERncTVvQS1ZZzZVZ01ReEJuUnJVNGdXeWgxQ18yTmJFYlB3ZHJlTTBsU0Q1a2RVYUNldExqc19wYU5OZ1Y0ZjVLTXlqQXF6YkNPaXNGeTl5d0JDNkpOWTVBTHJZWF9OZDJTT0FBMUloYVdjQlAzb2ttRjZYa0dJTEltUUd5b25hcThmSjMtZmhLZ1ozQnh30gGrAUFVX3lxTFBUWURrQXJGbjB3Nk9TMmg4NVRqR1hGNHZwVWo4b3FHVE5KYlRPa2UwQ05DWHlGVzhIb0RrQnE0Q1F0R19XYXY1djB6bWNMSlBIVjhxM2RmUFUwTFlSR0NKMEFZRUxoWnZNSW1GYjkxU1pTYzVpM3kyR1lXNE1CWDlaYnBZLW1vdEtsR0szZldSVnhkZzVRMHVDTC1JdXNzZlExMmN4TktWUDZCNA?oc=5",
    "publishedAt": "2026-02-03T08:00:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "뉴로핏 알츠하이머 영상 분석 AI FDA 510(k) 승인. 치료제 처방에 필수적인 영상진단 보조 AI 시장 확대"
  },
  {
    "id": "256a044a11e6",
    "title": "뉴로핏, 3번째 FDA 관문 통과…'아쿠아 AD 플러스' 허가 - v.daum.net",
    "description": "뉴로핏, 3번째 FDA 관문 통과…'아쿠아 AD 플러스' 허가  v.daum.net",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%EB%89%B4%EB%A1%9C%ED%95%8F%2C%203%EB%B2%88%EC%A7%B8%20FDA%20%EA%B4%80%EB%AC%B8%20%ED%86%B5%EA%B3%BC%E2%80%A6'/600/400",
    "url": "https://news.google.com/articles/CBMiT0FVX3lxTFBkODZWQWhsTFF3TmFVUTR2Q2hmWG1Tc1RpZHI2SkRxZ3hOR0ZNekdTN2k0aWFpdjNqUkRucGFNS0FZZ2llOWdKNHpsd01MS2M?oc=5",
    "publishedAt": "2026-02-03T08:00:00.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "뉴로핏, 3번째 FDA 인허가 관문 통과. 알츠하이머 진단 AI 연속 승인으로 미국 시장 입지 강화"
  },
  {
    "id": "68ddaf67b7d2",
    "title": "\"세 번째 美 인허가\"…'의료AI' 뉴로핏, FDA 510k 획득 - 뉴시스",
    "description": "\"세 번째 美 인허가\"…'의료AI' 뉴로핏, FDA 510k 획득  뉴시스",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%22%EC%84%B8%20%EB%B2%88%EC%A7%B8%20%E7%BE%8E%20%EC%9D%B8%ED%97%88%EA%B0%80%22%E2%80%A6'%EC%9D%98%EB%A3%8CAI'%20/600/400",
    "url": "https://news.google.com/articles/CBMiYEFVX3lxTE0wTGwwU2VGTG5RU0g4MEc3bTVYQm1YdkJkc3Q2Z1AxUERPSzdWS1Zxb1Z0ODJTRTBmdHAxV3MxakFGUUJhSVVQU3lhVEpGS2FpbThwWWYtbkI2akY4NUJFcdIBeEFVX3lxTE15aG5jMnNQM3pvcUZRY25aZnpJc2xsVmJWVWhQUzJEZy1TdUVsbmtzYVE0NlJwdXBST0E5dmJpd1lFUTF3anJKQlk1bHJUaGhzUVUtaUVfUmJGeVZFNEpPMlRuQmNXZG9ZRVpERExiRTNRM0wwejBSTA?oc=5",
    "publishedAt": "2026-02-03T08:00:00.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "뉴로핏, 세 번째 FDA 510(k) 획득. 의료 AI 기업의 연속 미국 인허가 성공으로 사업 확장 가속"
  },
  {
    "id": "7ed80de8fc3e",
    "title": "치매 치료의 게임체인저?…뉴로핏, 3번째 FDA 인허가 관문 통과 - ebn.co.kr",
    "description": "치매 치료의 게임체인저?…뉴로핏, 3번째 FDA 인허가 관문 통과  ebn.co.kr",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%EC%B9%98%EB%A7%A4%20%EC%B9%98%EB%A3%8C%EC%9D%98%20%EA%B2%8C%EC%9E%84%EC%B2%B4%EC%9D%B8%EC%A0%80%3F%E2%80%A6%EB%89%B4%EB%A1%9C%ED%95%8F%2C%203/600/400",
    "url": "https://news.google.com/articles/CBMiaEFVX3lxTE8tZEI5dkpGU0hzV1RwSDJzYTRycjl2Q2F3QjVtRDJWdW5XNnJtUjVGcklzM3NCTW5GZU9pVjZWRnFaeDVva0lva1FTV25HWjkyZGNLbUpmZ010UzJjOVgyajl6SEs0ZzNR?oc=5",
    "publishedAt": "2026-02-03T08:00:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "뉴로핏 3번째 FDA 인허가 통과, 치매 치료 게임체인저 가능성 평가. 진단 AI 솔루션이 치료 생태계 핵심 인프라로 부상"
  },
  {
    "id": "5aa4990134a7",
    "title": "알츠하이머 조기진단 시장 잡아라…혈액 검사도 등장 - 네이트",
    "description": "알츠하이머 조기진단 시장 잡아라…혈액 검사도 등장  네이트",
    "source": "Google News",
    "category": "market",
    "imageUrl": "https://picsum.photos/seed/%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%20%EC%A1%B0%EA%B8%B0%EC%A7%84%EB%8B%A8%20%EC%8B%9C%EC%9E%A5%20%EC%9E%A1%EC%95%84%EB%9D%BC%E2%80%A6%ED%98%88%EC%95%A1/600/400",
    "url": "https://news.google.com/articles/CBMiU0FVX3lxTE54dTVKLUpYTFdVQ2RJSEFwN2dycWNtcEVVVHdqN1h1djB5S0U0UG0ydUc0MFU2QktEUENwN1RiV2pjNWJxVEcwWWNIVnhVclUzUzNJ?oc=5",
    "publishedAt": "2026-02-03T08:00:00.000Z",
    "language": "ko",
    "importance": 5,
    "summary": "알츠하이머 조기진단 시장 경쟁 격화, 혈액검사까지 등장. 간편 진단 보급 확대가 치료제 처방 대상 환자 풀 증가 견인"
  },
  {
    "id": "1c3119d26b9e",
    "title": "EuBiologics builds third Korea plant to scale RSV, shingles, Alzheimer vaccines - CHOSUNBIZ - Chosunbiz",
    "description": "EuBiologics builds third Korea plant to scale RSV, shingles, Alzheimer vaccines - CHOSUNBIZ  Chosunbiz",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/EuBiologics%20builds%20t/600/400",
    "url": "https://news.google.com/articles/CBMigAFBVV95cUxQTWVaZkZ3ekc4d1B5ZGNXZ1BoUXgtVGh0THZOQXJUeVdXSGhsWGZCNFZQTjBnenAwSTFGRkZHamk5Und3UU8zVmVoOHI2OXF2blJ2dHJDXzRiZDlTTDlrRGlWT01qY3Q4MkhQOHE3aDlvMHZ6UkVPcDZyN19objVvadIBlAFBVV95cUxQWHdMWHd3M2lDOWFSMWo3bU9uV1U1Z2F4RnJzQWlmRGhEQm5SUjQ0Z3l5Q1Y4NzM3dV9xdkVpOW42QlZXd2pySjFGZVU5Q3oyM2E5ZmRld1lTQmlTZWJWMHk0Wl9WNW45dEtXVFBsT0laX0Y1MTAtZHRTOU1jX2pvTkxURmxJUm9TS3NnbldqeE5HQ1Q0?oc=5",
    "publishedAt": "2026-02-03T08:00:00.000Z",
    "language": "en",
    "importance": 3,
    "summary": "유바이오로직스, 한국 3공장 건설로 RSV·대상포진·알츠하이머 백신 생산 확대. 국내 백신 생산 인프라 투자 활발"
  },
  {
    "id": "c3e535cb7c2a",
    "title": "세계는 혁신신약 138종 개발중 …\"치매 정복, 고지가 보인다\" - 매일경제",
    "description": "세계는 혁신신약 138종 개발중 …\"치매 정복, 고지가 보인다\"  매일경제",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EC%84%B8%EA%B3%84%EB%8A%94%20%ED%98%81%EC%8B%A0%EC%8B%A0%EC%95%BD%20138%EC%A2%85%20%EA%B0%9C%EB%B0%9C%EC%A4%91%20%E2%80%A6%22/600/400",
    "url": "https://news.google.com/articles/CBMiTkFVX3lxTE9YQUIzM1NEMGFPT09GVWpyMzZsdlZ3d3VWY2ExQ0sxeG9HUzFzMmNCUDNsbGRoYktBTjZiWEt5dk9DbWdLS3laSGpmUXgwZw?oc=5",
    "publishedAt": "2026-02-03T08:00:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "전 세계 치매 혁신신약 138종 개발 중, 정복 가시권 진입 평가. 파이프라인 다양화가 AR1001 포함 후보물질 가치 지지"
  },
  {
    "id": "c96ea3281eea",
    "title": "‘검은 월요일’도 뉴로핏·비엘팜텍 등 바이오 상승세 못 꺾었다↑ [바이오맥짚기] - 팜이데일리",
    "description": "‘검은 월요일’도 뉴로핏·비엘팜텍 등 바이오 상승세 못 꺾었다↑ [바이오맥짚기]  팜이데일리",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%E2%80%98%EA%B2%80%EC%9D%80%20%EC%9B%94%EC%9A%94%EC%9D%BC%E2%80%99%EB%8F%84%20%EB%89%B4%EB%A1%9C%ED%95%8F%C2%B7%EB%B9%84%EC%97%98%ED%8C%9C%ED%85%8D%20%EB%93%B1/600/400",
    "url": "https://news.google.com/articles/CBMibkFVX3lxTE5fMEg0TDdUbkJlYWJOOHZ0TUY2S0tWTkx0WmJ3WTJVM3dyaEJGT0xTRkZJWkhVSDJDRDRldTdGa2JBdzlhYkItLVdLUTBZVGN0UDhNS3NOdHVtbHZqVW5rTEttbGZvSGtLOElGYmh3?oc=5",
    "publishedAt": "2026-02-03T08:00:00.000Z",
    "language": "ko",
    "importance": 2,
    "summary": "미 증시 급락에도 뉴로핏·비엘팜텍 등 바이오 상승세 유지. 치매 관련 테마주 투자 심리 견조한 흐름"
  },
  {
    "id": "38513cff7b05",
    "title": "뉴로핏, 알츠하이머 치료제 처방 지원 AI 솔루션 FDA 510(k) 획득 - 디지틀조선일보",
    "description": "뉴로핏, 알츠하이머 치료제 처방 지원 AI 솔루션 FDA 510(k) 획득  디지틀조선일보",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%EB%89%B4%EB%A1%9C%ED%95%8F%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%20%EC%B9%98%EB%A3%8C%EC%A0%9C%20%EC%B2%98%EB%B0%A9%20%EC%A7%80%EC%9B%90/600/400",
    "url": "https://news.google.com/articles/CBMihwFBVV95cUxOeWphSjlXMHc3T2JEMW11YTV5dmpIdU85MU9iTmNqQV9lM1hVOFg2TFYzYms3T0lKUXo3RTlPWWNJNl85ZXFKdk1wN2VvcFRqRXdTcEtWaWhPV1o0Ny05QVpoY2R5SUZId1Qxd0RRWktFa0tkeU0yNWdVMGxpZUtGLWdhSl9CWXfSAXtBVV95cUxPWXhFSWZtQU1fYWFEaUtUaTlxVzJxUGJiT0hOdkU5c2pWMHRyMTRiZWhoeGpRUl9hdmtyc3BJZjc0YjhoWmpTZHhILVdYN29kVFVaZ1U4LVBMLWNmbkVNcFlJakRDZmZMallsT3dpWlV0T2NKcVFBMlJ2NWc?oc=5",
    "publishedAt": "2026-02-03T02:51:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "뉴로핏, 알츠하이머 치료제 처방 지원 AI 솔루션 FDA 510(k) 획득. 진단·처방 보조 AI 수요 증가 추세"
  },
  {
    "id": "fef649514b38",
    "title": "'Neurofit Aqua AD Plus' Receives FDA 510(k) Clearance - 아시아경제",
    "description": "'Neurofit Aqua AD Plus' Receives FDA 510(k) Clearance  아시아경제",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/'Neurofit%20Aqua%20AD%20Pl/600/400",
    "url": "https://news.google.com/articles/CBMiY0FVX3lxTFBMTWNQTS02OUlEaVBETjZyMWhmSjg3V1VsUGl2c1ltUGtrdEhBblE0TFEwZmxFWUkzVV9GQTVtRGVMd1hNZVVXRmc5WmxRTm9Md3VqUG9ma21RRGczSkxmYy1GYw?oc=5",
    "publishedAt": "2026-02-03T00:31:00.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "뉴로핏 아쿠아 AD 플러스 FDA 510(k) 영문 보도. 국내 AI 기업의 글로벌 인허가 역량 입증"
  },
  {
    "id": "bac62e2d5fb1",
    "title": "뉴로핏, 알츠하이머병 AI 영상솔루션 “FDA 승인” - 파이낸스스코프",
    "description": "뉴로핏, 알츠하이머병 AI 영상솔루션 “FDA 승인”  파이낸스스코프",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%EB%89%B4%EB%A1%9C%ED%95%8F%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%EB%B3%91%20AI%20%EC%98%81%EC%83%81%EC%86%94%EB%A3%A8%EC%85%98/600/400",
    "url": "https://news.google.com/articles/CBMiakFVX3lxTE00MGZORGRzM1dmd3NfTFpnV2F6bHZxVE1GYngzRk1DVGIzTnpUY0xrRXNmUmZMODFBaEI2dFRRaUVhR3Jkb0taUWNrSUpTSXM1S2RSYVhKZjZmSlE0dk1tTy16clJDTzZGcGc?oc=5",
    "publishedAt": "2026-02-03T00:19:00.000Z",
    "language": "ko",
    "importance": 5,
    "summary": "뉴로핏 알츠하이머 AI 영상솔루션 FDA 승인 확정. 치료제 처방 필수 진단 인프라로 시장 생태계 내 위치 확보"
  },
  {
    "id": "99c952ae94d9",
    "title": "뉴로핏, '알츠하이머 처방 필수' 종합 분석 솔루션 美 FDA '본격 허가'…퀀텀 점프 '날개' - 프라임경제",
    "description": "뉴로핏, '알츠하이머 처방 필수' 종합 분석 솔루션 美 FDA '본격 허가'…퀀텀 점프 '날개'  프라임경제",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%EB%89%B4%EB%A1%9C%ED%95%8F%2C%20'%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%20%EC%B2%98%EB%B0%A9%20%ED%95%84%EC%88%98'%20%EC%A2%85/600/400",
    "url": "https://news.google.com/articles/CBMibEFVX3lxTE9kWkNic3RTdm4taC00Y0ZkNC1SeHQ1RTRjaExJMzNzQ1ZnN25tcEVKajNsbDduQ1I5YlpfVnNVWVNObnlqXzBjNUJFVmoxM25IS29HZjNuVFllM1prUERoQ1NJNmNJekJLMTNmVQ?oc=5",
    "publishedAt": "2026-02-02T08:00:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "뉴로핏, 알츠하이머 처방 필수 종합 분석 AI FDA 본격 허가. 치매 진단·치료 가치사슬 내 AI 솔루션 핵심 역할 부각"
  },
  {
    "id": "457bc36d6b5a",
    "title": "Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s - statnews.com",
    "description": "Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s  statnews.com",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Why%20Bristol%20Myers%20Sq/600/400",
    "url": "https://news.google.com/articles/CBMinAFBVV95cUxNMmlVSVBuRkxFdXVWQW56YUJaUDhLbjZtWTVmSDNYcjVpUWh2bHY0cWY0bU45UmtXX1dFa0h4cjRHLXZSd0czSjJxWndHOFRpbVlkZG9sQ3BYU3RaVXpFMjk1Z1ljUlNUTmsyQnByS2VsNDhfYmtSOTBXZUlsNkM1RDJDV20yMkJOT3NNWERmUVZpRkNtbWFpRnVDaVc?oc=5",
    "publishedAt": "2026-02-02T08:00:00.000Z",
    "language": "en",
    "importance": 4,
    "summary": "BMS, 수십 년 전 개발 약물의 알츠하이머 치료 가능성 재조명. 약물 재창출 전략으로 개발 비용 절감·속도 향상 기대"
  },
  {
    "id": "992b701a2b95",
    "title": "The brain diet that's proven to cut your dementia risk - and how vaccines and even Viagra may help - MSN",
    "description": "The brain diet that's proven to cut your dementia risk - and how vaccines and even Viagra may help  MSN",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/The%20brain%20diet%20that'/600/400",
    "url": "https://news.google.com/articles/CBMi3AFBVV95cUxPRVZ5cUVHcUp3dks5b21KMzd0WDFVVFVZSTRCV0FUbVk4R0xENmRXWURNa1lQMVJZNklWb3dybnNvYVgxMURtdkEwUGQwNWs0dHhIMlBvRkdsenF5c29EN0Y1ZzRRVGFrR0xkZEtJMDNQUU1fdGZzWmpYZlNOd3RiS1c5aEg1M3JfWXVMWHFiczl5akM3R2pPZTJJVDFfZWVKM08yX0JUM2tscmJFVEdyR0VyUVloN3dxbkUzZlBkUFNmUmJQdm1VMmoyMm54MkRpRXBCMHY2LVVOTTdl?oc=5",
    "publishedAt": "2026-02-01T10:35:39.000Z",
    "language": "en",
    "importance": 3,
    "summary": "MIND 식단 치매 위험 감소 효과와 백신·비아그라 등 재창출 약물 가능성. 비약물+약물 복합 예방 전략 동향"
  },
  {
    "id": "6b709709a2da",
    "title": "FDA warns ‘Dr. Goodenowe’ health centre founder that his recent supplement study put patient health at risk - CBC",
    "description": "FDA warns ‘Dr. Goodenowe’ health centre founder that his recent supplement study put patient health at risk  CBC",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/FDA%20warns%20%E2%80%98Dr.%20Goode/600/400",
    "url": "https://news.google.com/articles/CBMiuwFBVV95cUxPYW44MEpnLU5MS0MtRkdQaFZxQ09tT1hDMThBUUthTnZjbVZMNGljV0xESzZ2b0pWMEdjT1hQbHdVelEtUEZ5aXNQLV9YZmVVUmZSamZEX2NBWE1PaVVaQ3RoNDFEUTlxU1R6UDV6M0NzOVRMOUZkZHh0QzBjVDZFMDZyX2pWSVZOTkZOUlhSMFFhWlppeHJRank4cUhPMkxsMjkxQms5Z0c4R3JWWUJVTHh6UVRTRFJKZ3Fr?oc=5",
    "publishedAt": "2026-02-01T08:00:00.000Z",
    "language": "en",
    "importance": 1,
    "summary": "FDA, 건강보조제 업체에 임상시험 환자 안전 위반 경고. 알츠하이머 직접 관련 없는 규제 뉴스"
  },
  {
    "id": "fdd3e504d1c4",
    "title": "약값 5000만원인데 처방 폭증…치매 근본 원인 없애는 '이 약'[약전약후] - 뉴스1",
    "description": "약값 5000만원인데 처방 폭증…치매 근본 원인 없애는 '이 약'[약전약후]  뉴스1",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EC%95%BD%EA%B0%92%205000%EB%A7%8C%EC%9B%90%EC%9D%B8%EB%8D%B0%20%EC%B2%98%EB%B0%A9%20%ED%8F%AD%EC%A6%9D%E2%80%A6%EC%B9%98%EB%A7%A4/600/400",
    "url": "https://news.google.com/articles/CBMiYEFVX3lxTE4wVFlnZDdveFdNS29jSE1pWWx6TFplQ3BheXFqRHd4bFNGQ3lRUExlSmN0ZllQQjZHR3J5SW53aUJYcmx6SHMzMkpqWncyQUw4cFM5TkFzRXVpQ2JLTWZQcw?oc=5",
    "publishedAt": "2026-01-31T08:00:00.000Z",
    "language": "ko",
    "importance": 7,
    "summary": "치매 치료제 약값 연 5000만원에도 처방 폭증. 레켐비 국내 수요 급증이 치료제 시장 고성장세 방증"
  },
  {
    "id": "1ae7f432a532",
    "title": "Cassava Sciences Pivots After Clinical Setback - AD HOC NEWS",
    "description": "Cassava Sciences Pivots After Clinical Setback  AD HOC NEWS",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/Cassava%20Sciences%20Piv/600/400",
    "url": "https://news.google.com/articles/CBMiogFBVV95cUxNWW9wSElhR2JZNnZhZFJUOWtPb0paQnBxV2E1dlljeUFHZ2J1amVadFBUaTB2QnZYYVZkd1dYOGIydWg0aXBFbnMwaUlJaGVXOGpudnlfZy1Mb0VINURDdklaLXdfX2J1OUhzV0NXMmRsR2RRRTRBVXIyWHJPQzE4R28wZ1FfQlNwVWtUVUp5U0ZLNnNCT2lyN2wyYy1acjkxUXc?oc=5",
    "publishedAt": "2026-01-31T08:00:00.000Z",
    "language": "en",
    "importance": 7,
    "summary": "카사바 사이언스, 시뮤필람 임상 좌절 후 전략 전환. 경쟁 후보물질 탈락이 AR1001 시장 기회 확대에 긍정적"
  },
  {
    "id": "1483b570329d",
    "title": "치매 치료제 보장 경쟁 '앗 뜨거워!'...보장액·횟수 확대에 '과열' 우려도 - 파이낸셜포스트",
    "description": "치매 치료제 보장 경쟁 '앗 뜨거워!'...보장액·횟수 확대에 '과열' 우려도  파이낸셜포스트",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EC%B9%98%EB%A7%A4%20%EC%B9%98%EB%A3%8C%EC%A0%9C%20%EB%B3%B4%EC%9E%A5%20%EA%B2%BD%EC%9F%81%20'%EC%95%97%20%EB%9C%A8%EA%B1%B0%EC%9B%8C!/600/400",
    "url": "https://news.google.com/articles/CBMidEFVX3lxTE1yMjNCOE41WnVfUnBqS3JqU1dNckVmX2FHaGpZZmowaEF1ZnNReTB2Vm1jWnFDU3JPeHNJd1VxeGhTWlkwTjAzZHZ6YThWMG5CY1pNUmJudmxEa2hXbWxUSlQtLTBpeWQ2cENyU0JHd2lNNU5D?oc=5",
    "publishedAt": "2026-01-30T08:00:00.000Z",
    "language": "ko",
    "importance": 5,
    "summary": "손보사 치매 치료제 보장 경쟁 과열, 보장액·횟수 확대 이어져. 보험 보장 확대가 고가 신약 접근성 핵심 동력"
  },
  {
    "id": "1b45c8d6533a",
    "title": "Roche Earnings: Continuing Steady Underlying Growth in 2026 as Late-Stage Pipeline Shines - Morningstar Canada",
    "description": "Roche Earnings: Continuing Steady Underlying Growth in 2026 as Late-Stage Pipeline Shines  Morningstar Canada",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/Roche%20Earnings%3A%20Cont/600/400",
    "url": "https://news.google.com/articles/CBMixAFBVV95cUxObDg1U0Y1aENzNGxaX3h6T3ZJckl0LWNXNHFaWklITUVPRGZUTkVLUmo3b2RjUUpfeW9WRmpLaGZnZU5SaENkRDVBZ2hSZjY4RVVrWkVfTmdFRkwzMUNSeG9SN0xHMkZVTDl2anR1RlJYNzR6eE1aLVd1ZVhEQ3NQbExRRlNkRlFUd1NGWnQ4aTlNSmRReExWbkR0V0dPWUlkVEZFQkNFMnlLbzREVzdhNkNJcnZ5eFdyVFRfdzFTMVVpZktW?oc=5",
    "publishedAt": "2026-01-30T08:00:00.000Z",
    "language": "en",
    "importance": 7,
    "summary": "로슈, 2026년 꾸준한 성장 지속 전망. 후기 파이프라인 중 트론티네맙 등 알츠하이머 후보물질 진전 주목"
  },
  {
    "id": "f772a073099d",
    "title": "듀켐바이오, 영업이익 47% 성장… \"치매 진단제 수요 폭발로\" - 메디소비자뉴스",
    "description": "듀켐바이오, 영업이익 47% 성장… \"치매 진단제 수요 폭발로\"  메디소비자뉴스",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EB%93%80%EC%BC%90%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EC%98%81%EC%97%85%EC%9D%B4%EC%9D%B5%2047%25%20%EC%84%B1%EC%9E%A5%E2%80%A6%20/600/400",
    "url": "https://news.google.com/articles/CBMic0FVX3lxTE9sbGJFRkt4M09vQjlMQWNvMlVPaDFCNGZwWFlhVUx4UWYyNzh3Vk5sMWpoaEhjSHZDLUpkSEFJX0MyeWhhWVlYTVc2UHBCblNKYURFd003UERZWmFBZnRWWGduR2x5WFZMSGQ3ci1DQVNhclE?oc=5",
    "publishedAt": "2026-01-30T08:00:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "듀켐바이오, 치매 진단제 수요 폭발로 영업이익 47% 성장. 치료제 처방 증가가 진단 관련 기업 실적에 직접 반영"
  },
  {
    "id": "6ac15b6689a9",
    "title": "듀켐바이오, 지오영 효자 역할 ‘눈도장’ - 톱데일리",
    "description": "듀켐바이오, 지오영 효자 역할 ‘눈도장’  톱데일리",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EB%93%80%EC%BC%90%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EC%A7%80%EC%98%A4%EC%98%81%20%ED%9A%A8%EC%9E%90%20%EC%97%AD%ED%95%A0%20%E2%80%98%EB%88%88%EB%8F%84/600/400",
    "url": "https://news.google.com/articles/CBMiUEFVX3lxTE52VHBRXzkycHpRSno2VE1qQ3NkbEhhcmJvenhZR0QwMlp2V2dXaWthczRIQmlIc25aclJ5N2pYMmRGVzBNR2c3UTBzRkpna01T?oc=5",
    "publishedAt": "2026-01-30T08:00:00.000Z",
    "language": "ko",
    "importance": 2,
    "summary": "듀켐바이오, 치매 진단제 유통 호조로 수익성 개선. 치료제 시장 확대의 간접 수혜 기업 실적 확인"
  },
  {
    "id": "b87ea3618f6a",
    "title": "아리바이오, ERNS 심포지엄서 AR1001 개발 전략 발표 - 헬스케어N",
    "description": "아리바이오, ERNS 심포지엄서 AR1001 개발 전략 발표  헬스케어N",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20ERNS%20%EC%8B%AC%ED%8F%AC%EC%A7%80%EC%97%84%EC%84%9C%20AR/600/400",
    "url": "https://news.google.com/articles/CBMidEFVX3lxTE5Rbm5Ob1pjQkM0eUVNWmNmUDBqZHZEazhNUEpvcy1COW9nZW5GT0xYcXBfODdFUDZDNE9CdTJub1diVnhsV0NZNi1wWmthMW1hNnJKQ0RPTkIzVVFBN3I2S0Fya0p6NUFuYkFwV0ZpNWZyRlh2?oc=5",
    "publishedAt": "2026-01-29T16:50:18.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, ERNS 심포지엄서 AR1001 글로벌 개발 전략 발표. 국제 학회 무대에서 후보물질 가치 적극 홍보"
  },
  {
    "id": "c9fb0f3a1969",
    "title": "[모집]아리바이오, 홈캐어용 인지기능 개선 헤드밴드 판매파트너 모집 - 데일리메디팜",
    "description": "[모집]아리바이오, 홈캐어용 인지기능 개선 헤드밴드 판매파트너 모집  데일리메디팜",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%5B%EB%AA%A8%EC%A7%91%5D%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%ED%99%88%EC%BA%90%EC%96%B4%EC%9A%A9%20%EC%9D%B8%EC%A7%80%EA%B8%B0%EB%8A%A5/600/400",
    "url": "https://news.google.com/articles/CBMibkFVX3lxTE5TR1cwODNrRVdYZHA5cGNDVlRHUDVEZXJEOFI0TW1LWDBvTzNGRTY0OGRxMjRJNGMzZ1U2bkg1VWswMXUzQVdIemlZRC1BQ0xJXzlvajh3TXdGM2ZGUFRtc2Zud3hQU0QxaGZfMzl3?oc=5",
    "publishedAt": "2026-01-29T08:00:00.000Z",
    "language": "ko",
    "importance": 9,
    "summary": "아리바이오, 홈캐어용 인지기능 개선 헤드밴드 판매파트너 모집. 디지털치료제 상업화 단계 진입 시사, 매출원 다각화"
  },
  {
    "id": "4b33e9e8a8d7",
    "title": "치매 주사제 ‘레켐비’ 제형·용법 다변화… 먹는약 대항마 될까 - 코메디닷컴",
    "description": "치매 주사제 ‘레켐비’ 제형·용법 다변화… 먹는약 대항마 될까  코메디닷컴",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EC%B9%98%EB%A7%A4%20%EC%A3%BC%EC%82%AC%EC%A0%9C%20%E2%80%98%EB%A0%88%EC%BC%90%EB%B9%84%E2%80%99%20%EC%A0%9C%ED%98%95%C2%B7%EC%9A%A9%EB%B2%95%20%EB%8B%A4/600/400",
    "url": "https://news.google.com/articles/CBMiQkFVX3lxTFBfbHpkZ2htVXJURW1WdGJIUHpTdkZmVzFGRDJlaTZBbktHZE00dTlvVndQOGZ0Y0FldmZJZVVWV1g4Zw?oc=5",
    "publishedAt": "2026-01-29T08:00:00.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "레켐비 제형·용법 다변화 추진, 피하주사·경구 전환 논의. 먹는 약 대항마 등장 시 AR1001 경구제 경쟁력 재평가 필요"
  },
  {
    "id": "fb5a920a060f",
    "title": "\"최대 3000만원까지 보장\"…손보사들 레켐비 잡기 나섰다 - 아시아타임즈",
    "description": "\"최대 3000만원까지 보장\"…손보사들 레켐비 잡기 나섰다  아시아타임즈",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%22%EC%B5%9C%EB%8C%80%203000%EB%A7%8C%EC%9B%90%EA%B9%8C%EC%A7%80%20%EB%B3%B4%EC%9E%A5%22%E2%80%A6%EC%86%90%EB%B3%B4%EC%82%AC/600/400",
    "url": "https://news.google.com/articles/CBMiXkFVX3lxTE5JNk9SWWt3a29lbDNCaWdaTmJzY3lqcW9Lb1ZORUt0ZlVvV21kcV9WS0hXLVQzVjZ3TTNhS0R3WWFTWmdOMjYwbGMxWTlkQTBOM3BjQjhvaXBYVGxTZmc?oc=5",
    "publishedAt": "2026-01-29T08:00:00.000Z",
    "language": "ko",
    "importance": 7,
    "summary": "손보사 레켐비 보장 경쟁, 최대 3000만 원까지 보장. 보험 급여 확대로 고가 치료제 환자 접근성 대폭 개선"
  },
  {
    "id": "91e263900dc2",
    "title": "Why drug approval in Canada should not rely on foreign regulators - The Conversation",
    "description": "Why drug approval in Canada should not rely on foreign regulators  The Conversation",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Why%20drug%20approval%20in/600/400",
    "url": "https://news.google.com/articles/CBMiogFBVV95cUxQTWVxNjM3clBLeEJHcDdpZlh1MUMyNGVSSzBBZWQ2aHUzekZkcUZvY0MzdjBmbTIwRW8wRWpWY0haZHNyYkpjVktlZHdaanZVX3hfd050MnFva2UwSTZIMDhZUEZoTUxEUG5MbldtamU2czlaYlE3SmtBOUZrX0otaEJHQUhqdF94UjUtanNHMUZuR2VteFZ4cUoya3VveVZnU3c?oc=5",
    "publishedAt": "2026-01-29T08:00:00.000Z",
    "language": "en",
    "importance": 1,
    "summary": "캐나다 약물 승인 해외 규제기관 의존 문제 제기. 알츠하이머 치료제 글로벌 승인 경로에 간접 영향 가능"
  },
  {
    "id": "2d1c59dd5d6f",
    "title": "듀켐바이오, 알츠하이머 치료제 시장 확대에 따른 역대급 실적 개선 - 메디컬투데이",
    "description": "듀켐바이오, 알츠하이머 치료제 시장 확대에 따른 역대급 실적 개선  메디컬투데이",
    "source": "Google News",
    "category": "market",
    "imageUrl": "https://picsum.photos/seed/%EB%93%80%EC%BC%90%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%20%EC%B9%98%EB%A3%8C%EC%A0%9C%20%EC%8B%9C%EC%9E%A5%20/600/400",
    "url": "https://news.google.com/articles/CBMiXEFVX3lxTE96VkxwRjdyVjFodUlrcGNxbzVKMTQ1STVILXlIMXh0UUVpUnZEcUNjVlVxTFpRT0xsVFRtWklKOTJkTVo0ZzRqeGR4SV81Vk5Dc2ROOVBnZjNwczg20gFsQVVfeXFMUE14cHdRTWJ6RE1QdFZBU1JIZ0J1ei1qV0tfbmZ6azhHb1JvSm1VSWpxLUhPeGp5dGZ3SFN0NC02eGxBVVFDZU5jRXVxVy15MDByWlZwMi1mMnFVT3kzZnlSRkkyZDVOU2RwRG9u?oc=5",
    "publishedAt": "2026-01-29T08:00:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "듀켐바이오, 알츠하이머 치료제 시장 확대로 역대급 실적. 레켐비 처방 증가가 진단시약 수요 급증으로 연결"
  },
  {
    "id": "e7c7c643de3b",
    "title": "듀켐바이오, 지난해 영업익 74억…전년 대비 46.6%↑ - 약사공론",
    "description": "듀켐바이오, 지난해 영업익 74억…전년 대비 46.6%↑  약사공론",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EB%93%80%EC%BC%90%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EC%A7%80%EB%82%9C%ED%95%B4%20%EC%98%81%EC%97%85%EC%9D%B5%2074%EC%96%B5%E2%80%A6%EC%A0%84/600/400",
    "url": "https://news.google.com/articles/CBMibEFVX3lxTE1WR25QbENZbEQ3UFlCYzhXYkhDRzcwYmVEcXFwSC1kbXYzQV9ITlF3dVRWNEhoV0NvbDFzbzRnQ1lSSWZxU0EwR3NsQ1JlRWJCWEt4NUt1TjdUd3dpc1VMT0U2cWl4NjJzQ1NLbQ?oc=5",
    "publishedAt": "2026-01-29T08:00:00.000Z",
    "language": "ko",
    "importance": 2,
    "summary": "듀켐바이오, 2025년 영업익 74억 원 전년 대비 46.6% 증가. 치매 진단시약 매출 성장이 실적 견인"
  },
  {
    "id": "bfc1182b21d9",
    "title": "듀켐바이오, 알츠하이머 치료제 수요 확대에 영업익 47%↑ - 컨슈머타임스(Consumertimes)",
    "description": "듀켐바이오, 알츠하이머 치료제 수요 확대에 영업익 47%↑  컨슈머타임스(Consumertimes)",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EB%93%80%EC%BC%90%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%20%EC%B9%98%EB%A3%8C%EC%A0%9C%20%EC%88%98%EC%9A%94%20/600/400",
    "url": "https://news.google.com/articles/CBMiakFVX3lxTE4yU1RzQlE4QmRORmJIMWl2RWRoQVlPQ01nYUV3VVFjcl9GQWcycThjaGJEZTBnb2R3OE1nYkJBaHJONUVPNTBUZWhJZG0zUlgzZ2laeDNsYWN3ZlN6clRQTVJCZzZpZUJwalE?oc=5",
    "publishedAt": "2026-01-29T08:00:00.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "듀켐바이오, 알츠하이머 치료제 수요 확대에 힘입어 영업이익 47% 급증. 치매 치료 생태계 성장 수혜 확인"
  },
  {
    "id": "34442cfe32e1",
    "title": "릴리, 알츠하이머·비만 다음은 난청…차세대 모달리티로 ‘RNA·유전자편집' 낙점 - 팜이데일리",
    "description": "릴리, 알츠하이머·비만 다음은 난청…차세대 모달리티로 ‘RNA·유전자편집' 낙점  팜이데일리",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EB%A6%B4%EB%A6%AC%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%C2%B7%EB%B9%84%EB%A7%8C%20%EB%8B%A4%EC%9D%8C%EC%9D%80%20%EB%82%9C%EC%B2%AD%E2%80%A6/600/400",
    "url": "https://news.google.com/articles/CBMibkFVX3lxTE5kQ2EyOFlJY3F2SGpEZzlMZjNRR1JSQVR6YVRpTTRqTXYxWFYxb08wVndWMWpyN1VPd1ZFenNESUhveDlQN0J5Rm04azF5T29BWjh4NVVRWTJ0Sm1LNXZmUHhRVENVTGZVYnRJLWFR?oc=5",
    "publishedAt": "2026-01-29T08:00:00.000Z",
    "language": "ko",
    "importance": 5,
    "summary": "릴리, 알츠하이머·비만 이후 난청 치료 진출. RNA·유전자편집 등 차세대 모달리티 플랫폼으로 파이프라인 확장"
  },
  {
    "id": "669856c8b4d1",
    "title": "듀켐바이오, 2025년 영업익 74억원…전년比 47% ↑ - 한스경제",
    "description": "듀켐바이오, 2025년 영업익 74억원…전년比 47% ↑  한스경제",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EB%93%80%EC%BC%90%EB%B0%94%EC%9D%B4%EC%98%A4%2C%202025%EB%85%84%20%EC%98%81%EC%97%85%EC%9D%B5%2074%EC%96%B5/600/400",
    "url": "https://news.google.com/articles/CBMia0FVX3lxTE53N3hwcHdNblJuV0gzellkbGxsRklLZE1vVTYxSVIzelFqd0RFTVdWMkZWUld3czI1WUJHY1dkWjR6Z2ZZbDE1bG1YOTdKbEN6UkNGQk9wLWtXSkd3eGEyenlyNS0xWUFYT18w0gFvQVVfeXFMTTBDU09FcUhzX2tseFJTcUYzWFUzT3RndGgtQ0JYZGtXalFWa1JMc3JQem5HLUx2RDJPNnVQazhEc08tc0dCUFo2RmRtWFpDX3lkcVJwYy1mTWE5Vkc1WXVjRm5QYW83UU1wenpvZkpz?oc=5",
    "publishedAt": "2026-01-29T08:00:00.000Z",
    "language": "ko",
    "importance": 2,
    "summary": "듀켐바이오 2025년 영업익 74억 원, 전년비 47% 성장. 치매 진단 관련 매출 고성장 지속 확인"
  },
  {
    "id": "8d19cc9c0237",
    "title": "일라이 릴리, 알츠하이머·비만 다음으로 난청 치료제 개발 박차 - 메디컬투데이",
    "description": "일라이 릴리, 알츠하이머·비만 다음으로 난청 치료제 개발 박차  메디컬투데이",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EC%9D%BC%EB%9D%BC%EC%9D%B4%20%EB%A6%B4%EB%A6%AC%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%C2%B7%EB%B9%84%EB%A7%8C%20%EB%8B%A4%EC%9D%8C%EC%9C%BC/600/400",
    "url": "https://news.google.com/articles/CBMiXEFVX3lxTE9lQmswYUVlSDUtZnJSRGZYVEY2X2VVRkJzVmo4Q1FyY1pjX250SFdJODdkQkRZekp3eENaM2lGUE9JOERIS1JSUGwydlZTVWhFcFRVZVJSV0YtLVlp0gFsQVVfeXFMUDRmZzB0X1RaQ2RxM0FUQmZWcHNld0NlaWFLSVVIbnRlOVhKamNyNFBNTjRfMUxWZXQ0bFI5WEhTTVF5eHBGbGVRTGRhbElQTDFycjA5YVVYUkJiVENKMG1zUnJpcDRYUXAzYkVD?oc=5",
    "publishedAt": "2026-01-29T08:00:00.000Z",
    "language": "ko",
    "importance": 6,
    "summary": "릴리, 알츠하이머·비만 다음 타깃으로 난청 치료제 개발 가속. 다중 치료영역 확장으로 파이프라인 리스크 분산 전략"
  },
  {
    "id": "3293a2d822cd",
    "title": "글로벌서 관심 받는 중추신경질환 치료제…K-제약사 '기회의 영역' - 포인트데일리",
    "description": "글로벌서 관심 받는 중추신경질환 치료제…K-제약사 '기회의 영역'  포인트데일리",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EA%B8%80%EB%A1%9C%EB%B2%8C%EC%84%9C%20%EA%B4%80%EC%8B%AC%20%EB%B0%9B%EB%8A%94%20%EC%A4%91%EC%B6%94%EC%8B%A0%EA%B2%BD%EC%A7%88%ED%99%98%20%EC%B9%98%EB%A3%8C/600/400",
    "url": "https://news.google.com/articles/CBMicEFVX3lxTE5FUHBLcW5NLWJLanN2c3pkYXUyek9HVWxRcURQSFNkRXBfYkZXcFc5Y0lfMHk0TjFEVURkSnAwbXNzemJYRFpGdHFreVl3aEl1OC0xZk5IZE5USDczYU9MYUZLcXF4V0VlUmhXM0kwWmbSAXRBVV95cUxQVl9xUzJ1bE5ITTlfSDZJM3hYQUNOQ2ZrUUVCcm1rMzhzbHF1RU5OaVpPQWNlQzhnckU3ZU5obWFHcEVkSGdhaGY2dlRqZlZ0SzFYcDh2OEtaRzBOemo5aXpKME1DbUFoODUzdDMyNXFnb1NENw?oc=5",
    "publishedAt": "2026-01-29T08:00:00.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "글로벌 중추신경질환 치료제 주목, K-제약사 기회 영역 조명. 알츠하이머 포함 CNS 신약 한국 기업 경쟁력 분석"
  },
  {
    "id": "38db896c20fc",
    "title": "듀켐바이오, 지난해 영업이익 47% 증가한 74억 원 달성 - 메드월드뉴스",
    "description": "듀켐바이오, 지난해 영업이익 47% 증가한 74억 원 달성  메드월드뉴스",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EB%93%80%EC%BC%90%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EC%A7%80%EB%82%9C%ED%95%B4%20%EC%98%81%EC%97%85%EC%9D%B4%EC%9D%B5%2047%25%20/600/400",
    "url": "https://news.google.com/articles/CBMibkFVX3lxTFBkekp5M0dyZHNrQjZYTl9NTXA4VjN5b2lTcm52eTF3WnZKZjNacDdkMTZSME82UXFEamx0c2l6SktObWs1NFVWWWZPSmtqSFVMcUpwNENNU1FsTmpxOFlvN0hXZFpqVWhjd2cxOWhn?oc=5",
    "publishedAt": "2026-01-29T04:39:30.000Z",
    "language": "ko",
    "importance": 2,
    "summary": "듀켐바이오, 2025년 영업이익 47% 성장한 74억 원 달성. 치매 진단시약 수요 확대가 실적 성장 핵심 동인"
  },
  {
    "id": "ba8b17030590",
    "title": "“대마의 뇌 보호 효과는 살리고, 건망증은 지웠다”… 알츠하이머 치료의 ‘황금 조합’ 발견 - 금융경제플러스",
    "description": "“대마의 뇌 보호 효과는 살리고, 건망증은 지웠다”… 알츠하이머 치료의 ‘황금 조합’ 발견  금융경제플러스",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%E2%80%9C%EB%8C%80%EB%A7%88%EC%9D%98%20%EB%87%8C%20%EB%B3%B4%ED%98%B8%20%ED%9A%A8%EA%B3%BC%EB%8A%94%20%EC%82%B4%EB%A6%AC%EA%B3%A0%2C%20%EA%B1%B4/600/400",
    "url": "https://news.google.com/articles/CBMibEFVX3lxTE5qem5tZDZ3N0dJQWRLX2pIdGhHa0ZvdmVOMlRnQlJXX3k4bXZodjhRS0N6d3VIT1RiVjVzcXpBXzlyQWtSaXhHU2JaU3F4YTdNYlhRQzR6TlBfM3Jqd3F5TlhGaUdGcGs4dXVaUw?oc=5",
    "publishedAt": "2026-01-29T01:20:00.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "대마 뇌보호 성분+기존 약물 조합으로 알츠하이머 치료 '황금 조합' 발견. 건망증 부작용 제거한 전임상 성과"
  },
  {
    "id": "a9f639eab012",
    "title": "Regulatory Milestones Could Shape Annovis Bio’s Clinical Trajectory - AD HOC NEWS",
    "description": "Regulatory Milestones Could Shape Annovis Bio’s Clinical Trajectory  AD HOC NEWS",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Regulatory%20Milestone/600/400",
    "url": "https://news.google.com/articles/CBMivgFBVV95cUxPMGxwd2dUY2hVVE9KcnZ0UmJFTnRQb3duY3N0a0JaY3JOSUpBVXJ2R2RfVXczaklZdjlkcXVzcFJEcU5xZm5XMjhfVTBvaURyTE0zSFg1TnJTQkxBTWFjRmMyejVZcGZvTlZCenlQa3NkYUo2MmVpTDR1ZU9yTU5fcUpRQ0tfSXNEV0p1TzQ3NlpFY2trN1NNazZkYUdQbVdySjJ2Tzk4SkNiZzRvS3Frb2xZNGRjVlV4MnMxU1ZB?oc=5",
    "publishedAt": "2026-01-28T08:00:00.000Z",
    "language": "en",
    "importance": 7,
    "summary": "애노비스 바이오, 규제 마일스톤 달성이 분타네탑 3상 궤도 결정. 경구 다중표적제 임상 진전 모니터링 필요"
  },
  {
    "id": "b8af6af69156",
    "title": "선두주자 없는 CNS 시장…차세대 승부처로 부상 - 아주경제",
    "description": "선두주자 없는 CNS 시장…차세대 승부처로 부상  아주경제",
    "source": "Google News",
    "category": "market",
    "imageUrl": "https://picsum.photos/seed/%EC%84%A0%EB%91%90%EC%A3%BC%EC%9E%90%20%EC%97%86%EB%8A%94%20CNS%20%EC%8B%9C%EC%9E%A5%E2%80%A6%EC%B0%A8%EC%84%B8%EB%8C%80%20%EC%8A%B9/600/400",
    "url": "https://news.google.com/articles/CBMiWkFVX3lxTE13V0ExeGdwQ0xQT01OMGw0WV9IRUtXbkNfZU8zUFI1VXhId0FVQXBKLUJnWUJRVGdzMDJoNDZqUG9YWjl1T3JPd0dSUS1NS2R1SGNNV1ZCMXU2QdIBWEFVX3lxTE84MDJYUTR1dWZTZlJnUUF3cl9EanpBb0cwcGFnSEw4OUxuZ05WZ0ExckxOUkpOdzhTeTl1ZDk4VG40TlVSRURiV19rYS0xOXJsSFJRdUl1TjA?oc=5",
    "publishedAt": "2026-01-28T07:49:38.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "CNS 치료제 시장 선두주자 부재, 차세대 승부처로 부상. 알츠하이머 포함 뇌질환 신약 시장 기회 개방 상태"
  },
  {
    "id": "f99c27f2a96c",
    "title": "아리바이오, 이병건 전 한국바이오협회 이사장 특별고문 초빙 - 팜이데일리",
    "description": "아리바이오, 이병건 전 한국바이오협회 이사장 특별고문 초빙  팜이데일리",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EC%9D%B4%EB%B3%91%EA%B1%B4%20%EC%A0%84%20%ED%95%9C%EA%B5%AD%EB%B0%94%EC%9D%B4%EC%98%A4%ED%98%91%ED%9A%8C/600/400",
    "url": "https://news.google.com/articles/CBMibkFVX3lxTFBiazhpLUlMcVJaSWVBYUp0UVZ4MElUdHhfbkZwbWppVy1wdktDUlBERGxzdnQ3SWliS0RVUGltbzZaZnptaEl6Y183N3JwMlloOUNORE41U0Z5eE1selR5dXpMcE5IOFk4WnRpVzZ3?oc=5",
    "publishedAt": "2026-01-27T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, 이병건 전 한국바이오협회 이사장을 특별고문 초빙. 규제·산업 네트워크 강화로 사업 추진력 제고"
  },
  {
    "id": "13d23bcfc96b",
    "title": "아리바이오 ‘반전’ 신장·간질환 신약 나올까… 美 독점 계약 본격 체결 - 이코노미톡뉴스",
    "description": "아리바이오 ‘반전’ 신장·간질환 신약 나올까… 美 독점 계약 본격 체결  이코노미톡뉴스",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%20%E2%80%98%EB%B0%98%EC%A0%84%E2%80%99%20%EC%8B%A0%EC%9E%A5%C2%B7%EA%B0%84%EC%A7%88%ED%99%98%20%EC%8B%A0%EC%95%BD/600/400",
    "url": "https://news.google.com/articles/CBMibEFVX3lxTE9jcF9EOGZwRVhlblhUUXU3a1lYSTBCam1pWUFqWFA4d0NNc250Q0FUUVRrRGRkb29ROVJjV2RLa1Y0MDVuc1JtNHIwcmQ1U0p3WnkzcTJ1QVlIcU9sUjVDU1BMMThuOU9pUG9XZw?oc=5",
    "publishedAt": "2026-01-27T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, 신장·간질환 신약 미국 독점 계약 체결. AR1001 외 PDE-5 억제제 포트폴리오로 매출원 다각화 본격화"
  },
  {
    "id": "26ade1f6641c",
    "title": "에자이, ‘레켐비SC’ 시작치료 라벨 “FDA 우선심사” - 바이오스펙테이터",
    "description": "에자이, ‘레켐비SC’ 시작치료 라벨 “FDA 우선심사”  바이오스펙테이터",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%EC%97%90%EC%9E%90%EC%9D%B4%2C%20%E2%80%98%EB%A0%88%EC%BC%90%EB%B9%84SC%E2%80%99%20%EC%8B%9C%EC%9E%91%EC%B9%98%EB%A3%8C%20%EB%9D%BC%EB%B2%A8/600/400",
    "url": "https://news.google.com/articles/CBMiV0FVX3lxTE0xVFp4N3lyUmM4V3dQY2xGNWF0azl6WWdRMXVIc3hvbGZDT2xMUTYwbE9aNWNFN3dFa2RGNTJybHJSR1FuZ0pBTXVHLUhBRGtwbVZQeHFsZw?oc=5",
    "publishedAt": "2026-01-27T08:00:00.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "에자이, 레켐비 피하주사 시작치료 라벨 FDA 우선심사 지정. 투여 편의성 개선으로 시장 점유율 확대 가속 전망"
  },
  {
    "id": "a9d33015e486",
    "title": "에자이, 알츠하이머병 치료제 SC ‘레켐비 아이클릭’ 美 sBLA 우선심사 지정 - 더바이오",
    "description": "에자이, 알츠하이머병 치료제 SC ‘레켐비 아이클릭’ 美 sBLA 우선심사 지정  더바이오",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EC%97%90%EC%9E%90%EC%9D%B4%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%EB%B3%91%20%EC%B9%98%EB%A3%8C%EC%A0%9C%20SC%20%E2%80%98/600/400",
    "url": "https://news.google.com/articles/CBMibEFVX3lxTFBJbzBDeXNFbFl0bDR2VWo5ZUkyMjZrUk1ZSWFzSlhwbWpieFA1MWQ3ZE9DMVhUeWVjLXVnbVZlaWZDWnhmckZOaUFfQ0cwaWwtay1uVDY5Z0s0OWE1eTdITDB1dUVQS0xncGNkctIBcEFVX3lxTE5WTHg5YS1ETUVwWWxWc2RBVmEwel95U0JqY1R1UHFMVFlaNWNmU0pRS21QTHlpMlZtZWVOTFduQXBFRVRlTkNrUE5YNkNicUhXdEVjZkhzWFVWX01jbTdnUFdFSEhuZE1mcUI0NjZBSTY?oc=5",
    "publishedAt": "2026-01-27T08:00:00.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "에자이, 알츠하이머 치료제 레켐비 피하주사 미국 sBLA 우선심사 지정. 자가투여 시대 개막으로 경쟁 환경 변화"
  },
  {
    "id": "5880d4ac9536",
    "title": "레켐비, 美 FDA 우선심사 진입…‘주 1회 SC 개시요법’ 문턱 - 메디코파마",
    "description": "레켐비, 美 FDA 우선심사 진입…‘주 1회 SC 개시요법’ 문턱  메디코파마",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/%EB%A0%88%EC%BC%90%EB%B9%84%2C%20%E7%BE%8E%20FDA%20%EC%9A%B0%EC%84%A0%EC%8B%AC%EC%82%AC%20%EC%A7%84%EC%9E%85%E2%80%A6%E2%80%98/600/400",
    "url": "https://news.google.com/articles/CBMickFVX3lxTE5sVHFubnJMQ2I4Tm51dk1UcXVlSzYtdEVPVmV3YWVuN3pCWUlLZjNwelZIaURGenR1N0NRV3pRaE1RR2xuam85MGFzbTRMdUROWk9NTWd4Y1gtSjQ4ekE3RnNCOUpBeFZYZWlGNU03VHVQUQ?oc=5",
    "publishedAt": "2026-01-27T08:00:00.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "레켐비, 주 1회 피하주사 개시요법 FDA 우선심사 진입. 투여 편의성 대폭 개선으로 처방 장벽 낮아져 시장 확대 기대"
  },
  {
    "id": "88635effefbd",
    "title": "Developer granted patent in Japan for masitinib use in progressive MS - Multiple Sclerosis News Today",
    "description": "Developer granted patent in Japan for masitinib use in progressive MS  Multiple Sclerosis News Today",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/Developer%20granted%20pa/600/400",
    "url": "https://news.google.com/articles/CBMiywFBVV95cUxQTlJ4YUFjaG94ODFINnNnNUFFV05ENXNROVBFS3dxcUxZaEdfejRZX0FXMUNBeV96VGRDdTk1TC11eUczTWYzV3JnUnhxTzVQcjkzYlA2UUl1S3J0bVlUVTlPZlZtaC1hQjFWWktaU1lhelRpYUFiSWQ2SkRYd3VOUTBJUXNMMEJvU1NieTNpWWJfdURmWmFXLVF6SGlnX2tKSExPbzVMd1owZGZsR0JEU0ljTlhQS2VUcGlMV3IxbHFhcHVvanJNdFVXQQ?oc=5",
    "publishedAt": "2026-01-27T08:00:00.000Z",
    "language": "en",
    "importance": 5,
    "summary": "마시티닙, 일본에서 진행성 다발성경화증 특허 획득. 알츠하이머 적응증도 병행 개발 중으로 경쟁 파이프라인 주시"
  },
  {
    "id": "365464f36191",
    "title": "CTAD 2025: Highlights in Alzheimer Disease Research - Neurology Advisor",
    "description": "CTAD 2025: Highlights in Alzheimer Disease Research  Neurology Advisor",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/CTAD%202025%3A%20Highlight/600/400",
    "url": "https://news.google.com/articles/CBMihgFBVV95cUxNbDFQU3dXQ3FfSXVJTHU5MHZfRzU2Y3JsUDZrRE1oa2d6NVY2MXZFLWVVNlljMUw2UVRkYndrcDdCbkNwcVNsZDY3X040anhyWHdBQ3NZQS1OaEFiS1JCTWowX0tlZTBVbGxaUGJEbDV2bVQ1cDlQU3laZnBtZFdGdll1ai02dw?oc=5",
    "publishedAt": "2026-01-27T08:00:00.000Z",
    "language": "en",
    "importance": 4,
    "summary": "CTAD 2025 학회 알츠하이머 연구 하이라이트 정리. 최신 임상 데이터와 연구 트렌드 종합 리뷰"
  },
  {
    "id": "880eb6f27f75",
    "title": "Type C Meeting With FDA Completed for Zervimesine in Dementia With Lewy Bodies - Psychiatric Times",
    "description": "Type C Meeting With FDA Completed for Zervimesine in Dementia With Lewy Bodies  Psychiatric Times",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Type%20C%20Meeting%20With%20/600/400",
    "url": "https://news.google.com/articles/CBMitwFBVV95cUxPcldPZnZyeVA4TjJNazNVUllMN3NjcllENVN5SFFQdGJSN3kyNGJPSE9XR1RjdHdIZ2Z0ZDd5Y2tLYTZqSW81NmlJVi1jaUQxc2VoZTlHWERydm1TR2Q3TjBzV2l0clFQREQ4TzVFUlFCYm5FU2RjRzZVcDl0cDhkUmxPUGJhdmlkMmN1NDMtalc0V1hxRmt6akp1OWdsYUJPZmRCeG0zUGJGa1RXamZVZEdfYnd1bDQ?oc=5",
    "publishedAt": "2026-01-27T08:00:00.000Z",
    "language": "en",
    "importance": 3,
    "summary": "제르비메신, 루이체 치매 적응증 FDA Type C 미팅 완료. 루이체 치매 치료제 파이프라인 진전으로 치매 시장 확장"
  },
  {
    "id": "78bceeace5a2",
    "title": "China regulators suspend sale of Sun Pharma's dementia med after site inspection - Fierce Pharma",
    "description": "China regulators suspend sale of Sun Pharma's dementia med after site inspection  Fierce Pharma",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/China%20regulators%20sus/600/400",
    "url": "https://news.google.com/articles/CBMivgFBVV95cUxNbmFVY3U4dmlTcjljdGVkN3pYckxnaWhUc3YwYjhHc0NfS3ZfMGJpbFh6dzNzSEh3UU96ZFFseEUxRURzbEtjdUdnLXBBWFhNdjB5Ujd2eEc1UEprRVFwQ2Z0Q3dqVlJIRUtrUVM0anVvRjJtQzdOc2JJd1FTdVZneVdVUERoMWtKQmdWYnNFOHdRbGRnbU5XRmpvUkpfTUdzN1c0YWNBcmR4X0NwTlVtWG5GNG9xS0ZMejVIUXBn?oc=5",
    "publishedAt": "2026-01-27T08:00:00.000Z",
    "language": "en",
    "importance": 3,
    "summary": "중국 규제당국, 선파마 치매약 현장실사 후 판매 중단 조치. 중국 시장 규제 강화로 글로벌 치매약 진출 환경 변화"
  },
  {
    "id": "4165b5b0d3e8",
    "title": "'레켐비' 피하주사제 시작요법 FDA 승인신청 접수 - 메디파나뉴스",
    "description": "'레켐비' 피하주사제 시작요법 FDA 승인신청 접수  메디파나뉴스",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/'%EB%A0%88%EC%BC%90%EB%B9%84'%20%ED%94%BC%ED%95%98%EC%A3%BC%EC%82%AC%EC%A0%9C%20%EC%8B%9C%EC%9E%91%EC%9A%94%EB%B2%95%20FDA/600/400",
    "url": "https://news.google.com/articles/CBMia0FVX3lxTE1uOFZPSjYwSkVObWdXbDJESVBZZ0dUS1hDcGpGaWdoQWZKckhlRTlVZmdFcnZfNkxiVU0wR2t6R284cUxWdk14OEoxWUNxSVhWMS13RjBaVzRHX0FCV0JvYXJuWnhnXzJBY2JN?oc=5",
    "publishedAt": "2026-01-27T02:33:34.000Z",
    "language": "ko",
    "importance": 9,
    "summary": "레켐비 피하주사 시작요법 FDA 승인신청 접수. 정맥주사→피하주사 전환으로 환자 편의성 혁신, 처방 확대 가속"
  },
  {
    "id": "e469a18aabc6",
    "title": "FDA, 레켐비 피하주사 시작용량 우선심사 - 의약뉴스",
    "description": "FDA, 레켐비 피하주사 시작용량 우선심사  의약뉴스",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/FDA%2C%20%EB%A0%88%EC%BC%90%EB%B9%84%20%ED%94%BC%ED%95%98%EC%A3%BC%EC%82%AC%20%EC%8B%9C%EC%9E%91%EC%9A%A9%EB%9F%89%20%EC%9A%B0/600/400",
    "url": "https://news.google.com/articles/CBMiaEFVX3lxTE8wak9hbnBJTHJ4QXFSNmUyWUlWV08xTFZzN2dKZUVQd2Q0NDQxX0U0aGlIaUtUN2hVOFFseHFrX0FBWFdhYTZXbmphR1BESlAxRXZaXzJDUGlIdFFISlpTNDVvVVBSV2Ja?oc=5",
    "publishedAt": "2026-01-26T21:01:09.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "FDA, 레켐비 피하주사 시작용량 우선심사 결정. 올해 상반기 승인 전망으로 알츠하이머 치료 접근성 전환점"
  },
  {
    "id": "790e02bc3749",
    "title": "알츠하이머 치료, ‘병원’ 대신 ‘집’으로… 레켐비, 피하주사 시대 연다 - 금융경제플러스",
    "description": "알츠하이머 치료, ‘병원’ 대신 ‘집’으로… 레켐비, 피하주사 시대 연다  금융경제플러스",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%20%EC%B9%98%EB%A3%8C%2C%20%E2%80%98%EB%B3%91%EC%9B%90%E2%80%99%20%EB%8C%80%EC%8B%A0%20%E2%80%98%EC%A7%91/600/400",
    "url": "https://news.google.com/articles/CBMibEFVX3lxTFBnQjFLbzU2anllZFFUazAwVjcxWWp3b3UtV1JOQ0dmOG9LMENaaC1HTm9iS3U3bmhNajVab1JWcWxGQl81Qm1rLWs0ajN1OGhFYXVRM0R2RWc4OXAyLWpQS0x4WFVKZ2hrc0tDeQ?oc=5",
    "publishedAt": "2026-01-26T08:00:00.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "레켐비 피하주사 시대 개막, 병원 대신 가정 투여 가능. 치매 치료 패러다임 변화로 시장 규모 확대 전망"
  },
  {
    "id": "9b8fef1e22e7",
    "title": "피 한 방울로 치매 진단... 피플바이오·수젠텍 등 진단株 동반 상승랠리 - 핀포인트뉴스",
    "description": "피 한 방울로 치매 진단... 피플바이오·수젠텍 등 진단株 동반 상승랠리  핀포인트뉴스",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%ED%94%BC%20%ED%95%9C%20%EB%B0%A9%EC%9A%B8%EB%A1%9C%20%EC%B9%98%EB%A7%A4%20%EC%A7%84%EB%8B%A8...%20%ED%94%BC%ED%94%8C%EB%B0%94/600/400",
    "url": "https://news.google.com/articles/CBMic0FVX3lxTE1pcG1NY0JZLTliUkpzSFkzeTNaYnllQzREMmttY3ZQc0g0SlRtcUhtbGRiN0ZEUGc5VHQxckVOTzNtNU1YSkctUWF5VHRJQmFNbHdvaHpTVDB0YVMwTENWRTlKMlRmZVhUUmtrQ1g3Y0duYjTSAXdBVV95cUxQWklKU2FpanJTX2dKZmZRQ1h4NzhCSHo5MmVkR0tNMWZLSTVGSFVJZDQ5RUd4QzF0SVlZM3FrU0tKajdEbkhoUXdpekVVVUEyR2U5SmFlb0JXbFJLU3hjdVZiMWhUQnltcndNcmpzTnNHNEpCQ0FKMA?oc=5",
    "publishedAt": "2026-01-26T08:00:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "혈액 한 방울로 치매 진단 가능, 피플바이오·수젠텍 등 진단주 동반 상승. 간편 진단 기술이 치료제 시장 성장 촉매"
  },
  {
    "id": "ddeef26d3a78",
    "title": "\"에이비엘바이오 그랩바디 가치 10조 이상\"...'BBB 투과' 재평가-다올투자증권 - PRESS9",
    "description": "\"에이비엘바이오 그랩바디 가치 10조 이상\"...'BBB 투과' 재평가-다올투자증권  PRESS9",
    "source": "Google News",
    "category": "market",
    "imageUrl": "https://picsum.photos/seed/%22%EC%97%90%EC%9D%B4%EB%B9%84%EC%97%98%EB%B0%94%EC%9D%B4%EC%98%A4%20%EA%B7%B8%EB%9E%A9%EB%B0%94%EB%94%94%20%EA%B0%80%EC%B9%98%2010%EC%A1%B0/600/400",
    "url": "https://news.google.com/articles/CBMiZEFVX3lxTE55M3QxQUxvWjNOTnJ6T3lsekRuV3hwTzJUSmxGTEdoYlRvZmdYVDlYb0JYQjYtUDNScUJzYUJFTlVtdDBhX182NjZ5a1E5WkJqVW1KN09lbUwtVURmc2UtWFpheEQ?oc=5",
    "publishedAt": "2026-01-26T08:00:00.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "에이비엘바이오 그랩바디 플랫폼 가치 10조 이상 평가. BBB 투과 기술 재평가로 뇌질환 치료제 전달 기술 주목"
  },
  {
    "id": "925335b62a5b",
    "title": "치매 신약 '레켐비' 처방 1년 새 26배 폭증···약값만 연 5000만원 - 여성경제신문",
    "description": "치매 신약 '레켐비' 처방 1년 새 26배 폭증···약값만 연 5000만원  여성경제신문",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EC%B9%98%EB%A7%A4%20%EC%8B%A0%EC%95%BD%20'%EB%A0%88%EC%BC%90%EB%B9%84'%20%EC%B2%98%EB%B0%A9%201%EB%85%84%20%EC%83%88%20/600/400",
    "url": "https://news.google.com/articles/CBMic0FVX3lxTE5pbG04N0hneTVmLWwzekF3MUY4bEV5UGZpMmVoVEN6d2FlN0w0eTlNM2h5dlRYQ3ZCU3JPVkVhcnZ3dTV6eUFEUFZ2NW9BOW1ZVGVmZ1o0bzV1Y2NHdUh5ckh4RnRfYWRwNG5ZRlUycVhBTDTSAXdBVV95cUxQSl9vMlRDeHVGZTc2MEk5cXhNRndGT2ZtbF9nVTNjN0lJQ0prTlpiRlhhNjlWaE1jaThtaHlhcG5XSHBMY3Zkcm54QUFaZ25vdWM4cHl0aC1xSmJiTXB3UU84dTBXMmo1Yjh6M1VhUWRxdjlMZ2pXYw?oc=5",
    "publishedAt": "2026-01-25T13:57:22.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "레켐비 국내 처방 1년 새 26배 폭증, 연간 약값 5000만 원. 폭발적 수요 증가가 국내 알츠하이머 치료제 시장 고성장 입증"
  },
  {
    "id": "2cc19fe1da24",
    "title": "FDA Reviews Biogen's (BIIB) Alzheimer's Drug Lecanemab-irmb Appl - GuruFocus",
    "description": "FDA Reviews Biogen's (BIIB) Alzheimer's Drug Lecanemab-irmb Appl  GuruFocus",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/FDA%20Reviews%20Biogen's/600/400",
    "url": "https://news.google.com/articles/CBMiqAFBVV95cUxQWkpoRmtxMHJvUjJCWF90WGJoUzJjWHNfVkVXWjZKSnR1b21yQ0tJcUxaSDJNUlo1TmluaDBLd1NxN251Y1IyT1pJVm12MzBBS0xyZUFPYzZhZ2hlb1NJMHd6eVg0MHFBME1XN2c0X1cxUnowdENaZTV2alJPVFYxS1dxNk9STElINHg5UzRWbi1pSmlZR1VpbWd0TDdyczRlZ3JPLVhHSXI?oc=5",
    "publishedAt": "2026-01-25T08:00:00.000Z",
    "language": "en",
    "importance": 8,
    "summary": "FDA, 바이오젠 레카네맙-irmb 추가 적응증 신청 심사 개시. 알츠하이머 치료제 적응증 확대로 시장 성장 지속"
  },
  {
    "id": "791b418376e4",
    "title": "FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental - GlobeNewswire",
    "description": "FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental  GlobeNewswire",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/FDA%20Accepts%20LEQEMBI%C2%AE/600/400",
    "url": "https://news.google.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?oc=5",
    "publishedAt": "2026-01-25T08:00:00.000Z",
    "language": "en",
    "importance": 8,
    "summary": "레켐비 아이클릭(피하주사) 보충허가신청 FDA 접수, 우선심사 대상. 2026년 5월 심사 완료 예정으로 출시 임박"
  },
  {
    "id": "8b2ebbad73bc",
    "title": "Eisai and Biogen Launch LEQEMBI IQLIK, FDA Review Set for May 2026 - Intellectia AI",
    "description": "Eisai and Biogen Launch LEQEMBI IQLIK, FDA Review Set for May 2026  Intellectia AI",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/Eisai%20and%20Biogen%20Lau/600/400",
    "url": "https://news.google.com/articles/CBMioAFBVV95cUxQUFo1c2lOR2hpZm9Dc2ZBSFYybW9pdE1zNHpNVXo4WXZPcElvdXEzZ1ZCMXFndVJHRkJXUW5DRnNvbEVBZ2NBUmphQ2l4TWxIUXZCVmhnLXMtQW9DY0cwOEQwbTVfc2J5cWs4THgzOXE3b3BHdXdqWHpBS2ZtbGNBcFVZMXRzTWo2aktUY3NTTUQ2NnRBaDBfVEVvekxxQ0Zh?oc=5",
    "publishedAt": "2026-01-25T08:00:00.000Z",
    "language": "en",
    "importance": 8,
    "summary": "에자이·바이오젠, 레켐비 아이클릭 출시 추진. FDA 심사 2026년 5월 예정, 자가주사 시대 도래 카운트다운"
  },
  {
    "id": "bab7072306d7",
    "title": "아리바이오, 3300억원 규모 'PDE-5 억제제' 美 라이선스 계약 체결 - 한국경제",
    "description": "아리바이오, 3300억원 규모 'PDE-5 억제제' 美 라이선스 계약 체결  한국경제",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%203300%EC%96%B5%EC%9B%90%20%EA%B7%9C%EB%AA%A8%20'PD/600/400",
    "url": "https://news.google.com/articles/CBMiWkFVX3lxTE50bkNhaUZxWmlRbnc3eG9sdlNFanBjT2plSU80UEc0RWNSR3ZYclBlMFZLUk5UaXNGVU4wUTNaOUZTNnoyWW9WOTBkcmNGeTdoNWRFZEZvRnZ3d9IBVEFVX3lxTFB3MHRzOEtpQjhUUGZvd3JqUDBLd2l3b3phTWpObGU5WUxGeldIUXo4N1RReG1KVDBfS3hZaVJyN2VreGVuS3dPekhHQ0NydGdIVHRLbg?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, PDE-5 억제제 미국 독점 라이선스 3300억 원 규모 계약 체결. AR1001 기반 신장·간질환 적응증 확장 대형 성과"
  },
  {
    "id": "c6e754e5f10b",
    "title": "아리바이오, 美기업에 신장·간질환 신약물질 3300억 수출 - sedaily.com",
    "description": "아리바이오, 美기업에 신장·간질환 신약물질 3300억 수출  sedaily.com",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%E7%BE%8E%EA%B8%B0%EC%97%85%EC%97%90%20%EC%8B%A0%EC%9E%A5%C2%B7%EA%B0%84%EC%A7%88%ED%99%98%20%EC%8B%A0/600/400",
    "url": "https://news.google.com/articles/CBMiT0FVX3lxTE40UXhhcnQwcDBZWHJpd3FWekJaYzVpd29MLXNmbTQweVFldGN6WERFYTFmazBrTHp4eU05SU85b3dWYjdLTzlnNS16MnE0Ukk?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, 미국 기업에 신장·간질환 신약물질 3300억 원 기술수출. PDE-5 억제제 플랫폼 상업적 가치 입증"
  },
  {
    "id": "a1b366011974",
    "title": "아리바이오, 美 레스타리와 3300억 규모 'PDE-5i' 신약 계약 - 히트뉴스",
    "description": "아리바이오, 美 레스타리와 3300억 규모 'PDE-5i' 신약 계약  히트뉴스",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%E7%BE%8E%20%EB%A0%88%EC%8A%A4%ED%83%80%EB%A6%AC%EC%99%80%203300%EC%96%B5/600/400",
    "url": "https://news.google.com/articles/CBMia0FVX3lxTE84VmNuMlhhMUpYZGU2N2ZjakxMQnN6bm51ZlcxbmM5RXpNSEZ5ZkxRbllOOHdWNlZSWmpTRzl0MU1mSHEtUC0yaUtaYURQVlRPc05TUXhCdGNhU2diTGx0anQ5dkJaVUxLS1Zr?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, 미국 레스타리와 3300억 규모 PDE-5 억제제 신약 계약. 알츠하이머 외 적응증 확장으로 기업가치 재평가"
  },
  {
    "id": "1a514ec1e026",
    "title": "아리바이오, 차세대 PDE-5 억제제 2.3억 달러 규모 美 독점 계약 체결 - 팜이데일리",
    "description": "아리바이오, 차세대 PDE-5 억제제 2.3억 달러 규모 美 독점 계약 체결  팜이데일리",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EC%B0%A8%EC%84%B8%EB%8C%80%20PDE-5%20%EC%96%B5%EC%A0%9C%EC%A0%9C/600/400",
    "url": "https://news.google.com/articles/CBMibkFVX3lxTE1CNEtQdzhhZlJQMk95cVktTFhvZnc0WUtGUGsyUnN0SW5WcThmVVM2N3o2Z1VoY0tyUWZmSXl5OVVrbW43RWRfQXlIYW5qRVB1QXJXYkVLNW9LeVZOOHRPQUZVQzZ6SHB3S0JqS2FR?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, 차세대 PDE-5 억제제 2.3억 달러 규모 미국 독점 계약. 신장·간질환 확장으로 매출 다각화 기반 확보"
  },
  {
    "id": "2904f09f627c",
    "title": "아리바이오, 미국 기업에 신장·간질환약 수출…3천억원 규모 - 연합뉴스",
    "description": "아리바이오, 미국 기업에 신장·간질환약 수출…3천억원 규모  연합뉴스",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EB%AF%B8%EA%B5%AD%20%EA%B8%B0%EC%97%85%EC%97%90%20%EC%8B%A0%EC%9E%A5%C2%B7%EA%B0%84%EC%A7%88%ED%99%98/600/400",
    "url": "https://news.google.com/articles/CBMiW0FVX3lxTFBYaC11Ny1ibHlGY1ptaXZKSnZqY0lnT1BFemNhcXI0Tm1PTjRpN2JQblZmdnlOWlZ5dDhrblo2VzlYRU93UUNlejB4WEo0RWdMYlpsWS1jeUJVTlXSAWBBVV95cUxQeVlJclU0eEdaSzZ1bFA4WHZqb0hsOTZPS1I1SHB1MDByTlJlZTI3SG5mc2l0dDRFRG5rWlN6V3FqNkhLZW1fZkVkbEhCRVlLcmVGTU5ad3Y3cTFXRFdheTU?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, 미국 기업에 신장·간질환 약 수출 3000억 원 규모. 국내 바이오 대형 기술수출 사례로 업계 주목"
  },
  {
    "id": "4e9059419428",
    "title": "아리바이오, 신장·간질환 치료제 상업화 계약 체결… 3300억 규모 - 조선일보",
    "description": "아리바이오, 신장·간질환 치료제 상업화 계약 체결… 3300억 규모  조선일보",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EC%8B%A0%EC%9E%A5%C2%B7%EA%B0%84%EC%A7%88%ED%99%98%20%EC%B9%98%EB%A3%8C%EC%A0%9C%20%EC%83%81%EC%97%85/600/400",
    "url": "https://news.google.com/articles/CBMidkFVX3lxTE9vZTdOWnV0U2hDZEItVWJ3MW5tT2dxdjZpdkZZY2dUTWswRHNWSnQ4V0djd1E1MG11NGRKU2lVZ2FTVU1YUENSRVowand0MXdZMm9OU3RvQmhVc01ZLVUxTGZhdXROamhGZXBudmF0N2JHZU9WZnc?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, 신장·간질환 치료제 3300억 규모 상업화 계약 체결. PDE-5 억제제 플랫폼 기반 글로벌 사업 확장 가속"
  },
  {
    "id": "3673cd96cfb1",
    "title": "아리바이오, 美 기업에 3300억 기술 수출 - 조선비즈 - Chosunbiz",
    "description": "아리바이오, 美 기업에 3300억 기술 수출 - 조선비즈  Chosunbiz",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%E7%BE%8E%20%EA%B8%B0%EC%97%85%EC%97%90%203300%EC%96%B5%20%EA%B8%B0/600/400",
    "url": "https://news.google.com/articles/CBMihwFBVV95cUxNaWpOaDFsd3BiVkw0V0pWb09fOFlNNm5BcS1TRWVXeFZWS2JDVW1uR0t0a1ZTUUJQU0kzQUthQ2dITFNCX2hqc2NCZ19IYk1Wei15S04yZGNHZExpOXJ5SzVjT3d2NnVDejhFYnRrendTQTdGYnZublQ4dzI3Qzk5aklROXBJcEHSAZsBQVVfeXFMUGpfSTVCLXR0VTNqZFVyQXIyZ0tyTjNvQVA1N1otdmRtY1R6WWROUXZwakQtbUEyUGhfM0ZKZjhpam16enVaTWo0QktHcW1HYS1HcExyWlJqTmtZMlZnd255TlZqLVZjc3FzbENKSWpWc0dDLUtpWEhCOVVxTUVQX0d1cFY2aGFvZmhqbjhxZ1IxemZBcktQMjZmcW8?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, 미국 기업에 3300억 원 기술수출 성사. AR1001 핵심기술의 적응증 확장을 통한 대규모 수익화 달성"
  },
  {
    "id": "45572833a992",
    "title": "'확실한 한방' 절실해진 K바이오, '3상 결과' 내놓을 기업에 주목 - mt.co.kr",
    "description": "'확실한 한방' 절실해진 K바이오, '3상 결과' 내놓을 기업에 주목  mt.co.kr",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/'%ED%99%95%EC%8B%A4%ED%95%9C%20%ED%95%9C%EB%B0%A9'%20%EC%A0%88%EC%8B%A4%ED%95%B4%EC%A7%84%20K%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20/600/400",
    "url": "https://news.google.com/articles/CBMiakFVX3lxTFBmS0dlVEhwT3lkYzEtQ1ZyWXRFZzVacEY3TjA4NVd6dFotUi02a3E4MWVOZ3Fma1FUeldUU1QyVnlNNjRRSFZnVEZuaEp1OFhNVTl1TlN6NXVYRG5WNTBHT1pIVTFnVVVVQnc?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 7,
    "summary": "K바이오 올해 3상 결과 발표 주목 기업 분석. 아리바이오 포함 임상 이벤트 보유 기업 투자 관심 집중"
  },
  {
    "id": "ce3c5e27d2fc",
    "title": "아리바이오, 간·신장 신약 3300억 규모 美 기술이전 - sportalkorea.com",
    "description": "아리바이오, 간·신장 신약 3300억 규모 美 기술이전  sportalkorea.com",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EA%B0%84%C2%B7%EC%8B%A0%EC%9E%A5%20%EC%8B%A0%EC%95%BD%203300%EC%96%B5/600/400",
    "url": "https://news.google.com/articles/CBMiggFBVV95cUxPVjI1azdHUUN2ZVVZZGhxRHZSV1hLVW5rYnVPX050MWQ1X3JIS1lXUFd6cEZNZTQ0amNMUTdqX0xJeTNUNFFGb2ZVd3lBVXVqeDRuNHhJV3luNm9fdGVfQmc3XzRnejNkWVZoTGhaT1pvWENmNVRXMFRNNV9CVGRpUlVn?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, 간·신장 신약 3300억 규모 미국 기술이전 완료. PDE-5 플랫폼의 다중 적응증 전략 성과 가시화"
  },
  {
    "id": "422768d4e5df",
    "title": "아리바이오, 미 바이오 기업 레스타리에 기술수출…3,300억원 규모 - 한국경제TV 홈페이지",
    "description": "아리바이오, 미 바이오 기업 레스타리에 기술수출…3,300억원 규모  한국경제TV 홈페이지",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EB%AF%B8%20%EB%B0%94%EC%9D%B4%EC%98%A4%20%EA%B8%B0%EC%97%85%20%EB%A0%88%EC%8A%A4%ED%83%80%EB%A6%AC/600/400",
    "url": "https://news.google.com/articles/CBMid0FVX3lxTFBkd1ZpcFcyZklLZUV4Y0lmbGh4TUVQdTVqcW5aaUZiSlI4a0pkdjZtNmU5cHFLY3d6ay1lOTRZbjByMC1lV0N6X1RETUhxaEgxdGU0TXhaZmFRc1FmdEd1WlVtZmVvTVJsV2FYaVZTUlZORFFqSERZ?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, 미국 바이오 기업 레스타리에 3300억 원 기술수출. 대형 라이선스 계약으로 재무구조 개선 기대"
  },
  {
    "id": "4fc3edb2f71b",
    "title": "아리바이오 \"美 독점 라이선스 계약...희귀 신장·간질환으로 확장\" - 뉴스핌",
    "description": "아리바이오 \"美 독점 라이선스 계약...희귀 신장·간질환으로 확장\"  뉴스핌",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%20%22%E7%BE%8E%20%EB%8F%85%EC%A0%90%20%EB%9D%BC%EC%9D%B4%EC%84%A0%EC%8A%A4%20%EA%B3%84%EC%95%BD./600/400",
    "url": "https://news.google.com/articles/CBMiXEFVX3lxTE1qUUxRVFNaOEZfQVJaczVhUkx2bmpPSkZjclBuR0M1anl0Mng1d3hfVUVaTVdfRXZmY2Rpb0Z4NFNiTzdGNVZiTEhaZTgwbkxWSy13WXNkNlIySHNI?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 10,
    "summary": "아리바이오, 미국 독점 라이선스 계약 체결. 희귀 신장·간질환까지 적응증 확장으로 PDE-5 억제제 플랫폼 가치 극대화"
  },
  {
    "id": "c6ee3e398e95",
    "title": "아리바이오, 3300억원 판권 계약...물개박수 '글쎄' - 프리스탁뉴스",
    "description": "아리바이오, 3300억원 판권 계약...물개박수 '글쎄'  프리스탁뉴스",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EC%95%84%EB%A6%AC%EB%B0%94%EC%9D%B4%EC%98%A4%2C%203300%EC%96%B5%EC%9B%90%20%ED%8C%90%EA%B6%8C%20%EA%B3%84%EC%95%BD./600/400",
    "url": "https://news.google.com/articles/CBMib0FVX3lxTE52OEZvZjdONGZmQUN3UjZlV3cxT19oc0pYTlNiMUFxV3BFaDJaZks4V0VyWWlDMm05eVhtY2NQWW1yVmdydTBrQloxX0FnNkc2TDZOLUxfMm94MExxRUtpcmZrSzA2VUtZLTJiR2lmaw?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 9,
    "summary": "아리바이오, 3300억 원 판권 계약에 시장 반응 엇갈려. 계약 규모 대비 실수령액·마일스톤 구조에 대한 분석 필요"
  },
  {
    "id": "8fb79d9873fc",
    "title": "‘레켐비’ 이후 판도는? 글로벌 빅파마, 치매 신약 ‘제형·기전’ 다각화 - 뉴스더보이스헬스케어",
    "description": "‘레켐비’ 이후 판도는? 글로벌 빅파마, 치매 신약 ‘제형·기전’ 다각화  뉴스더보이스헬스케어",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%E2%80%98%EB%A0%88%EC%BC%90%EB%B9%84%E2%80%99%20%EC%9D%B4%ED%9B%84%20%ED%8C%90%EB%8F%84%EB%8A%94%3F%20%EA%B8%80%EB%A1%9C%EB%B2%8C%20%EB%B9%85%ED%8C%8C/600/400",
    "url": "https://news.google.com/articles/CBMibkFVX3lxTE5nYnZlc25KbW91WEE5MGdZVURTdWJZdnE0VTVoLUEweVE1MVN1OTMyLUdIZnVCWGFCRllWQmZadEtHclRtS0VZTXZDbGt6UExHMGxQUWxEWlZXdnVTcGloZmctU05vM1VWYm9CUkpn?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 7,
    "summary": "레켐비 이후 글로벌 빅파마 치매 신약 제형·기전 다각화 경쟁. 경구제·피하주사·다중표적 등 차세대 전략 조망"
  },
  {
    "id": "7f1fe2fd6e19",
    "title": "유방암 치료제 '아베마시클립', 알츠하이머 치매 정복의 새로운 열쇠 되나, 타우 단백질 잡는 '이중 기전' 규명 - BRIC",
    "description": "유방암 치료제 '아베마시클립', 알츠하이머 치매 정복의 새로운 열쇠 되나, 타우 단백질 잡는 '이중 기전' 규명  BRIC",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EC%9C%A0%EB%B0%A9%EC%95%94%20%EC%B9%98%EB%A3%8C%EC%A0%9C%20'%EC%95%84%EB%B2%A0%EB%A7%88%EC%8B%9C%ED%81%B4%EB%A6%BD'%2C%20%EC%95%8C%EC%B8%A0/600/400",
    "url": "https://news.google.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?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 5,
    "summary": "유방암약 아베마시클립, 타우 단백질 분해 이중 기전으로 알츠하이머 치료 가능성 규명. 약물 재창출 유망 후보로 부상"
  },
  {
    "id": "3587b3863c50",
    "title": "암이 치매 막는다?…\"암세포가 알츠하이머 원인 단백질 분해\" - 동아사이언스",
    "description": "암이 치매 막는다?…\"암세포가 알츠하이머 원인 단백질 분해\"  동아사이언스",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EC%95%94%EC%9D%B4%20%EC%B9%98%EB%A7%A4%20%EB%A7%89%EB%8A%94%EB%8B%A4%3F%E2%80%A6%22%EC%95%94%EC%84%B8%ED%8F%AC%EA%B0%80%20%EC%95%8C%EC%B8%A0%ED%95%98/600/400",
    "url": "https://news.google.com/articles/CBMiUEFVX3lxTE1pc0dKVG9rMFFxRWdsNmJFSnIwam1vVGotY0t6RHZVRVhGSHNoS1ZBNTA3UmYyRW15cXBrd1FFSWVYM2hOWUF4U09YVl9CakVH?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "암세포가 알츠하이머 원인 단백질 분해한다는 연구 결과. 암-치매 역상관관계 규명으로 새로운 치료 표적 발굴 가능성"
  },
  {
    "id": "fa3420e9f81e",
    "title": "The Truth About Eisai Co Ltd: Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS",
    "description": "The Truth About Eisai Co Ltd: Why Everyone Is Suddenly Watching This Stock  AD HOC NEWS",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/The%20Truth%20About%20Eisa/600/400",
    "url": "https://news.google.com/articles/CBMixgFBVV95cUxOMlNnYUpUNUJKemNMWVNUaUFLWGRoMjA3QmVEdG9xbldLay0xaDQ1ZEhCQlE5NlQ5djd6SkdOcExWTUZFNWI1UHUwWlg1MnpjUHFTR01yUGQ4TXRpZWFuODhpQ1JJejJhOVNlSFNscHRnaHB4TGRzSVAxd2w2TmVjU0tFYVJQMEVsUXVRNGFhREU2T0FqWjJPVzRSWmoxRzRlZURjLXJpaFhJc1V0clpxTWo1RDZ1NVE2NWNablVOUV90aFptbFE?oc=5",
    "publishedAt": "2026-01-23T08:00:00.000Z",
    "language": "en",
    "importance": 6,
    "summary": "에자이 주가 급부상, 시장 관심 집중 이유 분석. 레켐비 매출 성장·파이프라인 진전이 투자 매력 핵심"
  },
  {
    "id": "a5477dd647cc",
    "title": "K-바이오, 기술수출 넘어 글로벌 시장 주도권 가지려면[기고문] - 연합뉴스",
    "description": "K-바이오, 기술수출 넘어 글로벌 시장 주도권 가지려면[기고문]  연합뉴스",
    "source": "Google News",
    "category": "market",
    "imageUrl": "https://picsum.photos/seed/K-%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EA%B8%B0%EC%88%A0%EC%88%98%EC%B6%9C%20%EB%84%98%EC%96%B4%20%EA%B8%80%EB%A1%9C%EB%B2%8C%20%EC%8B%9C/600/400",
    "url": "https://news.google.com/articles/CBMiW0FVX3lxTE1QRG8xbmRXeXlPenY5bWZCbHZrVm5vVTRjUDROQ0xxVlUwYzlwSlpKS3lVMkVyZmlxMHNaSE9mbExaX0VBT25SUjRiUWtGU1o4Wm54TWVNbWpoaGfSAWBBVV95cUxPRzRCZmRrLWZnclF6eVdfTk9ZODZBZVZNQTFTUDRibFhVdXk2Y2pFWlQxc01Ib2ZHbUFEOThPMWIzb25faWRnb1Z3RjJfRk9VYmh4TWowYVlwNUQzUzdRNkQ?oc=5",
    "publishedAt": "2026-01-22T08:00:00.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "K-바이오 기술수출 넘어 글로벌 시장 주도권 확보 과제 제기. 아리바이오 등 기술이전 기업의 장기 전략 시사점"
  },
  {
    "id": "c02451264237",
    "title": "‘치매 정복’ 여전히 까마득…레켐비 능가할 후발주자 누구 - 이투데이",
    "description": "‘치매 정복’ 여전히 까마득…레켐비 능가할 후발주자 누구  이투데이",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%E2%80%98%EC%B9%98%EB%A7%A4%20%EC%A0%95%EB%B3%B5%E2%80%99%20%EC%97%AC%EC%A0%84%ED%9E%88%20%EA%B9%8C%EB%A7%88%EB%93%9D%E2%80%A6%EB%A0%88%EC%BC%90%EB%B9%84%20/600/400",
    "url": "https://news.google.com/articles/CBMiVEFVX3lxTE1VM2VwWU1xc0V3cmhraDg2RkVnWUZ2eHV5eEd2NmtENGcxVHJnNjVDM2VlM1FUNV9mVjBGUnZha01jNUtEeXpvVXU3WFZ6Ml9kT2F4eQ?oc=5",
    "publishedAt": "2026-01-22T08:00:00.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "치매 정복 여전히 난제, 레켐비 능가할 후발주자 탐색. AR1001 포함 차세대 후보물질의 시장 기회 분석"
  },
  {
    "id": "7cf1e9b9df60",
    "title": "흔들리는 K-바이오, 위기 속 ‘튼튼한 사과나무’를 고르는 시간 - 금융경제플러스",
    "description": "흔들리는 K-바이오, 위기 속 ‘튼튼한 사과나무’를 고르는 시간  금융경제플러스",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%ED%9D%94%EB%93%A4%EB%A6%AC%EB%8A%94%20K-%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%EC%9C%84%EA%B8%B0%20%EC%86%8D%20%E2%80%98%ED%8A%BC%ED%8A%BC/600/400",
    "url": "https://news.google.com/articles/CBMibEFVX3lxTE5DXzdOZGp3c09pNXNKUnV0Z0NpdWxYT0pnSF9tR3pWRUczMDdRUVgtSTFpcTVwUE0teDh1S3c4bi1FS1VNTmRKUUcxQjI3dnZ1bU5jcVJkamNqQ1ZFNnlUeVlxcl9FVHRFdHowNg?oc=5",
    "publishedAt": "2026-01-22T08:00:00.000Z",
    "language": "ko",
    "importance": 2,
    "summary": "K-바이오 위기 속 실력 있는 기업 선별 시간. 임상 성과·기술이전 역량 기반 투자 종목 선별 전략 필요"
  },
  {
    "id": "cf3ffd3c192a",
    "title": "America has an Alzheimer’s problem. Can Trump fix it? - Washington Examiner",
    "description": "America has an Alzheimer’s problem. Can Trump fix it?  Washington Examiner",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/America%20has%20an%20Alzhe/600/400",
    "url": "https://news.google.com/articles/CBMiwAFBVV95cUxPdnM1NkUzNmxQZkhBUkszbWpKYm1VUTdVUWcxSWNlUVM3NUY1bHJERk10aC1pWmx4aDl6S1dUeEZlLWctWnUwVTg5bmt4aTlMNjdmWUtHcWNNM1NEbmE2Wk5STU02dmdseUJtR3kyNjJKeUt0TlBNTGxpa1JkOFcxS2UxY3VVOHdUaHg4N0ZsNXI3QWFEbTRKS25yUGdocWVmMUJJbVUwSk1TRFNDdlBwcWZ5NGhBWkMyQVJVc24tSFM?oc=5",
    "publishedAt": "2026-01-21T08:00:00.000Z",
    "language": "en",
    "importance": 3,
    "summary": "미국 알츠하이머 문제 심각, 트럼프 행정부 대응 능력 의문. 정책 방향에 따라 치료제 보험급여·연구비 영향 가능"
  },
  {
    "id": "66852c92b277",
    "title": "에스포항병원 신경과 정은환 진료과장, 알츠하이머 신약 치료 새 프로토콜 발표 - 영남경제",
    "description": "에스포항병원 신경과 정은환 진료과장, 알츠하이머 신약 치료 새 프로토콜 발표  영남경제",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%EC%97%90%EC%8A%A4%ED%8F%AC%ED%95%AD%EB%B3%91%EC%9B%90%20%EC%8B%A0%EA%B2%BD%EA%B3%BC%20%EC%A0%95%EC%9D%80%ED%99%98%20%EC%A7%84%EB%A3%8C%EA%B3%BC%EC%9E%A5%2C/600/400",
    "url": "https://news.google.com/articles/CBMiZ0FVX3lxTE9hUUxnNG92V2phbHcxRm9IOUpSY0xKaGZvTE4ybEI0XzdMM3lqV3U5NnpVNlZSZVJyVmo0M3BIOHZONU1vbE03RG5GY0RKNnlfY1FWMXk5ZlBZbFRDRk1pUEFoQl9Qc1U?oc=5",
    "publishedAt": "2026-01-21T08:00:00.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "포항 에스병원, 알츠하이머 신약 치료 새 프로토콜 발표. 국내 지역병원까지 치매 신약 처방 확산 가속"
  },
  {
    "id": "638f7c9be2cf",
    "title": "Exciva raises $59m to ease Alzheimer’s agitation - Longevity.Technology",
    "description": "Exciva raises $59m to ease Alzheimer’s agitation  Longevity.Technology",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Exciva%20raises%20%2459m%20t/600/400",
    "url": "https://news.google.com/articles/CBMiiAFBVV95cUxPemU1OU9rT0p1OElUemZCQ0ZHd3FJTElLX0NxakFUTnBVTWhnbDBvRXdNOHZBM2ZXNDlCWjRTSWloQ0dYWUVsb2Yycm84NFA5aUlKdnJBVXdhMGRZLWRfbWczNmZKU09SdUd3dEVSMWlOVjVZYjh5T0h3aVpBSnpNUllkdE5RZ1VM?oc=5",
    "publishedAt": "2026-01-21T08:00:00.000Z",
    "language": "en",
    "importance": 4,
    "summary": "Exciva, 알츠하이머 초조증상 완화 치료제 5900만 달러 자금 조달. 비인지 증상 치료 틈새시장 공략 본격화"
  },
  {
    "id": "1f165422bca4",
    "title": "미충족 수요 타깃 ‘K바이오’, 상반기 ‘에이프릴·디앤디파마텍·아리바이오’ 주목 - 더바이오",
    "description": "미충족 수요 타깃 ‘K바이오’, 상반기 ‘에이프릴·디앤디파마텍·아리바이오’ 주목  더바이오",
    "source": "Google News",
    "category": "aribio",
    "imageUrl": "https://picsum.photos/seed/%EB%AF%B8%EC%B6%A9%EC%A1%B1%20%EC%88%98%EC%9A%94%20%ED%83%80%EA%B9%83%20%E2%80%98K%EB%B0%94%EC%9D%B4%EC%98%A4%E2%80%99%2C%20%EC%83%81%EB%B0%98/600/400",
    "url": "https://news.google.com/articles/CBMibEFVX3lxTE1RRzFFVFB3MDY5VlZvbVhHWG93OTJmQzJ1Y1BaX285UXd1SnVYRVBfaVMwMzdZTE5FbElKRHQyX2ozUHZkejNOUFFvRjF0X0dFMUs2THBQYzRmRGVvVVB1SFBZZkNDbFEwQWZFaNIBcEFVX3lxTE5oWWV5dTZoX0FLenVaVUllaXFHc0hUYkt0S1dsVkttTUlIdkQtcWt4SDBJMXN2RGpTWDhjcjdMbTNoVElSU3l1TlNhdGRiVGs1QlJSdGEwTkFONzR2TEhUMGRWNWNlck9JUzR3bE1rNms?oc=5",
    "publishedAt": "2026-01-20T08:00:00.000Z",
    "language": "ko",
    "importance": 9,
    "summary": "미충족 수요 타깃 K바이오 상반기 주목 기업으로 에이프릴·디앤디파마텍·아리바이오 선정. 아리바이오 투자 관심 지속"
  },
  {
    "id": "4e381d0989ad",
    "title": "Missing tissue, missing data: Resolving brain volume loss caused by anti-amyloid therapies - PLOS",
    "description": "Missing tissue, missing data: Resolving brain volume loss caused by anti-amyloid therapies  PLOS",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/Missing%20tissue%2C%20miss/600/400",
    "url": "https://news.google.com/articles/CBMihAFBVV95cUxQY2xKWWszMC1NWkNOeWFRWGE0cG5nYThSTE9CbXA2dHR4elNaWXQzUFpYLWY1V1RkUjhwWjhPMVI0RkNkeU56c0ZFWVZJNUNwZ2VPLUdXeGFWeGJPdzdfQ2pEZjdmQ2twWVdOVDh2SjJBQWdyanY5Skt1amZ6a3NDYXh2eHo?oc=5",
    "publishedAt": "2026-01-20T08:00:00.000Z",
    "language": "en",
    "importance": 6,
    "summary": "항아밀로이드 치료제 뇌용적 감소 부작용 데이터 분석. 치료 효과와 안전성 균형이 경쟁 약물 평가의 핵심 변수"
  },
  {
    "id": "f6fd7ba11c75",
    "title": "BGI Genomics, Roche roll out diagnostic tests for Alzheimer's in China - ETHealthworld.com",
    "description": "BGI Genomics, Roche roll out diagnostic tests for Alzheimer's in China  ETHealthworld.com",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/BGI%20Genomics%2C%20Roche%20/600/400",
    "url": "https://news.google.com/articles/CBMiygFBVV95cUxPckhuNWpuLVFkRG9OSmQwRTB2SlViMFJRSDdPLTZJSnoxQjJaWGxkbDhYODN4WkIyZGRLSTZ5V01uel9GSTIwVDFUSzB4d1BuTFlsN09SVEVHbDhrTFoxdVRFSG5NVU9manlMVi1FbnlOdVoyeFV5eXFYbGFGamdnM1lCbklqc2NIY0hkSGljc1hPV1hvbThpeEJUT2ZKazhybzJoNzk5eXRTNWx3QmlOWFJDU24ySFlsSkVKYWRHYzhnZkJMME5IZHV3?oc=5",
    "publishedAt": "2026-01-20T08:00:00.000Z",
    "language": "en",
    "importance": 5,
    "summary": "BGI 지노믹스·로슈, 중국에서 알츠하이머 진단 검사 공동 출시. 아시아 진단 시장 확대로 치료제 수요 기반 확충"
  },
  {
    "id": "f8343bc69c37",
    "title": "(영상+) 담보 하나로 ‘보장공백’ 한 번에 메운다… 삼성화재 ‘레켐비플랜’, 치료비 보장 완성 - 보험저널",
    "description": "(영상+) 담보 하나로 ‘보장공백’ 한 번에 메운다… 삼성화재 ‘레켐비플랜’, 치료비 보장 완성  보험저널",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/(%EC%98%81%EC%83%81%2B)%20%EB%8B%B4%EB%B3%B4%20%ED%95%98%EB%82%98%EB%A1%9C%20%E2%80%98%EB%B3%B4%EC%9E%A5%EA%B3%B5%EB%B0%B1%E2%80%99%20/600/400",
    "url": "https://news.google.com/articles/CBMib0FVX3lxTE8ydXZXRG5sZkFDMzlYWUtiMTdzNkJZZERCQnFFenhsczc1V3pENWNBQnVKdy1mUk5EcHdXRlpiS2FyQllYRXF1QzZZMmkwZWZTSFFyaVRqVVJ3RS1vYmMwaUFubVFRSVNHdGZLSlNfMA?oc=5",
    "publishedAt": "2026-01-20T08:00:00.000Z",
    "language": "ko",
    "importance": 7,
    "summary": "삼성화재 '레켐비플랜' 출시, 담보 하나로 치매 치료비 보장 공백 해소. 보험상품 경쟁이 치료제 접근성 개선 견인"
  },
  {
    "id": "f27d001e812e",
    "title": "흥국화재, 표적치매치료 'MRI 검사비' 보장 배타적사용권 6개월 - 연합뉴스",
    "description": "흥국화재, 표적치매치료 'MRI 검사비' 보장 배타적사용권 6개월  연합뉴스",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%ED%9D%A5%EA%B5%AD%ED%99%94%EC%9E%AC%2C%20%ED%91%9C%EC%A0%81%EC%B9%98%EB%A7%A4%EC%B9%98%EB%A3%8C%20'MRI%20%EA%B2%80%EC%82%AC/600/400",
    "url": "https://news.google.com/articles/CBMiW0FVX3lxTE9MS3d1OXFFRE55dnZMNlBQLXBnNHlRQ3p4NmVSTUY2N3JYeHV0YnBCa3BUeXdqNVl6TkpSb2NCSWwwNVJjb1ZWU0NvRkpOaGJNWEVnZkhMZGhGcEXSAWBBVV95cUxNb0FEQW52QUhpR0U5X00tWnpaSy05VU5DdXBpZ1FLSGhwRXZXaWl4MHE5UUZ2aW1HTnlJdThYX0NrczZvTzZleVY1eUZWbDJYZi0tY0ZUZ01uWVVuMFJaczg?oc=5",
    "publishedAt": "2026-01-20T08:00:00.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "흥국화재, 표적치매 MRI 검사비 보장 배타적사용권 획득. 치매 진단·치료 보험 보장 확대 추세 지속"
  },
  {
    "id": "7ba213bd60b2",
    "title": "흥국화재, 업계 최초 ‘치매 MRI 검사비’ 150만원 지원…보장 공백 메운다 - 더페어",
    "description": "흥국화재, 업계 최초 ‘치매 MRI 검사비’ 150만원 지원…보장 공백 메운다  더페어",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/%ED%9D%A5%EA%B5%AD%ED%99%94%EC%9E%AC%2C%20%EC%97%85%EA%B3%84%20%EC%B5%9C%EC%B4%88%20%E2%80%98%EC%B9%98%EB%A7%A4%20MRI%20/600/400",
    "url": "https://news.google.com/articles/CBMicEFVX3lxTE42OUVTOFp5a29QQWJCeXMzOHFrSFdfdG5PSGlheEIycWxjbHhnM3VVSW90aXk0dmJNbWRQVzdqQnJsS0dqdWxjOFk0dmxVNUJRVThuamd2dldVcmZGSVdVdTNTLTVHbFBXbXozOU1JVVjSAXRBVV95cUxOamZLWFU1SHE1MUFoWko1a2VxUHFNNHUxb3ZneGVycDVKLU5ISm93S1QxT2pUSk5VdFJWVjM4UnJoZnoyUnhtTXhLdUZnZWwycUh3N0FIajJLcG54RjVXdk56ZEdmZUxaWkRVZWpfZGJDc29Uag?oc=5",
    "publishedAt": "2026-01-20T08:00:00.000Z",
    "language": "ko",
    "importance": 3,
    "summary": "흥국화재, 업계 최초 치매 MRI 검사비 150만 원 보장. 진단 비용 보장 확대가 치료제 처방 전 검사 접근성 개선"
  },
  {
    "id": "9493024eaa08",
    "title": "House and Senate appropriators endorse NIH budget increase, reject Trump’s proposed cuts - statnews.com",
    "description": "House and Senate appropriators endorse NIH budget increase, reject Trump’s proposed cuts  statnews.com",
    "source": "Google News",
    "category": "research",
    "imageUrl": "https://picsum.photos/seed/House%20and%20Senate%20app/600/400",
    "url": "https://news.google.com/articles/CBMiogFBVV95cUxQd2UyeE1sUVVOTmI0d2c4V2s0aG1XdTlmdjJPQTZpOThnMHFzcW5oaElQNVhPcmxfbDNSNDEyaWVobUl3bTBHSjVnMUZlT0V0Tng4OG5FRDN2TXRsM08yMTFRTWlZRTdueUYzQS0yRzZnOHliY3d4QVF1S2ZxZlk1Z2RoXzNpU21zRXJkWTBTaG42TFV1YzJEZzhGY1BUT1ZEMWc?oc=5",
    "publishedAt": "2026-01-20T08:00:00.000Z",
    "language": "en",
    "importance": 3,
    "summary": "미국 의회, NIH 예산 증액 지지·트럼프 삭감안 거부. 알츠하이머 포함 연구비 유지로 신약 개발 환경 긍정적"
  },
  {
    "id": "8744ba5a5688",
    "title": "EQT, 알츠하이머 치료제 개발에 5,100만 유로 공동 투자 - Investing.com 한국어",
    "description": "EQT, 알츠하이머 치료제 개발에 5,100만 유로 공동 투자  Investing.com 한국어",
    "source": "Google News",
    "category": "market",
    "imageUrl": "https://picsum.photos/seed/EQT%2C%20%EC%95%8C%EC%B8%A0%ED%95%98%EC%9D%B4%EB%A8%B8%20%EC%B9%98%EB%A3%8C%EC%A0%9C%20%EA%B0%9C%EB%B0%9C%EC%97%90%205/600/400",
    "url": "https://news.google.com/articles/CBMicEFVX3lxTFBTMUlGeVh2akhwWS1zbGxteEtfajdWbDM1TnBMM1B6eW4xNFRqd3E0Z2NhZnFvdmd5T2RqY2RLaXhxU003ZTVJNW9oLS1SMVZjZ1VUWGVsbXRTWGszcUFGdmF2MGgtWUdnSmxzdUtYdmk?oc=5",
    "publishedAt": "2026-01-20T08:00:00.000Z",
    "language": "ko",
    "importance": 4,
    "summary": "EQT, 알츠하이머 치료제 개발에 5100만 유로 공동 투자. 글로벌 PE의 치매 치료제 투자로 섹터 자금 유입 활발"
  },
  {
    "id": "82cb68ca96ff",
    "title": "JP모건으로 모인 K-바이오, ‘기술–사업화–공급망’이 경쟁 갈랐다 - 의학신문",
    "description": "JP모건으로 모인 K-바이오, ‘기술–사업화–공급망’이 경쟁 갈랐다  의학신문",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/JP%EB%AA%A8%EA%B1%B4%EC%9C%BC%EB%A1%9C%20%EB%AA%A8%EC%9D%B8%20K-%EB%B0%94%EC%9D%B4%EC%98%A4%2C%20%E2%80%98%EA%B8%B0%EC%88%A0/600/400",
    "url": "https://news.google.com/articles/CBMiaEFVX3lxTE5zd0VLTXgtU3lINVN5T3daZEZtWk1qVnZVbm5IOUtKdGhyNWxtRTRJQ0ZpY0NYUGNCZ3ZjSGt1WjBZZEFWYmpwS0NqTnNpTHIxR092U0UySWpfV3VlbUI1MndtbVV3emFy?oc=5",
    "publishedAt": "2026-01-19T08:00:00.000Z",
    "language": "ko",
    "importance": 2,
    "summary": "JP모건 헬스케어서 K-바이오 기술·사업화·공급망 경쟁력 평가. 글로벌 빅파마 대비 차별화 전략 필요성 부각"
  },
  {
    "id": "11da92edc756",
    "title": "레켐비로 인한 '95% 매출 급증', 키순라로 이어질 것...듀켐바이오 최대 수혜주 부상 - 포브스코리아",
    "description": "레켐비로 인한 '95% 매출 급증', 키순라로 이어질 것...듀켐바이오 최대 수혜주 부상  포브스코리아",
    "source": "Google News",
    "category": "competition",
    "imageUrl": "https://picsum.photos/seed/%EB%A0%88%EC%BC%90%EB%B9%84%EB%A1%9C%20%EC%9D%B8%ED%95%9C%20'95%25%20%EB%A7%A4%EC%B6%9C%20%EA%B8%89%EC%A6%9D'%2C/600/400",
    "url": "https://news.google.com/articles/CBMickFVX3lxTE1rb2t1b09uaHY4OU1SRzROa0ZmX1J2ZG9HdWhEVUNyUEN5MUwxSDRZVTg1d1c5RTZWWllMQVhlQmRWQ2xUUW8yYUtMNElrOW1hcFpmb2xoU0lWTFJRSllmVVkwYmlvQmY1U1FZUVhTTGxpUQ?oc=5",
    "publishedAt": "2026-01-19T08:00:00.000Z",
    "language": "ko",
    "importance": 8,
    "summary": "레켐비 95% 매출 급증 효과가 키순라로 이어질 전망. 듀켐바이오 최대 수혜주 부상, 치매 치료제 생태계 수혜 확산"
  },
  {
    "id": "9d086b7ffa92",
    "title": "FDA Approves Copper Histidinate Treatment for Pediatric Menkes Disease - HMP Global Learning Network",
    "description": "FDA Approves Copper Histidinate Treatment for Pediatric Menkes Disease  HMP Global Learning Network",
    "source": "Google News",
    "category": "regulation",
    "imageUrl": "https://picsum.photos/seed/FDA%20Approves%20Copper%20/600/400",
    "url": "https://news.google.com/articles/CBMiwAFBVV95cUxQYkItWV9zb1RrUG1XS1drWGgwV0NMZWY3ajdoR011UnpHWnZUOHZ3dmNRVG9XOW1Hd09nZG5NUnFGT0ktcWNGZGJBcHR6ejk0VjJ1VU93bERtSTBnM2hHNWJ0VWs3R09MVUlyOHpDNHZTdGNvd0M2ZFRCNjktaXNlQjZROEstbTdpTF9YNXlTai1CeUtTSjFka3pPYmxFTmx3QXdUUFBwcmFRUlJ0TkljblFqVUtyNFFYMmk2SjhpYzU?oc=5",
    "publishedAt": "2026-01-19T08:00:00.000Z",
    "language": "en",
    "importance": 1,
    "summary": "FDA, 소아 멘케스병 치료제 구리 히스티디네이트 승인. 알츠하이머와 직접 관련 없는 희귀질환 승인 뉴스"
  }
]